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I 
Abstract 
The Epidermal Growth Factor Receptor family has been associated with the 
development of advanced prostate cancer (Carrion-Salip et al., 2012). The family 
consists of 4 tyrosine kinase receptors – EGFR, HER2, HER3 and HER4 (Burgess, 
2008). Previous research has focussed on targeting the EGFR and HER2 receptors 
however, the role of HER3 in driving PI3K/Akt signalling and mediating drug 
resistance has shifted the attention towards this signalling partner.  This project provides 
additional understanding regarding the functioning of this receptor family in prostate 
cancer and establishes the therapeutic potential of a novel pan-inhibitor.  The expression 
levels of HER2 and HER3 were validated in patient biopsy samples and elevated 
cytoplasmic and nuclear expression was observed with disease progression. Patients 
differentially expressing low HER2 and strong HER3 levels correlated significantly 
with poor survival rates. The nuclear translocation of these receptors was further 
validated in-vitro upon ligand induced activation and their total and phosphorylated 
forms were found to be present in the nucleus and bound to chromatin. The differential 
expression of the receptors was also explored in-vitro and in-vivo by transient and stable 
over-expression and the importance of HER3 mediated signalling was established by 
the observation of increased MAP Kinase and PI3 Kinase cell signalling pathway 
activities. This over-activation translated to vital cellular processes in cancer 
progression, with significant increases in cell proliferation, migration and invasion. The 
role of these receptors in acquired drug resistance revealed elevated expression and 
activity of EGFR and HER3 receptors in Lapatinib resistant cells. AZD8931, an EGFR, 
HER2 and HER3 inhibitor, radically reduced the functioning of these receptors and 
their regulated cellular processes. The findings of this project opens new avenues for 
research and suggests the use of a pan-inhibitor as a novel and attractive therapeutic 
approach in the treatment of advanced prostate cancer. 
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Chapter 1 Introduction 
1.1 Introduction to cancer  
Cancer is a disease that is caused by unregulated cell growth. There are many types of 
cancer that affect different parts of the body. The disease originates when normal cells 
evolve to a neoplastic state due to the acquisition of certain traits that enable them to 
become tumorigenic and eventually malignant. These traits have been described as the 
‘Hallmarks of Cancer’ (Hanahan and Weinberg, 2011) (Figure 1-1). 
  
Figure 1-1: Hallmarks of Cancer  
This diagram represents all the hallmarks of cancer discussed in the revised review by 
Hanahan and Weinberg (2011). The review explains how the cancer uses these 
hallmarks in the establishment and progression of the disease. 
Research based upon these hallmarks, helps us understand the various mechanisms 
employed by the cancerous cell, developing and maintaining the disease. Key findings 
have helped in the development of many anti-cancer agents. However, many cancers 
continue to lack an adequate therapeutic regime. Hence, it is very important to review 
the disease and its various approaches for sustenance and survival, to help in identifying 
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and designing improved therapeutic targets.  
This project focuses on the role of the epidermal growth factor receptor (EGFR) family 
members in prostate cancer and their potential role as therapeutic targets. These 
receptors have been largely researched for helping the cancer cells in attaining the 
‘sustaining proliferative signalling’ hallmark of cancer and recent work indicates that 
they can also be contributing to attain additional hallmarks, thus helping the cancer to 
survive and progress. The following sections of this chapter give a brief understanding 
of the prostate gland and its associated cancer, the EGFR family receptors and their 
functions and previous research findings that helped develop the structure of this PhD 
project. 
1.2 Prostate gland  
1.2.1 Function of the prostate gland 
The prostate gland is part of the male reproductive system where its main function is to 
produce a fluid that forms a part of the ejaculate. This fluid contains prostate specific 
antigen (PSA) produced by the prostate which helps in maintaining the liquid state of 
the semen thus, aiding the motility of the sperm (Lilja et al., 1987; Vincent T. DeVita 
Jr., 2008). Testosterone, in the form of dihydrotestosterone (DHT), is required for the 
normal functioning of the prostate gland (Lamb and Neal, 2013).  
1.2.2 Anatomy of the prostate gland 
The prostate gland was first described in 1536 (Jathal et al., 2011). It is an exocrine 
gland situated just below the bladder, behind the pubic bone and just in front of the 
rectum. The gland can be divided into three glandular zones (peripheral, central and 
transitional) and an anterior fibromuscular stroma (Figure 1-2). 
Peripheral zone – This zone accounts for around 65% of the prostate’s volume and is 
around the posterolateral peripheral parts of the gland. The prostatic acini present in this 
region have a role of discharging the prostatic secretions into the urethra at the time of 
ejaculation to help liquefy the seminal fluid. Prostatic carcinoma, chronic prostatitis and 
post-inflammatory atrophy are relatively more common in the peripheral zone. About 
60-70% of prostatic cancers arise from the peripheral zone (Schulz et al., 2003; Hedvig 
Hricak, 2009). 
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Figure 1-2: Normal prostate gland 
The diagram describes the zones of the prostate gland. SV-seminal vesicle, CZ-central 
zone, V-verumontanum, PZ-peripheral zone, TZ-transitional zone, AFS-anterior 
fibromuscular stroma (Vincent T. DeVita Jr., 2008). 
Central zone – The central zone makes up the majority of the prostatic base and 
accounts for around 25% of the prostate’s volume. The zone is cone-shaped and 
surrounds the ejaculatory ducts. The ducts of this region join the urethra at the 
verumontanum. This zone comprises of epithelial cells that contain pepsinogen, a 
gastric proenzyme. Only around 5-10% of the cancers originate from the central zone 
(Reese et al., 1988; Schulz et al., 2003). 
Transitional zone – This is the smallest zone of the prostate and accounts for only 5 - 
10% of the prostate and is made up of two symmetrical lobules on either sides of the 
prostatic urethra. 10- 20% of prostatic carcinomas arise from this zone and has clinical 
relevance, as it grows with age and is mainly involved in the development of age-related 
benign prostatic hyperplasia (BPH) (Villers et al., 1991; Hedvig Hricak, 2009; Amin M, 
2010).  
Anterior fibromuscular stroma – This region separates the transition zone from the 
central and the peripheral zones. This region is mainly composed of striated and smooth 
muscle. The distal and proximal regions of the stroma are important for voluntary and 
involuntary sphincter functions, respectively (Hedvig Hricak, 2009). 
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1.3  Pre-malignant prostatic diseases 
1.3.1 Benign prostatic hyperplasia (BPH) 
The normal prostate is made up of luminal, basal and neuroendocrine epithelial cells 
(Figure 1-3). The normal prostate epithelia predominantly consist of luminal cells 
whose main function is to produce prostatic secretory proteins. These cells possess the 
androgen receptor (AR) and are known to be androgen dependent (Liu et al., 1997).  
Between the luminal cells and the basement membrane are another type of epithelial 
cells called the basal cells. These cells continuously line the human prostate and are 
known to express low levels of AR along with anti-apoptotic genes including Bcl2 
(Abate-Shen and Shen, 2000). Another type of epithelial cells called neuroendocrine 
cells are distributed throughout the basal layer. These cells assist the growth of the 
luminal cells by providing paracrine signalling and are androgen-independent 
(Abrahamsson, 1999).  
Benign prostatic hyperplasia is a condition wherein the prostate enlarges by the 
proliferation of epithelial cells and smooth muscles present in the transitional zone of 
the prostate (Lee et al., 1997).  It is a condition that has been observed in older men and 
has been diagnosed in 50% of men over 60 years of age. Previous findings also reveal 
that one or more symptoms associated with BPH are present in 75% of men over the 
age of 70 and ultimately 90% of men over the age of 85 reveal symptoms attributed to 
BPH (Platz et al., 2002). The enlargement of the gland often obstructs the urethra and 
leads to lower urinary tract symptoms (LUTS) which include hesitancy, weak urine 
stream, sensation of incomplete emptying and also urgency, increased frequency of 
urination and nocturia (Priest et al., 2012). These symptoms can have a significant 
impact on the quality of life considering the condition is rarely life threatening. For the 
condition to advance, the interaction between the epithelial cells and the surrounding 
stroma is crucial with the encouragement from the androgen receptor and its ligand 
dihydrotestosterone (DHT) (Cunha et al., 1983). 
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Figure 1-3: Schematic representation of a prostatic duct 
The figure shows the prostatic duct comprising of the basal, luminal and neuroendocrine 
cells surrounded by stroma (Abate-Shen and Shen, 2000). 
1.3.2 Prostatic intraepithelial neoplasia (PIN) 
PIN was initially characterised by McNeal and Bostwick (1986). It is most commonly 
found in the peripheral zone and rarely in the transitional zone and the central zone 
which is similar to the incidences of prostate cancer (Montironi et al., 2011). PIN can be 
characterized by certain changes in cytological features. It is identified by the presence 
of prostatic ducts that are lined by atypical cells. It is then categorised as low grade or 
high grade PIN depending on the degrees of nuclear enlargement, hyperchromasia and 
nucleolar prominence (Brawer, 2005). High grade PIN and prostate cancer have 
common markers and the disease is widely classed as a transitional stage between 
benign disease and invasive malignant carcinoma (Figure 1-4) (Sakr et al., 1994). 
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Figure 1-4: Schematic representation of the development and progression of prostate 
cancer 
The diagram describes the cellular morphological changes that occur in the prostate 
during the progression from benign to malignant disease (Abate-Shen and Shen, 2000). 
1.4 Prostate cancer  
Prostate cancer is the second most frequently diagnosed cancer and the fifth leading 
cause of cancer death worldwide (Torre et al., 2015). The first case of prostate cancer 
was established by histological examination in the mid-19th century (Adams, 1853) and 
research since then has led to a better understanding of the development of the disease 
and has subsequently resulted in the identification of multiple druggable targets.  
1.4.1 Etiology  
Many factors have been linked to the occurrence of prostate cancer. Some of these are 
mentioned below. 
 
Age - Prostate cancer is most commonly diagnosed in older men. 65% of the diagnosed 
cases are from patients above the age of 65 (Jathal et al., 2011). Similar trends have 
been observed in the UK (Figure 1-5). According to Cancer Research UK, an average 
of 36% of the total cases diagnosed between years 2009 and 2011 included men aged 
over 75 years and only 1% of the diagnosed cases include men aged under 50 years. 
Autopsy based studies have revealed that many men develop lesions at earlier ages 
(between 20 and 30) and suggests that prostate cancer can have a long initiation period 
(Gann, 2002). 
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Figure 1-5: Age specific incidence rates in the UK (2009-2011) 
(CancerResearchUK, Prostate cancer - UK incidence)  
The graph shows the average number of new cases diagnosed in the UK each along with 
the age specific incidence rates   
Race – There have been observations made by comparing the incidence rates to race 
and ethnic background. It has been observed that African men are three – times more 
likely to be affected than Caucasian men while Asian men have a lower risk of 
developing the disease. However, migration to other places can affect the incidence 
rates in the ethnic groups. For example, immigration of Japanese men to the USA 
caused an increase in disease incidence within the race and this has been linked to the 
changes in various environmental factors like diet (Sonn et al., 2005; Ben-Shlomo et al., 
2008). 
Family history – The likelihood of developing the disease increases if there is a history 
of relatives diagnosed with prostate cancer. The risk is known to be greater if the 
relatives have been diagnosed at an early age (Jathal et al., 2011). 
The above mentioned factors have been established, but other risk factors are still under 
investigation. These include diet, oxidant damage, physical activity, endogenous 
hormones like insulin-like growth factor – 1 (IGF-1) and the presence of other medical 
conditions (Kolonel, 2001; Cimino et al., 2014; Doolan et al., 2014; Cao et al., 2015; 
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Tsilidis et al., 2015). 
1.4.2 Diagnosis  
The diagnosis of prostate cancer is routinely made by measuring the levels of PSA in 
the serum, digital rectal examination (DRE) and histological analysis of transrectal 
ultrasonography (TRUS)-guided biopsy samples. The aggressiveness of the disease is 
determined by assigning the appropriate Gleason score after histological analysis 
(Sciarra et al., 2012). 
Prostate specific Antigen (PSA) 
PSA, also known as kallikrein-3, is a serine protease that belongs to the kallikrein 
family of proteases and is produced by the epithelial cells of the prostate tissue. As 
mentioned earlier, the main function of this protease is to liquefy the ejaculate to 
increase the motility of the sperm and to also dissolve the cervical mucus (Lilja et al., 
1987). Under normal conditions, the glandular ducts act as barriers in preventing the 
outflow of PSA into the serum. The increase in PSA serum levels has been linked to 
diseases of the prostate, including prostate cancer. The assessment of PSA in blood was 
first performed in 1980 (Kuriyama et al., 1980) and the correlation with prostate cancer 
was established in 1987 (Stamey et al., 1987). The screening for PSA for diagnosis of 
prostate cancer was subsequently approved by the U.S. Food and Drug Administration 
in 1994 and is currently the mostly widely used oncological biomarker (Ablin and 
Haythorn, 2009).  However, there are limitations with respect to the specificity of PSA 
screening as elevated PSA levels can be detected in non-malignant conditions like BPH 
and prostatitis (Oesterling, 1991). The PSA cut-off levels for diagnosis are continually 
being revised. These revisions of the screening have led to the both under and over 
diagnosis and treatment of prostate cancer (Duskova and Vesely, 2015). 
Histopathology 
Despite the initial PSA screen and digital rectal examination, the presence of prostate 
cancer is confirmed only after histopathological examination of transrectal 
ultrasonography (TRUS)-guided biopsy samples.  The samples are evaluated based on 
the Gleason grading system. The system was established by the combined effort of    
Dr. Donald. F. Gleason and the Veterans Administration Cooperative Urological 
Research Group (VACURG) (Gleason, 1966; Gleason and Mellinger, 1974). The 
analysis is performed by staining the biopsied tissue sections with haematoxylin and 
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eosin stains (a.k.a H&E staining) and observing the arrangement patterns of the 
cancerous cells. A Gleason score is then assigned by adding the 2 most commonly 
observed patterns. The Gleason patterning system has recently been revised and 
describes the different morphological changes commonly observed as seen in (Figure 
1-6) (Epstein, 2011) 
.  
Figure 1-6: Schematic of different Gleason patterns  
The above diagram describes the different Gleason patterns used in establishing a final 
Gleason score. Grade 1 comprised of well differentiated and closely packed glands and 
occurs quite rarely. Grade 2 can be identified with a slightly lesser well-defined mass 
and tumour-stromal boundary of the gland. The size and shape of the gland also vary. 
Grade 3 is the most common pattern observed in prostate carcinoma and consists of 
moderately differentiated glands of varied size and the most prominent feature is the 
presence of invasive stroma. Grade 4 is considered as high grade and poorly 
differentiated carcinoma and is characterised by the presence of ill-defined glands and 
chains of malignant epithelial cells. Grade 5 is the most undifferentiated pattern and can 
resemble other undifferentiated cancers of other organs. The highest Gleason sum 
scores are associated with metastatic disease and have poor prognosis (Humphrey, 
2004; Epstein, 2011). 
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1.4.3 Treatment  
Depending on the clinical stage of the cancer and whether the patients are considered to 
be at a low or high risk of cancer progression, different treatment regimens are 
followed. Organ confined disease is initially considered for conservative treatment with 
watchful waiting and active surveillance by using PSA and digital rectal examination 
(DRE) screening. This is a common choice in low risk and older patients, as the risk of 
dying from the disease is minimal and also to spare the patients from the morbidity 
caused by the treatment options (Xu et al., 2012). However, localised prostate cancer 
can be treated surgically by performing radical prostatectomy which essentially involves 
the removal of the entire prostate along with the seminal vesicles (Trojan et al., 2005).  
Other options include external beam radiotherapy and also brachytherapy which 
involves the permanent placement of radioactive seeds (iodine-125 or palladium-103) in 
the prostate (Yu et al., 1999). When the disease is diagnosed as being locally advanced 
and metastatic, the therapy provided aims at preventing distance metastases and 
improving quality of life, respectively. These are achieved by androgen withdrawal 
therapy (AWT) and chemotherapy. The discovery of eliminating testosterone for 
prostate cancer treatment was described by Charles Huggins and Clarence Hodges and 
in recognition of their work were awarded a Nobel Prize in 1966 (Huggins and Hodges, 
1941). Androgen-withdrawal causes a reduction in the androgen receptor (AR) 
signalling cascade (explained in section 1.5), which is essential for prostate cancer 
maintenance and progression. AWT targets tumour growth that is androgen dependent 
and can be achieved by surgical and medical castration. Surgical castration involves 
complete removal of both the testes which is more commonly known as bilateral 
orchiectomy and can deplete the testosterone levels by >95% (Miyamoto et al., 2004). 
This removal of the primary source of testosterone reduces the availability of androgens 
for tumour cell proliferation. Alternative methods, such as medical castration, target the 
hypothalamus – pituitary and testicular axis of androgen production by using oestrogens 
and gonadotropin releasing hormone (GnRH) analogues like Zoladex (Brogden and 
Faulds, 1995). Adrenal androgen production can also be inhibited by targeting CYP17 – 
a bi-functional enzyme present in the testis and adrenal glands and is involved in the 
biosynthesis of androgens from cholesterol (Ang et al., 2009). Abiraterone, a recent 
drug developed by the Institute of Cancer Research in London, blocks the dual activity 
of CYP17 and results in the reduction of androgen synthesis (Goyal and Antonarakis, 
2013). The enzyme 5α- reductase that converts testosterone to the potent form of  
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Figure 1-7: Surgical and medical castration in prostate cancer treatment 
The above figure describes the various methods used in prostate cancer treatment for 
inhibiting androgen production and function. The hypothalamus and pituitary gland 
control the production of androgens in the testes and adrenal gland by the release of 
luteinising hormone and adrenocorticotropic hormone (ACTH) respectively. This 
hypothalamic–pituitary–gonadal axis can be controlled with the use of GnRH 
analogues. Surgical castration reduces 5α- reductase and CYP17 enzymes that play a 
role in gonadal androgen synthesis. However, adrenal androgens can still be produced 
by the production of dehydroepiandrosterone (DHEA) from cholesterol, which can then 
be converted to DHT in the prostate. This is inhibited with the use of CYP17 inhibitors 
like Abiraterone. Further reduction in the AR signalling can be achieved with the use of 
anti-androgenic compounds such as Enzalutamide and ARN-509 (Yin and Hu, 2014). 
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dihydrotestosterone (DHT) has also been used as a target to inhibit the activity of the 
androgen receptor (Titus et al., 2014). Anti-androgens have also been used in the 
treatment of prostate cancer and function by competitive inhibition of androgen binding 
to the androgen receptor. First generation anti-androgens such as Casodex have been 
extensively used in prostate cancer treatment.  However, they have been ultimately 
unsuccessful due to their poor binding affinity to the androgen receptor and to their 
agonistic properties (Masiello et al., 2002). Second generation anti-androgens like 
Enzalutamide and ARN-509 have since been developed and have showed promise in 
clinical trial studies with the observation of increased anti-tumour activity (Scher et al., 
2010; Smith et al., 2012). Treatment regimens can involve intermittent and maximal 
androgen blockade with the combined used of GnRH analogues along with 
antiandrogens (Perlmutter and Lepor, 2007).  
Unfortunately, the majority of patients undergoing AWT eventually relapse with a more 
aggressive form of androgen-independent disease and is more commonly known as 
castration- resistant prostate cancer (CRPC) (Attard et al., 2011). This advanced form of 
the disease most commonly metastasise to the bone and can lead to other ailments like 
spinal cord compression, fractures, anaemia and lastly death (Petrylak, 2014). Patients 
who present with this form of advanced metastatic disease are then treated by 
chemotherapeutic agents such as Docetaxel and Cabazitaxel in combination with the 
corticosteroid Prednisone as a final palliative treatment (Kelly et al., 2012; Heidenreich 
et al., 2013). The androgen receptor signalling axis remains overactive in CRPC and 
research in recent years has focussed on understanding the mechanisms sustaining this 
activity. 
1.5 Androgen receptor 
The androgen receptor is a nuclear transcription factor belonging to the steroid hormone 
receptor superfamily and uses androgens to carry out its biological functions.  Its gene is 
located on chromosome X q (11-12) and comprises of 8 exons (Brown et al., 1989) 
(Figure 1-8). These exons together encode the different structural components of the 
receptor and consists of the N-terminal domain (NTD), the DNA-binding domain 
(DBD), the ‘hinge’ region (HR) and the ligand-binding domain (LBD) (Jenster et al., 
1991) (Figure 1-8). The signalling of the androgen receptor initiates with the 
intracellular conversion of testosterone by 5α- reductase into a more potent form, 5α-
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dihydrotestosterone (DHT) (Figure 1-9).  The AR is located primarily in the cytoplasm 
and is kept inactive by the interaction of heat shock proteins (HSP90, HSP70, HSP56, 
and HSP27) (Zoubeidi et al., 2007). The high affinity binding of DHT to the AR, 
displaces the HSPs and the conformational change allows the interaction of the N and C 
terminal domains of the AR and also to its co-activators (van de Wijngaart et al., 2012). 
The NTD contains the activation function-1 (AF-1) and two transcription activation 
units (TAUs). TAU-1 encourages AR transcriptional activity upon activation,  
 
Figure 1-8: Structure of the androgen receptor  
The gene of the AR comprises of 8 exons that make up its different domains – the N-
terminal domain (NTD), the DNA-binding domain (DBD), the ‘hinge’ region (HR) and 
the ligand-binding domain (LBD). Ligand association allows conformational change of 
the receptor that then helps in recruiting co-activators to carry out its functional 
properties (Ferraldeschi et al., 2015). 
and TAU-5 provides constitutive activity to the AR in the absence of the ligand-binding 
domain (LBD) (Callewaert et al., 2006). The NTD/LBD interaction stabilizes the AR 
protein by reducing the dissociation rate of the ligand and is crucial for its 
transcriptional activity (He et al., 2000). The activation of the receptor is observed with 
its phosphorylation and dimerization to other activated forms of the AR (Nazareth and 
Weigel, 1996). The role of the nuclear localization signal (NLS) then takes over which 
is located between the DBD and the hinge regions and is responsible for nuclear 
transport of the receptor through the recruitment of the nuclear importin complex 
(Cutress et al., 2008). The receptor then binds to specific androgen response elements 
(AREs) and recruits a variety of co-regulatory proteins and initiates the transcription of 
specific target genes such as PSA, leading to the regulation of important cellular 
responses such as survival and growth (Bennett et al., 2010; Hsu et al., 2011).
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Figure 1-9: AR signalling cascade  
Free testosterone gets converted to dihydrotestosterone (DHT) by the enzyme 5α-
reductase. Binding and strong association of DHT to the androgen receptor (AR) 
induces dissociation from heat-shock proteins and also results in receptor 
phosphorylation. The AR subsequently dimerizes and translocates to the nucleus where 
it binds to androgen-response elements in the promoter regions of specific target genes 
that are involved in biological responses such as growth and survival (Feldman and 
Feldman, 2001). 
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1.5.1 Androgen receptor signalling in castrate resistant prostate cancer  
Despite androgen withdrawal therapy, PSA protein levels are detected in CRPC patients 
indicating that the AR signalling pathway is active.  The sustained AR signalling 
mechanisms have been extensively researched in the recent years, a summary of which 
is explained in the below sections (Figure 1-10).  
 
Figure 1-10: Mechanisms for AR activity in CRPC  
The above figure represents the various mechanisms involved in the sustenance of the 
AR signalling in CRPC.  (1) Despite castration, continual steroidogenesis adds to the 
production of testosterone and DHT assisting in AR activation (2) AR mutations can 
cause activation by alternative ligands and can also cause increased affinity to 
androgens. (3) The amplification of the receptor can lead to its abundance causing over 
activity. (4) Cross-talk with other signalling pathways can lead to the activation and 
nuclear translocation of the AR (5) Increased co-activators and decreased co-repressors 
can alter regulation of AR activity. (6) The AR independent bypass pathways functions 
through positively regulating of anti-apoptotic proteins, such as Bcl2 (Harris et al., 
2009). 
  
 16 
Continual androgen production – Increased activity of enzyme 5α reductase can 
cause an enhanced rate of testosterone to DHT conversion, thus producing more ligand 
to activate the AR (Radmayr et al., 2008). Substitute ligands like progesterone can 
persistently activate the AR to maintain its transcriptional function (Yuan and Balk, 
2009). Additionally, the action of intratumoural steroidogenesis along with the 
conversion of circulating adrenal androgens provides continual and adequate androgen 
concentrations to activate the AR despite low testosterone caused by AWT (Locke et 
al., 2008). 
AR mutations – Mutations have been observed in the NTD, hinge and LBD of the 
receptor, at sites that are crucial for protein-receptor interaction, transactivation activity 
and ligand binding (Brooke and Bevan, 2009). The sensitivity to alternative ligands 
including other circulating steroid hormones such as oestrogen, progesterone along with 
AR antagonists can be caused by AR mutations. A well characterised mutation showing 
this effect is the missense mutation that causes a threonine to alanine amino acid change 
at position 877 (T877A) seen in the ligand binding domain of the AR. The mutation, 
originally characterised in the LNCaP cell line, can occur with the treatment of anti-
androgen Flutamide and also steroid hormones like progesterone (Han et al., 2005; 
Jennifer and Iain, 2005). Patients exhibiting resistance to the currently used second 
generation anti-androgen drugs like Enzalutamide and ARN-509, have been noted to 
attain AR mutations like T877A and other mutations like F876L (phenylalanine to 
leucine substitution), causing the drugs to have an agonistic effect and have also been 
linked to assist the cells in achieving drug resistance (Joseph et al., 2013; Azad et al., 
2015).  
AR over-expression and variant forms – AR over-expression can be caused by gene 
amplification or by increased transcriptional activity and protein stabilisation (Visakorpi 
et al., 1995; Miyoshi et al., 2000; Zhang et al., 2009; Lin et al., 2013). This can cause 
the AR to be hypersensitive to low levels of androgen and continue tumour proliferation 
(Waltering et al., 2009). The over-expression of the AR has been reported to also cause 
a shift in the behaviour of the antiandrogen Casodex in an agonistic manner (Chen et 
al., 2004). 
The presence of AR variants has also been observed in advanced prostate cancer. The 
truncated version of the receptor contains the NTD and the DBD but not the LBD and is 
caused by structural rearrangements and/or alternative splicing of the AR gene (Hu et 
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al., 2009; Liu et al., 2014).  A variety of receptor variant forms have been discovered 
with different properties and have been targets for novel therapeutic agents (Lallous et 
al., 2013). The AR-V7 variant is the most commonly detected AR variant in advanced 
prostate cancer and remains constitutively active (Hu et al., 2012). Its activity has been 
reported to be enhanced by anti-androgenic drugs such as Enzalutamide and 
Abiraterone (Mostaghel et al., 2011; Li et al., 2013). Current research is focussing on 
understanding the diverse roles of these variant forms in advanced and drug resistant 
prostate cancer which can then further help in the formulation of more robust AR 
targeted therapies (Xu et al., 2015).  
Co-regulators and repressors – Altered expression and activity of co-regulators and 
co- repressors of the AR can also lead to the development of advanced prostate cancer 
(Chandrasekar et al., 2015). These proteins form part of the transcriptional complex and 
can alter the activities of the AR by influencing its DNA binding, nuclear translocation, 
chromatin remodelling and is achieved by altering the phosphorylation, methylation, 
acetylation or ubiquitylation profiles (Lee and Chang, 2003; Wolf et al., 2008). For 
example, co-activators that possess histone acetyltransferase (HAT) activity, such as 
cAMP response element binding protein (CREB)-binding protein (CBP)/p300 and 
p300/CBP-associated factor (p/CAF) can interact with AR and enable chromatin 
remodelling (Shen et al., 2005). However, co-repressors like silencing mediator for 
retinoid and thyroid hormone receptors (SMRT) can disrupt the N and C terminal 
interaction of the AR and can do this in a ligand dependent or independent manner 
(Heinlein and Chang, 2002).  By competing with co-activators such as SRC/p160, 
SMRT then recruits histone deacetylases (HDAC) that package the DNA into 
nucleosomes and thus inhibits the transcription machinery from binding to the promoter 
or enhancer regions and ultimately represses gene transcription (Liao et al., 2003).  
The above mentioned mechanisms involve the androgen receptor. The androgen 
independent ‘bypass’ mechanism also plays a role in the progression of prostate cancer.  
For example, the infiltration of B and T cells, caused by the inflammatory response of 
apoptotic prostate cancer cells, can cause an upregulation of Stat3 signalling which 
ultimately promotes androgen-independent growth (Ammirante et al., 2010). Similarly, 
castration induced apoptosis can trigger the upregulation of anti-apoptotic genes such as 
Bcl2 (Setlur and Rubin, 2005). 
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1.5.2 Kinase signalling pathways regulating AR activity  
The activity of the AR can also be controlled by crosstalk with other pro-survival and 
proliferative pathways and is discussed in the following sections. 
The phosphatidylinositol 3-kinase (PI3K) pathway – This is one of the most 
commonly activated signalling pathway in cancer including prostate cancer (Courtney et 
al., 2010; Chen et al., 2014). The pathway controls many diverse cellular functions 
including cell proliferation, metabolism and differentiation (Engelman et al., 2006). The 
activity of this pathway initiates by signals generated by growth factors like fibroblast 
growth factor (FGF) and insulin-like growth factor (IGF) and also G-protein coupled 
receptors (GPCRs) (Skolnik et al., 1991; Stephens et al., 1994). The generated signals 
activate the PI3 Kinases whose main function is to phosphorylate the downstream 
phosphatidylinositol and phosphoinositides at their 3’ hydroxyl groups, which is 
achieved by the activities of their catalytic and regulatory subunits (Carpenter et al., 
1993).  The oncogene RAS can also bind to the catalytic subunit p110 of PI3 Kinase 
integrating the PI3 Kinase and MAP Kinase signalling pathways (Goc et al., 2011). The 
downstream serine/threonine kinase AKT is a target of the PI3 Kinase pathway and its 
phosphorylation at serine 473 increases its activity by 10-fold (Sarbassov et al., 2005). 
Active AKT subsequently regulates the expression of genes like forkhead box O 
(FOXO), p27, BAD and eNOS that play a role in cell proliferation, metabolism and 
angiogenesis (Manning and Cantley, 2007). The downstream effector of AKT is mTOR, 
another serine/threonine kinase. The complexes involving mTOR –mTORC1 and 
mTORC2 regulate processes involving protein synthesis, cell proliferation and 
differentiation (Brown et al., 1995).  
 The PI3K-AKT-mTOR pathway plays an important role in prostate tumourigenesis 
(Majumder et al., 2003). The deregulation of the pathway has been linked to the 
reduced expression of PTEN tumour suppressor gene, a negative regulator of the PI3 
Kinase pathway and has been observed in patients with a high Gleason score 
(McMenamin et al., 1999). The importance of the mTORC1 and mTORC2 complexes 
in prostate cancer development has also been established by in-vivo knockout models 
(Guertin et al., 2009; Nardella et al., 2009). 
The PI3 Kinase signalling pathway and the AR signalling axis collaborate with each 
other in the progression of castrate resistant prostate cancer.  AKT can phosphorylate 
the AR at serine residues 217 and 791 leading to its activation and has been observed in 
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prostate cancer (Wen et al., 2000). The inhibition of the AR signalling cascade by the 
various androgen withdrawal therapies causes a reduction in FKBP5 and subsequently, 
PHLPP- a phosphatase negatively regulating AKT. This causes an upregulation in PI3 
Kinase signalling and supports prostate cancer progression (Carver et al., 2011; 
Mulholland et al., 2011). Since this pathway is commonly deregulated in many cancer 
types, there have been many inhibitors developed to act against its activity. There are a 
range of inhibitors that target different proteins in the pathway. The PI3K pan-inhibitors 
target the catalytic subunits of all its isoforms and are currently in Phase I/II clinical 
trials in combination with AR targeting drugs like Abiraterone and Enzalutamide 
(Edlind and Hsieh, 2014). AKT targeted inhibitors like AZD5363 have been shown to 
delay CRPC progression in combination with Casodex (Thomas et al., 2013). The use 
of mTOR inhibitors (rapamycin and similar derivatives) has had limited success in 
prostate cancer clinical trials (Nakabayashi et al., 2012; Templeton et al., 2013). 
Currently, newer ATP site mTOR inhibitors like MLN0128 are in early stage clinical 
trials (Rathkoph, 2015). These inhibit both the mTORC complexes in an ATP 
dependent manner as opposed to allosteric mTORC1 specific inhibitors (rapalogues) 
that can cause an upregulation of AKT. The results from the clinical trials will 
determine the efficacy of targeting this pathway. There are also dual PI3K/mTORC1/2 
inhibitors that target all the p110 isoforms of P13K along with the mTOR complexes 
and suggest to be more robust in inhibiting the signalling pathway. One such inhibitor, 
BEZ235 was shown to reduce tumour growth formation on its own. However, this 
inhibition led to an increase in HER3 levels and a reactivation of the AR signalling 
pathway was observed. The reduction in cell proliferation was more pronounced when 
the EGFR/HER2 signalling axis was inhibited along with the activity of the PI3 Kinase 
pathway (Carver et al., 2011). The figure below is a summary of the pathway and the 
interventions used (Figure 1-11).  
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Figure 1-11: The PI3 Kinase pathway and its directed inhibitors  
The PI3 kinase pathway can activate the AKT pathway and the MAP Kinase pathway. 
The indicated downstream components have been used as targets for therapy with the 
ultimate goal of inhibiting the signalling axis that contributes to overall cell survival. 
mTOR (mechanistic target of rapamycin); mTORC (mTOR complex); PI3K 
(phosphoinositide 3-kinase); PIP2 (phosphatidylinositol 4,5-bisphosphate); PIP3 
(phosphatidylinositol (3,4,5)-triphosphate); PTEN (phosphatase and tensin homolog); 
RTK (receptor tyrosine kinase); TSC (tuberous sclerosis protein) (Downward and 
Weigelt, 2012). 
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The Mitogen-activated protein kinase (MAPK) pathways – The MAPKs are 
serine/threonine kinases that are involved in regulating a variety of cellular processes 
through the activation of different signalling cascades (McCubrey et al., 2006). There 
are 4 different pathways regulated by the following MAP Kinases -  the extracellular-
signal regulated kinases (ERK1/2 or p42/44 MAP kinase), Big MAP kinase 
(BMK/ERK5), c-jun N-terminal kinase (JNK/stress activated protein kinase-1 
(SAPK1)),and p38 MAPK (SAPK2/RK) (Koul et al., 2013). Upstream MAP Kinase 
Kinases (MAPKK) that are in-turn activated by further upstream MAP Kinase Kinase 
Kinases (MAPKKK), regulate the activities of these key signalling proteins (Fang et al., 
2012). The signalling cascade is initiated by a variety of stimulants like growth factors, 
cytokines, death and stress receptors and also oxidative stress (Rodriguez-Berriguete et 
al., 2012) (Figure 1-12).  
The majority of ERK signalling is activated through the RAS-RAF signalling cascade 
(Junttila et al., 2008) and has been associated with advanced prostate cancer and poor 
prognosis (Keller et al., 2004). ERK signalling has been observed to upregulate 
interleukin-6 (IL-6), an inflammatory cytokine in CRPC (Nguyen et al., 2014). ERK 
signalling also regulates NF-κB which then positively controls the expression of anti-
apoptotic genes such as those belonging to the Bcl2 family (Aggarwal, 2000). Research 
on ERK5 has revealed its role in upregulating tumour growth, migration and invasion in 
advanced prostate cancer (McCracken et al., 2008; Ramsay et al., 2011). 
The role of the JNK signalling in prostate cancer has been linked to inducing apoptosis 
due to androgen deprivation (Lorenzo and Saatcioglu, 2008).  Proteins involved in cell 
adhesion, invasion, and migration such as matrix metalloproteinases (MMPs)  and 
urokinase-type plasminogen activator (u-PA) were upregulated due to JNK signalling in 
prostate cancer cells and hence suggests to play a role in the disease progression (Hung 
et al., 2009). p38 MAPK signalling can be activated by pro-inflammatory (IL-6) and  
anti-inflammatory (EGF) cytokines along with other stress signals (Whyte et al., 2009). 
Similar to the other MAPK pathways, p38 has been seen to be over-expressed in 
prostate cancer leading to the upregulation of IL-6 and also regulates TGF-β-mediated 
activation of MMPs thus assisting prostate cancer growth and metastasis (Lin et al., 
2001; Shen et al., 2010) 
The use of MEK1 inhibitor PD184352 effectively reduced tumour growth by inhibiting 
ERK1/2 and ERK5 signalling activity (McCracken et al., 2008). Recent studies have 
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shown that inhibiting both the PI3 Kinase and MAP kinase signalling with the use of 
dual PI3K/mTOR inhibitor GSK2126458 as well as AZD6244, a MEK inhibitor, 
inhibited prostate cancer tumour growth both in-vitro and in-vivo (Park et al., 2015).  
 
Figure 1-12: MAP Kinase signalling pathways 
The diagram shows the 4 regulatory signalling pathways mediated through MAP 
kinases ERK1/2, p38, JNK and ERK5. The pathways are activated by various signals as 
indicated and regulate the expression of a range of proteins that are involved inhibiting 
apoptosis (inhibitory of apoptosis proteins -IAPs). The pathways also positively regulate 
the activities of transcription factors like c-myc and promotes cancer progression 
(Rodriguez-Berriguete et al., 2012). 
There are other signalling pathways that are altered in prostate cancer. Other growth 
factors like IGF along with its respective receptors have been reported to be over-
expressed in prostate cancer (Nickerson et al., 2001; Lin and Wang, 2010) and IGF 
inhibition was found to regress prostate cancer proliferation, migration and invasion 
(Kato et al., 2015). FGF receptor expression was also found to be upregulated in 
prostate adenocarcinoma and the increased expression of its growth factor led to the 
increase in AR protein levels linking it to the AR-signalling axis (Acevedo et al., 2007; 
Memarzadeh et al., 2007). The expression of FGFR has also been linked to prostate 
cancer progression by increasing angiogenesis, cell migration and invasion (Feng et al., 
2012; Wan et al., 2014). The various roles of multiple kinases are thus evident in 
advanced prostate cancer. The remaining sections of this chapter give a brief update on 
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the roles of the EGFR family in prostate cancer development and progression, leading 
to the aims and objectives of this project. 
1.6 Epidermal growth factor receptor (EGFR) family 
The EGFR family of receptors consists of four closely related type 1 transmembrane 
tyrosine kinase receptors; epidermal growth factor receptor (EGFR, also known as 
HER1 (Human Epidermal growth factor Receptor-1/ ErbB1), HER2 (ErbB2), HER3 
(ErbB3) and HER4 (ErbB4) and were assigned the gene symbol ErbB as they are 
homologous to Erythroblastic Leukemia Viral Oncogene (Roskoski, 2014). These 
receptors control activities such as cell division, differentiation, migration adhesion and 
apoptosis. Various studies have shown that these receptors have a vital role in tissue 
development and maintenance (Jathal et al., 2011). The EGFR family are receptor 
tyrosine kinases (RTKs) that are known to activate both the MAPK and the PI3 Kinase 
pathway and hence play a major role in prostate cancer development and progression 
(Baselga and Swain, 2009). The properties of the members of the family are explained 
in the following sections. 
1.6.1 Structure  
The EGF receptors exist as inactive monomers but dimerize after being activated by 
mesenchymal ligands. The overall structure of the EGF receptors consists of an 
extracellular domain, a transmembrame domain, a tyrosine-kinase domain followed by a 
c-terminal domain (Figure 1-13) (Jathal et al., 2011). The extracellular domain is 
further divided into four sub-domains. Subdomains I (amino acids 1–165) and III 
(amino acids 310–480) have leucine-rich repeats and assist ligand binding.  Domains II 
(amino acids 165–310) and IV (amino acids 480–620) have multiple cysteine residues 
that are involved in the formation of disulphide bonds, and their interaction prevents 
subdomains I and III from binding to the ligand by disrupting the ligand-binding pocket. 
Ligand binding relieves these inhibitory interactions and encourages dimerization of 
one monomer and a second ligand bound monomer through the interaction of their 
domain II loops. The transmembrane domain consists of a mere 19–25 amino acid 
residues and is separated on either side by the extra and intracellular juxtamembrane 
segments. This is followed by the tyrosine-kinase domain and the c-terminal tail (amino 
acids 953–1186) (Lemmon et al., 2014). The receptor dimer now activates the kinase 
domain and specific tyrosine residues within the cytoplasmic tail are phosphorylated. 
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These phosphorylated residues serve as docking sites for different proteins that 
subsequently activate intracellular signalling pathways (Di Lorenzo et al., 2003; 
Sithanandam and Anderson, 2008; Jathal et al., 2011).  
 
Figure 1-13: Structure of EGF receptors  
All members of the EGF receptor family have a large extracellular ligand-binding 
region (with subdomains I-IV), a small intracellular transmembrane domain, a 
cytoplasmic tyrosine kinase domain and a C-terminal tail, which contains the 
phosphorylation sites for the effector signalling phosphotyrosine molecules. 
Subdomains I and III are involved in in ligand binding and are also known as called L1 
and L2. Subdomains II and IV are also known as CR1 and CR2 and maintain the 
inactive conformation of the receptor. Ligand binding counteracts the inhibitory 
interactions and initiates receptor dimerization through domain II of two monomers. 
The stable receptor dimer then activates the kinase domain through phosphorylation of 
specific tyrosine residues in the cytoplasmic tail, which in-turn act as docking sites for a 
range of proteins resulting in the subsequent activation of intracellular signalling 
pathways (Jathal et al., 2011). 
1.6.2 Ligands and receptor isoforms 
13 known ligands, including EGF, transforming growth factor alpha (TGF-α), 
amphiregulin (AR), betacellulin (BTC), heparin-binding EGF-like growth factor (HB-
EGF), epiregulin (EPR), epigen (EPG) and neuregulins 1 – 4 (NRG) can activate the 
EGF receptor family members (Han and Lo, 2012). 
The functional activity of the receptors varies in spite of them having the same domain 
structures. The receptors can function through the formation of homodimers and 
heterodimers. EGFR, HER2 and HER4 possess active tyrosine kinase domains and their 
ligands for EGFR and HER4 are known. However, HER2 has no known ligand and 
HER3 lacks a functional tyrosine kinase domain and hence activation via 
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heterodimerization is essential for transmission of their signals (Sithanandam and 
Anderson, 2008; Baselga and Swain, 2009; Jathal et al., 2011). 
The receptors also express isoforms with EGFR having only one, and HER2 with two 
full length isoforms that only slightly differ due to their alternative mRNA splicing. 
HER3 also has 2 full length receptors with one of them missing the first 59 amino acids.  
HER4 however has 4 different isoforms (JMaCTa, JMaCTb, JMbCTa, and JMbCTb.) 
due to different versions of the extracellular juxtamembrane (JMa and JMb) and the 
carboxyterminal tail (CTa and CTb) and are also produced by alternative mRNA 
splicing. EGFR can be activated by seven growth factors (EGF, TGF-α, AR, EPG, 
BTC, HB-EGF and EPR) while HER3 is activated by Neuregulins 1 and 2. HER4 has 
also seven activating growth factors (Neuregulins 1- 4, BTC, HB-EGF and EPR) but 
HER2 has no ligands and lacks a functional ligand binding domain.  A total of 614 
possible combinations of receptors can occur when the 11 growth factors and the 28 
possible dimers are considered. However, when the non-functional combinations of the 
HER2/HER2 and HER3/HER3 homdodimers are eliminated, a grand total of 611 active 
combinations are possible (Elenius et al., 1997; Roskoski, 2014). The ligand precursors 
which are initially expressed as membrane proteins undergo protein ectodomain 
shedding which involves the proteins being cleaved and released by proteases belonging 
to the A disintegrin and metalloproteases family (ADAMs) (Blobel, 2005). The 
members ADAM 10 and ADAM17 are mainly involved in processing of ligands that 
activate the EGFR family (Scheller et al., 2011). This protease family is also involved 
in processing other growth factors and their receptors and control a range of important 
cellular processes including neurogenesis and myogenesis (Rocks et al., 2008). 
The abundance and membrane distribution of the EGF receptors are tightly regulated by 
mechanisms such as Clathrin-dependent and independent endocytosis, ubiquitylation 
and degradation (Longva et al., 2002).  However, these mechanisms are altered in 
cancer cells causing receptor clustering in the plasma membrane and cause an increase 
in receptor dimerization and cell signalling (Casaletto and McClatchey, 2012). A recent 
study has reported that HER3 translocated to the nucleus via Clathrin-independent 
endocytosis and importin β1 complex (Reif et al., 2015). There is also evidence 
suggesting that the signalling activity of these receptors is retained in the endosomes 
that can also help in transporting these receptors to the nucleus (Vieira et al., 1996). The 
receptors also have nuclear localisation sequences (NLS) that help in the interaction 
with nuclear importin complexes involved in intracellular protein trafficking (Lo et al., 
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2006).  
1.6.3 Epidermal growth factor receptor (EGFR/HER1/ErbB1)  
The EGF receptor was the first growth factor receptor to be identified in cancer cells 
(Carpenter et al., 1975) after the discovery of its ligand EGF in 1962 (Cohen, 1962). 
EGFR gene is located on chromosome 7q12 and is 170 KD in size (Puri and Salgia, 
2008; Ooi et al., 2009). EGFR has been known for its role in epithelial cell development 
(Jathal et al., 2011). Once activated by its ligand, it can initiate signalling pathways 
including Ras-Raf-MEK, PI3K-AKT-mTOR and JAK2-STAT (Han and Lo, 2012). The 
C-terminal domain contains five autophosphorylation sites (Purvis et al., 2008). Among 
these sites, tyrosine (Tyr) 1068, Tyr1148, and Tyr1173 act as major sites and Tyr992 
and Tyr1086 act as minor sites for phosphorylation (Chattopadhyay et al., 1999). 
Depending on the site of phosphorylation, different downstream signalling cascades are 
initiated by EGFR. Phosphorylation at Tyr1068 leads to the recruitment of GAB-1 or 
Grb2, and subsequently activation of their downstream signalling pathways 
(Chattopadhyay et al., 1999; Yarden, 2001). 
EGFR and prostate cancer 
As mentioned earlier, EGFR has been known to control signalling pathways that 
modulate growth, differentiation, adhesion, migration and survival of cancer cells and is 
known to be over-expressed in several types of cancer including prostate, breast, 
colorectal, lung, oesophageal, pancreatic and head and neck cancers (Yewale et al., 
2013). Progression of tumours in becoming invasive and metastatic has been associated 
with increased EGFR signalling. The activity of the receptor is increased in cancer due 
to activating mutations or over-expression.  Mutations have been identified on exons 19, 
20 and 21 in patients with prostate cancer and the presence of G735S, G796S and 
E804G mutations led to an increase in cell proliferation and invasion (Cai et al., 2008). 
EGFR can contribute to cancer progression not only by activating signalling pathways, 
but can also translocate to the nucleus where it acts as a transcription factor for cell 
proliferative and survival genes including cyclin D1, inducible nitric oxide synthase 
(iNOS), cyclooxygenase-2 (COX-2), aurora A and c-Myc. It has also been shown to 
have a role in DNA damage repair by interacting with DNA-dependent protein kinase 
(DNA-PK) (Brand et al., 2011; Han and Lo, 2012). A truncated form of the receptor, 
EGFRvIII has been detected in advanced prostate cancer and its expression has been 
associated with poor survival outcome (Edwards et al., 2006). This form lacks the 
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ligand binding domain (amino acids 6- 273) and remains constitutively active (Yewale 
et al., 2013). In the normal prostate, EGFR levels are down regulated in an androgen 
dependent manner and this regulation is lost in advanced prostate cancer suggesting its 
role in driving androgen independent prostate cancer (Cai et al., 2009; Traish and 
Morgentaler, 2009). 
1.6.4 HER2 (Neu/ErbB2)  
The HER2 receptor is encoded by the HER2 gene, a proto-oncogene located on 
chromosome 17q21. The protein has 1255 amino acids and is 185kD in size. The gene 
was initially identified in rat neuroectodermal tumours (hence also the name - Neu) 
(Schechter et al., 1984). As mentioned earlier, HER2 lacks a functional ligand binding 
domain and relies on heterodimerization with another family member. However, the 
over-expression of HER2 has been reported to form functional homodimers (Ghosh et 
al., 2011). HER2 has the strongest catalytic kinase activity and hence HER2 containing 
heterodimers have the strongest signalling activity. The HER2- HER3 heterodimer is 
the most potent in terms of strength of interaction, ligand induced tyrosine 
phosphorylation and downstream signalling (Sithanandam and Anderson, 2008; Baselga 
and Swain, 2009; Jathal et al., 2011). The activity of HER2 is induced by the 
phosphorylation of 4 major sites Tyr1139, Tyr1196, Tyr1221/1222, and Tyr1248 
(Olayioye et al., 2000), however phosphorylation at Tyr1028 impairs the receptor’s 
function (Dankort et al., 1997). Other receptors such as insulin-like growth factor 
receptor I (IGF1) and estrogen receptor (ER) can also activate the receptor. HER2 
majorly mediates the mitogen activated protein kinase (MAPK) pathway and 
phosphatidylinositol 3-kinase (PI3K) pathway (Tai et al., 2010; Gutierrez and Schiff, 
2011).  
HER2 and prostate cancer 
HER2 amplification and over-expression can be tumorigenic and this has been reported 
in a number of human tumours, including in 18–25% of human breast cancers, ovarian 
cancers, gastric carcinoma, salivary gland tumours and prostate cancer (Baselga and 
Swain, 2009; Tai et al., 2010) and is associated with poor prognosis (Edwards et al., 
2004). According to Signoretti et al. (2000), HER2 was found to be over-expressed in 
25% of untreated primary tumours, 59% of  tumours after hormone therapy and 78% of 
metastatic tumours. HER2 has also been associated with the progression to CRPC. 
Previous research has shown that HER2 can promote phosphorylation of AR and 
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activate AR signalling. This leads to stabilisation of AR protein levels and enhances its 
binding to the promoter regions of AR regulated genes (Wen et al., 2000; Mellinghoff 
et al., 2004). HER2 has also been associated as one of the factors responsible for 
promoting cell survival in an androgen-depleted environment. HER2 was negatively 
regulated by the AR in the presence of androgens and was thus inferred to play an 
important role in activating and re-establishing the AR pathway and encouraging 
prostate cancer cell survival following androgen ablation (Berger et al., 2006). A 
soluble truncated form of the receptor consisting of only the extracellular domain has 
been located in the serum of prostate cancer patients over-expressing HER2 and 
correlates with aggressive disease (Domingo-Domenech et al., 2008). 
1.6.5 HER3 (ErbB3)  
HER3 was identified in 1989. It is located on chromosome 12q13.2 and the protein is 
180 kDa in size (Kraus et al., 1989).  HER3 mRNA has been detected in the early 
stages of development suggesting its role in cell growth and differentiation. In human 
adults, HER3 is detected in the brain, spinal cord, liver, prostate, kidney and lung 
tissues. Growth factors belonging to the Heregulin-1 (HRG-1) and HRG-2 groups are 
known to activate the receptor (Zimonjic et al., 1995b; Seshacharyulu et al., 2012).  The 
C-terminal domain of HER3 is slightly longer than those of EGFR and HER2. HER3 
was recently characterized to have very low catalytic activity but it is sufficient to 
phosphorylate HER2, its most favourable dimerization partner.  Once activated, they 
phosphorylate each other’s tyrosine sites thus creating docking sites for downstream 
signalling proteins (Shi et al., 2010). The HER2-HER3 heterodimer mainly activates the 
MAPK and PI3K signalling pathways (Figure 1-14). Tyr1289 in HER3 serves as a 
binding site for the p85 regulatory subunit of PI3K and allows subsequent activation of 
the pathway. They also have a nuclear localization signal at its C-terminus 
(Sithanandam and Anderson, 2008). However, HER3 homodimers have been reported 
to have weak autophosphorylation activity (1/1000th the autophosphorylation activity of 
EGFR) despite being kinase-impaired (Shi et al., 2010).  
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Figure 1-14: Downstream signalling of HER2 and HER3  
Ligand binding initiates cell signalling by receptor dimer formation. Cross-
phosphorylation of the dimer partners creates docking sites for the recruitment of 
downstream signalling partners to form signalling complexes. MAPK pathway and 
PI3K–Akt pathways are the two key signalling pathways activated by the EGFR family 
and promotes tumour cell proliferation and survival (GSK3β -glycogen synthase kinase 
3β; NF-κB - nuclear factor-κB; PDK1 - pyruvate dehydrogenase kinase 1; PIP2 - 
phosphatidylinositol biphosphate; PIP3 -phosphatidylinositol triphosphate) (Baselga 
and Swain, 2009). 
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HER3 and prostate cancer  
HER3 presence has been detected in prostate cancer and cancer cell lines. HER3 over-
expression in tumours mainly results due to abnormal functioning of HER3 regulating 
mechanisms. Neuregulin receptor degradation protein 1 (Nrdp1) is an E3 ubiquitin 
ligase and was recently discovered to regulate HER3 degradation. Ubiquitination of 
HER3 occurs via the N-terminal RING finger domain of Nrdp1 and is also responsible 
for its turnover. Chen et al. (2010) reported that the AR functioning negatively 
regulated HER3 in an androgen dependent manner but not in CRPC and observed 
elevated levels of HER3 in castration resistance cells. Their research uncovered that in 
CRPC cells, AR was unable to regulate Nrdp1 transcription thus increasing HER3 
levels, which in turn stabilised AR activity along with HER2.  HER3 also regulates the 
AR through EBP1 (ErbB3 binding protein 1). Zhang et al. (2008) showed that EBP1 
suppressed AR activity through physical interaction. EBP1 is initially bound to HER3 
and upon HER3 stimulation, EBP1 gets phosphorylated and released. It then 
translocates to the nucleus and binds to AR promoter regions and prevents its activation. 
EBP1 over-expression down regulated expression of AR in LNCaPs, an androgen-
dependent cell line. The presence of nuclear HER3 has also been linked to CRPC 
progression and elevated nuclear HER3 expression was found in lymph node metastases 
of the disease. The nuclear form of HER3 – p45 sHer3 – a secreted isoform of the 
receptor, has been found in bone metastases of the disease (Myers et al., 1994; Chen et 
al., 2007). HER3 over-expression was also been linked to a less favourable prognosis in 
prostate cancer (Sithanandam and Anderson, 2008; Jathal et al., 2011). These findings 
reveal the diverse roles that HER3 holds in prostate cancer. Recently, HER3 mutations 
in the extracellular and kinase domains of the receptor have been identified in a variety 
of human malignancies, particularly in gastric and colon cancers. Interestingly, the 
G284R mutation in the extracellular domain is hypothesized to encourage a 
conformation suitable for its dimerization even in the absence of ligand (Jaiswal et al., 
2013). The presence of HER3 mutations in prostate cancer is not widely reported and 
should be investigated. 
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1.6.6 HER4 (ErbB4) 
The HER4 gene is located on chromosome 2q (33.3–34) (Zimonjic et al., 1995a). EGF 
family ligands (betacellulin, epiregulin, heparin-binding EGF-like ligand) and 
neuregulins can activate the receptor. HER4 can regulate diverse biological activities 
and cellular responses that mainly include activation of pro-apoptotic pathways, cell 
cycle arrest and forms complexes with transcription factors to modulate cell 
proliferation via activity of its intracellular domain. Unlike HER3, isoforms of HER4 
have been observed due to alternative splicing of its mRNA.  The intracellular C-
terminal fragment of HER4 is known to translocate into the nucleus following gamma 
secretase-mediated cleavage (Koutras et al., 2010; Seshacharyulu et al., 2012). 
HER4 and prostate cancer 
HER4 expression is not seen in most prostate cancer cells and their expression appears 
to disrupt cancer cell growth (Baselga and Swain, 2009).  HER4 expression is observed 
to be lost in most prostate cancer patients permitting HER3 to only dimerize with EGFR 
and HER2 (Jathal et al., 2011). However, breast, oral cavity, esophagus, ovary, cervix 
and skin cancers have been detected with a truncated C-terminal HER4 in the cancer 
nuclei and have been linked to poor clinical prognosis (Seshacharyulu et al., 2012). 
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1.7 EGFR family as therapeutic targets in prostate cancer  
EGFR family members have been recognised as targets for therapy as they are over-
expressed and deregulated in many types of cancer. They remain to be targets for the 
development of novel anticancer agents and to add to the range of existing small 
tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (Baselga and Swain, 2009) 
(Figure 1-15). In 1998, the first inhibitor of the EGFR family –Trastuzumab 
(Herceptin), was approved by the US Food and Drug Administration (FDA) 
(Goldenberg, 1999). This monoclonal antibody targets the extracellular region of HER2. 
Similarly Cetuximab, also a mAb, binds to the extracellular domain of EGFR and 
prevents ligand-receptor interaction and promotes receptor internalization (Martinelli et 
al., 2009). The small molecule TKIs Gefitinib and Erlotinib reversibly inhibit EGFR 
and prevent autophosphorylation (Roskoski, 2014). Patients suffering with CRPC have 
been on clinical trials of Trastuzumab, Gefitinib and Erlotinib to test single-agent 
therapeutic efficacy. However, these trails reached only phase II as the results were 
unsatisfactory (Lara et al., 2004; Canil et al., 2005; Gravis et al., 2008; Guerin et al., 
2008; Dhupkar et al., 2010). Similar results were obtained with Pertuzumab, a second-
generation anti-HER2 antibody (de Bono et al., 2007). The dual kinase inhibitor 
Lapatinib (targeting both EGFR and HER2) instead had lesser side effects but provided 
no PSA responses (Sridhar et al., 2010). The use of the more recent drug Afatinib (also 
targeting EGFR and HER2) has also shown limited success in clinical trials (Molife et 
al., 2014). The poor success of EGFR and HER2 inhibitors has been associated with the 
over-expression of HER3. The role of HER3 in driving PI3K/AKT signalling and 
mediating drug resistance has shifted the attention on this signalling partner of EGFR 
and HER2 (Jathal et al., 2011). Multi-EGFR family inhibitors have also been developed 
to inhibit more than one individual EGF receptor at one time. Previous research on in-
vitro and in-vivo models has demonstrated greater anti-tumour activity by employing 
dual- or multi-EGFR family inhibitors (Hsieh and Moasser, 2007; Seshacharyulu et al., 
2012). 
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Figure 1-15: Inhibitors against EGFR family  
The above figure describes a few of the different inhibitors that have used in the 
treatment for prostate cancer but have been largely unsuccessful as they target a single 
or dual member of the family (Huang et al., 2009). 
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AstraZeneca's AZD8931 is a recently-documented pan-EGFR family inhibitor and 
targets EGFR, HER2 and HER3 signalling. Initial studies revealed greater effect of the 
inhibitor against the activity of the HER2-HER3 dimer and hence is expected to be of 
particular use in solid tumours that are managed through these receptors (Hickinson et 
al., 2010). The characterisation of this drug was mainly performed on lung and breast 
cancer cell lines. The drug is currently in clinical trials for oesophageal cancer 
(CRUKD/12/007) and bowel cancer (CRUKD/12/015). Recent published results in 
breast cancer research suggest that the compound could be a novel strategy in the 
treatment of the disease (Mu et al., 2014). However, there is no available literature on 
the use of this compound in prostate cancer. 
It is evident from previous research that the EGFR family plays a significant role in 
many cancers like breast, ovarian, gastric and also the prostate. Many anticancer agents 
have been developed and tested against this receptor family. The outcomes of the 
clinical trials with the use of these agents have been different among the various cancer 
types. However, none of these agents have had a formidable outcome in prostate cancer. 
It is therefore essential to study the molecular mechanisms of the EGFR family in 
prostate cancer and try new therapeutic approaches that target the family. 
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1.8 Aims and objectives  
The principle aims of this project are -  
i. To characterise the expression levels of EGFR family receptors in prostate cancer 
tissues and cell lines 
 
ii. To study their effects on cancer progression (by over-expression experiments) 
 
iii. To study the efficacy of the pan inhibitor AZD8931 (AstraZeneca) in prostate 
cancer cell lines which specifically targets EGFR, HER2 and HER3. 
 
The broader aim of this project is to identify patients who could benefit from pan-EGFR 
family inhibition and initiate a Phase I/II clinical trial with the compound alone or with 
combination of other treatments. 
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Chapter 2 Materials and Methods 
2.1 General laboratory procedures 
All laboratory procedures were carried out in accordance with the departmental safety 
policy as outlined in the ‘Northern Institute for Cancer Research – Paul O’Gorman 
Building Safety Policy.’ The Standard Operating Protocol (SOP) for the respective 
techniques was followed and Personal Protective Equipment (PPE) was worn at all 
times. The necessary COSHH (Control of Substances Hazardous to Health) and 
BioCOSHH (Biological Control of Substances Hazardous to Health) forms were filed 
before the commencement of the procedure. 
2.2 Immunohistochemistry 
2.2.1 Human tissue samples 
Immunohistochemistry was carried out on archival formalin-fixed paraffin wax- 
embedded serial sections of clinical prostate samples that were cleared from the 
Newcastle upon Tyne ethics committee. A database of patients diagnosed with prostate 
cancer was generated from the Freeman Hospital, Newcastle upon Tyne database.  
Transurethral resection of prostate (TURP) samples from patients at the Freeman 
Hospital between 1993 and 2003 were collected. An anonymous database was 
maintained with information of all the samples (Demographic data, pathological data, 
hormone manipulation, and other treatment modalities). The database was securely 
stored according to good clinical laboratory practice guidelines 
2.2.2 Processing and grading samples 
Immediately after extraction, the tissue samples were fixed overnight in 10% formalin 
buffered to pH–7. They were then embedded in paraffin blocks after they were trimmed 
and processed in graded ethanol and xylene using the routine processing and embedding 
equipment (Miles Scientific VIP processor, Leica EG1160). Blocks selected for tissue 
microarray (TMA) construction were then cut at 5μm thickness using a standard 
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microtome onto slides (Superfrost Plus, Thermo Scientific) and stained with 
haematoxylin and eosin (H&E). The presence of the pathology of interest (various 
Gleason grades, PIN and BPH) was confirmed by Dr Mathers, uropathologist, RVI, 
Newcastle upon Tyne. The blocks were appropriately marked with different colours to 
represent different grades. 
2.2.3 Construction of Tissue Microarray (TMA) 
Tissue Microarrays (TMA) were constructed according to a pre-determined layout (X 
and Y co-ordinates for each sample) by using a MTA1 arrayer (Beecher instruments). 
Briefly, a recipient block was made out of paraffin wax. A 0.6mm wax core was taken 
from the recipient block at the appropriate location and the cavity created was then 
replaced by the appropriate tissue sample. The recipient block could be moved precisely 
on both the X and Y axes with the help of the micrometer. Subsequent cores were 
placed at 1mm intervals.  Once the layout was completed in this manner, the block was 
incubated at 37ºC for 30 minutes to provide stability to the cores. The block was then 
cooled to room temperature and sectioning using a standard microtome and water bath. 
With a core depth of 3 mm, up to 600 sections of 5μm thickness could be cut from a 
single TMA. The slides were baked at 60ºC for 2 hours before storing them at room 
temperature. 
2.2.4 Methodology 
The samples were initially deparaffinised in xylene for 5 minutes (2 times) and 
rehydrated through a series of graded alcohols (100%, 100%, 70%, and 50%) with a 
final wash in distilled water. Antigen retrieval was achieved by incubating the slides in 
citrate buffer using a decloaker (Table 2-1). Endogenous peroxide activity was blocked 
by treating the samples with 3% hydrogen peroxide for 10 minutes. The sections were 
then washed under running tap water for 5 minutes and placed in TTBS. The area 
around the sections were marked with a hydrophobic PAP pen (Dako). Unspecific 
binding was blocked prior to antibody application by incubating the sections for 5 
minutes using protein block (Dako). Primary antibody was incubated overnight at 4ºC. 
The next day, the slides were washed twice for 5 minutes in TTBS (Tris buffered saline 
– Tween20) and continued with the instructions from the detection system depending on 
the antibody species. After DAB (Diaminobenzidine tetrahydrochloride) incubation (5 
mins) the slides were washed in tap water for 5 minutes, counter stained in Harris 
Haematoxylin for 15 seconds, immediately washed with tap water and treated with 
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Scotts tap water for 30 seconds. Finally, the tissue sections were dehydrated in a series 
of graded alcohols (50%, 70%, 100%, and 100%) followed by two 5 minute xylene 
washes, and mounted in DPX. 
X-Cell-Plus HRP detection kit (Menapath) 
After primary antibody incubation, the slides were incubated with either HRP 
(Horseradish Peroxidase) polymer (for rabbit Ab) for 30 minutes alone or universal 
probe for 30 minutes followed by a wash in TTBS for 5 minutes subsequently followed 
by incubation with HRP polymer as before (for mouse Ab). This was followed by a 10 
minute wash in tap water and DAB incubation for 5 minutes after which the sections 
were counterstained, dehydrated and mounted as mentioned previously. 
Scoring 
Once stained, the TMA was then scored for nuclear and cytoplasmic staining. The 
expressions were scored by two independent observers (average values were finally 
considered), using a histoscore method, also known as H-score. The method considers 
the intensity of staining and the percentage of cells with the same intensity of staining 
across the sample. The score is calculated by using the formula: 
𝐻𝑖𝑠𝑡𝑜𝑠𝑐𝑜𝑟𝑒 = (1 x % 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ 𝑤𝑒𝑎𝑘 𝑠𝑡𝑎𝑖𝑛𝑖𝑛𝑔)
+ (2 x % 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ 𝑚𝑜𝑑𝑒𝑟𝑎𝑡𝑒 𝑠𝑡𝑎𝑖𝑛𝑖𝑛𝑔)
+ (3 x % 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ 𝑠𝑡𝑟𝑜𝑛𝑔 𝑠𝑡𝑎𝑖𝑛𝑖𝑛𝑔) 
This method has been well established (Ahmad et al., 2011) and is useful for scoring 
heterogeneous staining of samples.  It provides a maximum score of 300 (100% cells 
with strong staining) and a minimum of 0 (100% cells with no staining) which makes 
the data quantifiable. Once the scores for cytoplasmic and nuclear HER2 and HER3 
expression were established, the available patient clinic-pathological data was used to 
analyse the expression profiles in cancer patients.The expression was classed as being 
low (histoscore between 0-100), moderate (histoscore between 100-200) or strong 
(histoscore between 200-300) and the available survival data was analysed by plotting 
Kaplan-Meier Curves. This uses an appropriate nonparametric statistical test called the 
log-rank test. The test considers the null hypothesis that there is no difference between 
the populations in the probability of an event (here a death secondary to prostate cancer) 
at any time point (Bland and Altman, 2004).
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Target Ag retrieval Primary Antibody Washes Detection kit 
HER2 
0.01 M sodium 
citrate buffer, 
pH 6.0 
Decloaker 
(Menapath) 
1:500 
1% BSA in PBS as 
diluent 
 
Overnight 
incubation 
 
Santa Cruz 
Neu (3B5): 
Cat no - sc-33684 
(Mouse 
monoclonal – 
raised against 
synthetic peptide 
corresponding to 
amino acids 1242-
1255 of human 
HER2) TTBS 
X-Cell-Plus HRP 
Detection Kit 
(Menapath) 
HER3 
 
1:100 
1% BSA in PBS as 
diluent 
 
Overnight 
incubation 
 
Santa Cruz 
ErBb3 (C-17): 
Cat no - sc-285 
(Rabbit polyclonal 
– raised against a 
peptide mapping 
the c-terminus  of 
human HER3) 
 
Table 2-1: IHC conditions 
The antibodies used for IHC were first validated for its specificity by performing 
western blotting using appropriate control samples. A test TMA consisting of different 
tissue types (including benign and cancerous prostate tissue) was then used to optimise 
the correct antigen retrieval buffer and antibody concentration. A negative control 
(without primary antibody incubation) was included during the all the optimisation and 
final experiments. 
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Clinical details TMA1 TMA4 
Age (Mean;Range) 70 yrs (55-88) 72 yrs (55-89) 
Total number of patients n=76 n=81 
Previous treaments Naïve Naive 
Gleason sum score   
4-6 n=7 n=15 
7 n=10 n=12 
8-10 n=53 n=45 
Gleason single score   
3 n=11 n=25 
4 n=28 n=31 
5 n=28 n=16 
Organ confined disease n=34 n=45 
Locally invasive disease n=27 n=28 
Metastases n=16 n=23 
Subsequent metastates n=16 n=18 
Table 2-2: Clinical details of patients that were analysed for HER2 and HER3 
expression. 
  
 42 
2.3 Mammalian cell culture 
2.3.1 Cell culture reagents 
Full medium (FM) 
RPMI 1640 medium (500 ml - Sigma Aldrich) containing HEPES (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid) buffer (25 mM) and L-glutamine (2 mM) was 
supplemented with foetal calf serum (FCS) (56 ml=10% - Gibco). This standard 
medium was used to maintain prostate cancer cell lines that required androgens for their 
growth.  
Steroid depleted medium (SDM)  
Steroid depleted serum (56 ml=10% Gibco) was added to RPMI 1640 medium (500 ml 
-Gibco) containing HEPES buffer (25 mM) and L-glutamine (2 mM). This medium is 
required to culture cells in androgen depleted conditions. In principle, this is achieved 
by treating FCS using dextran-coated charcoal (DCC) (that depletes materials such as 
hormones and certain growth factors without having an effect on essential salts and 
amino acids. Any steroid depleted conditions in experiments were established using this 
medium as is referred to as SDM in this study. 
Basal medium (BM) 
RPMI 1640 medium (500 ml-Gibco) containing HEPES buffer (25 mM) and L-
glutamine (2 mM) was supplemented with bovine serum albumin (BSA) at a final 
concentration of 250 µg/ml to produce a medium devoid of any serum. Experiments 
with 
Heregulin treatments were carried out by starving the cells overnight (16 hours) in this 
media. 
Freezing medium (FzM) 
The composition of freezing medium for cells consists of 80% of the respective growth 
medium, 10% of dimethylsulphoxide (DMSO) (Sigma Aldrich) and 10% of serum 
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(serum in respective medium i.e. FM or SDM). 
Phosphate buffered saline (PBS) 
PBS containing sodium chloride - NaCl (137mM), potassium chloride -  KCl (2.7mM), 
disodium hydrogen phosphate - Na2HPO4 .2 H2O (10mM) and potassium dihydrogen 
phosphate (2mM) was set to pH–7.4 and autoclaved. 
Trypsin/EDTA (Ethylenediaminetetraacetic acid)  
10 X Trypsin stock (0.5g trypsin, 0.2g EDTA and 0.85g NaCl per litre (Sigma Aldrich)) 
was diluted to 1X  working concentration using sterile PBS. 
2.3.2 Cell lines and their characteristics 
All cell lines were authenticated after purchase/donation and were only used at low 
numbered passage (i.e. frozen stocks were made soon after the cell lines were acquired. 
When a vial of cells were used, subsequent stocks were made and the cells in culture 
were passaged not more than 30 times). 
LNCaP 
The LNCaP prostate cancer cell line (Clone FGC- Fast Growing Clone; Passage 19) 
was purchased from the American Type Culture Collection (ATCC, Rockville, 
Maryland, USA). This cell line was derived from a 50- year old Caucasian male by 
using the needle aspiration biopsy sample of a lymph node metastasis showing 
metastatic prostate carcinoma. The cell line is well characterized confirming that they 
are androgen responsive and possess a mutated AR (Horoszewicz et al., 1983). 
LNCaP–AI  
The LNCaP – Androgen Independent cell line was derived in-house by Prof. Craig 
Robson (Urology Research Group, NICR) from the LNCaP cell line. The cells were 
continuously passaged under androgen depleted conditions for a period of 9 months. 
The cell line was later characterized to be proliferative without the requirement of 
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androgens but retains androgen responsiveness. The parental LNCaP cell line with 
matched passage numbers was also maintained (McCracken et al., 2008). 
LNCaP-7B7 
This cell line was a kind gift from Jan Trapman (Erasmus Medical Centre, Netherlands). 
The LNCaP-7B7 cell line was established by stably transfecting the LNCaP cell line 
with a pPSA luciferase reporter (Cleutjens et al., 1996). This cell line can thus be 
utilised to investigate the effects on AR transcriptional activity using luciferase assays.  
PC3 
The PC3 cell line (Passage 27) was purchased from the European Collection of Animal 
Cell Cultures (EACC, Salisbury, UK). This cell line was derived from a metastatic bone 
lesion isolated from a 62-year old Caucasian male. The cell line is not hormone 
sensitive and does not express prostate specific antigen (PSA) or the androgen receptor 
protein. (Kaighn et al., 1979). 
2.4 Compounds  
2.4.1 Heregulin-1 
Cells were treated with Heregulin (R&D Systems). The stock concentration was 1µg/ml 
in sterile PBS were stored at -80 ºC. Treatments were done by using a working 
concentration of 20ng/ml. 
2.4.2 Dihydrotestosterone (DHT)  
DHT (Sigma Aldrich) at 10mM stock concentration (dissolved in ethanol and stored at -
80 ºC) was diluted 1:1000 in basal medium to get 10 µM stock. This was further diluted 
to the final required working concentrations. 
2.4.3 AZD8931 
The pan-HER inhibitor was provided by AstraZeneca. Stocks of 30mM of the 
compound were made in DMSO and stored at -80 ºC. Further dilutions were made in 
DMSO and stored at -20 ºC and repeated freeze thaw of the compound was avoided. 
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2.4.4 Lapatinib 
Lapatinib was purchased from Selleck Chemicals and stocks of 30mM concentration 
were made in DMSO and stored at the recommended temperature of -20 ºC. Further 
dilutions were made in DMSO and stored at -20 ºC and repeated freeze thaw of the 
compound was avoided. 
2.4.5 Enzalutamide  
Enzalutamide was purchased from Selleck Chemicals and stocks of 30mM 
concentration were made in DMSO and stored at the recommended temperature of -80 
ºC. Further dilutions were made in DMSO and stored at -20 ºC and repeated freeze thaw 
of the compound was avoided. 
2.5 Generation of resistant cell lines 
2.5.1 LNCaP-Lapatinib resistant cell line 
LNCaP cells were continuously grown in the presence of Lapatinib using the GI50 
concentration (1 µM) which was estimated using colony formation assay (2.16.1). After 
a few passages, the cells were treated with 3 µM of Lapatinib. A mixed populations of 
cells were grown that were resistant at this dose after which these cells were further 
subjected to a final concentration of 5 µM of the drug. The cells were maintained in the 
media for a minimal of 12 weeks prior to analysis. The cells hereafter were maintained 
in the presence of 5 µM Lapatinib. 
2.6 Routine culturing of cell lines 
All cell lines were routinely cultured using flasks and petri dishes (Corning) in a 37 ºC 
incubator (Sanyo) with 5% CO2 humidified atmosphere. LNCaP–AI cells were 
maintained in SDM whereas all other cell lines were maintained in FM. All reagents 
were heated to 37 ºC prior to use. Handling of cell lines were done under sterile 
conditions in a Laminar Air Flow (LAF) hood. All reagents and equipment to be used 
inside the hood were made sterile by cleaning them with 70% alcohol (Fisher 
Scientific). Briefly, the media on the cells was removed, washed with PBS and 
incubated with Trypsin/EDTA (least amount required to cover surface area) at 37 ºC 
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until cellular detachment. Cells were then suspended at appropriate volumes in their 
respective growth medium to neutralize the effect of trypsin on the cells. The cells were 
pelleted at 400g for 5 minutes. The pelleted cells were re-suspended, counted if 
necessary and passaged (1:5 for LNCaP cell lines, 1:10 for other cell lines) onto fresh 
dishes or flasks. 
Cells were subjected to routine mycoplasma testing in 1 month intervals using the 
Mycoalert mycoplasma detection kit (Cambrex, Berkshire, UK). 
2.6.1 Cell counting 
Cell concentration/ml was estimated with the use of an improved neubauer 
haemocytometer (VWR International). Briefly, 10 µl of re-suspended cells were applied 
to the haemocytometer and viewed under a light microscope using the 20x objective. 
The cell number present in the counting grid (25 large squares of the central 1 mm2) was 
multiplied by 1 x 104 to get the cells/ml concentration of the cell suspension. Based on 
the number of cells required for the experiment, the volume of cells required was 
calculated with the use of this concentration. 
2.6.2 Cryopreservation 
Monolayer cultures were pelleted down and re-suspended in freezing medium. 1ml 
aliquots with cell concentrations between 2-5 x 106 cells /ml were made in cryovials 
(ThermoScientific) and labelled with the name of the cell line, passage number and 
date. The cells were frozen at a controlled rate to – 80 ºC and subsequently stored in 
liquid nitrogen. Frozen cells were re-cultured by defrosting the cells at 37 ºC and re-
suspending the cells in 10ml of its respective fresh medium. The cells were then 
pelleted and cultured as mentioned in section 2.6. Medium was replaced after 24 hours 
to remove dead cells. 
2.7 Protein analysis 
2.7.1 Sample preparation 
Cell lysates were generated with the addition of RIPA buffer (150 mM NaCl pH 7.5; 
50mM Tris-Hcl pH 7.5 (Fisher Scientific); 1% NP40 (BDH Chemicals); 1mM EDTA; 
0.25% sodium deoxycholate (Sigma Aldrich). The buffer was supplemented with fresh 
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protease and phosphatase inhibitor tablets (Roche) following the recommended 
protocol. Briefly, cells were washed with chilled PBS and lysed in RIPA buffer for 30 
minutes at 4 ºC after which the samples were sonicated for 5 minutes and cell debris 
was pelleted by centrifugation at 12,000g at 4 ºC for 10 minutes. The supernatant 
(whole cell lysate) was then used for further analysis. Protein concentration was 
estimated using BCA assay (Section 2.7.2) and equal amounts of protein was added to 
appropriate amounts of 5x SDS sample buffer (250 mM Tris-HCl pH6.8; 10% SDS; 
30% glycerol (Fisher Scientific), 5% -mercaptoethanol, 0.02% bromophenol blue 
(Sigma Aldrich) and analysed using western blotting. 
2.7.2 Protein quantification using BCA assay 
Protein concentration of samples was estimated using the Pierce BCA protein assay kit. 
Briefly, a standard curve was made by serially diluting known concentrations of bovine 
serum albumin (BSA). 10 µl of all samples (standard curve and unknowns) were loaded 
in triplicate onto a 96 well plate and the working reagent was added using the sample to 
reagent ratio 1:20. The plate was placed on a shaker for 30 seconds and incubated at 37 
ºC for 30 minutes. The absorbance was read at 570nm using the BioRad Model 680 
microplate reader. 
2.7.3 Western Blotting 
SDS-PAGE (Sodium dodecyl sulfate - polyacrylamide gel electrophoresis) 
Polyacrylamide gels were routinely prepared using the Bio-Rad Protean Mini-II series 
system. Clean glass gel casting plates of 0.75mm spacers were used. First the resolving 
gel was poured and overlaid with water. Once set, the water was poured off and the 
stacking gel was overlaid. To assist sample loading, a comb was placed in the stacking 
gel. The gels were placed in the running tanks containing 1x Tris-glycine running 
buffer. The respective samples were loaded along with a multicolour broad range 
protein ladder (Spectra Fermentas Life Sciences) to confirm protein transfer and to 
assess protein size. Gels were run at 180V. The proteins on the gel were then transferred 
onto a nitrocellulose membrane. (Table 2-3). 
Electrophoretic transfer 
Hybond C-Extra (Amersham Biosciences) and 2 pieces of Whatman filter paper (VWR) 
was first soaked in 1x transfer buffer. The gel was disassembled from the glass plates 
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and then placed on the membrane between the filter paper. Any air bubbles between 
these layers that might affect the transfer were removed by flattening the assembly. This 
was laid in a cassette between 2 sponges that aid the assembly to remain wet during the 
transfer. The cassette was placed in a Bio-Rad Protean II transfer cell system containing 
1x transfer buffer and transfer was performed at 100V for 1 hour. (Table 2-3). 
Immunoblotting 
To prevent non-specific binding, the membrane was blocked in 5% (w/v) non-fat dried 
milk (Marvel) in 1x TBS for an hour at room temperature on an orbital shaker. The 
membrane was then washed with 1x TTBS for 5 minutes and then incubated with 
primary antibody solution for 1 hour at room temperature or at 4 ºC overnight with 
rotation. The antibodies were diluted in 5% (w/v) non-fat dried milk at the required 
concentration (Table 2-4, Table 2-5 and Table 2-6) in 1x TTBS. Following incubation, 
the membrane was then washed twice with TTBS for 5 minutes to remove excess 
antibody and was further incubated for 1 hour at room temperature with the appropriate 
secondary antibody (HRP-tagged, Dako or Cell Signalling). Depending on the species, 
the secondary antibody was either rabbit-anti-mouse or swine-anti-rabbit. Finally, 
unbound antibody was removed by washing the membrane twice in TTBS for 10 
minutes followed by a wash with TBS for 5 minutes. 
Chemiluminescent detection 
Luminol-based enhanced chemiluminescence (ECL) HRP substrate (Amersham 
Biosciences or ThermoScientific) was used to detect the protein of interest according to 
the manufacturer’s instructions. The system uses the principle of oxidation of HRP 
which catalyses the luminol in the presence of peracid and phenolic enhancers, to emit 
light. The emitted light signal was captured on X-ray film (Super RX Fuji Medical X-
ray FilmTM) in a high-speed cassette (Generic Research Instrumentation) and then 
developed and fixed using Mediphot 937 X-ray film processor (ACI-Colenta 
International, Cambridgeshire, UK). 
Membrane stripping 
The membrane was stripped of bound antibody by incubating in stripping buffer (Table 
2-3) at 50 ºC incubator for 30 minutes with agitation. Membranes were then washed 
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with TTBS (twice for 10 minutes) before proceeding with immunoblotting. Membranes 
were re-probed no more than three times. 
 
 Technique Reagent Constituents 
SDS-PAGE 
 
6% stacking gel 
6% acrylamide:bis-acrylamide 
(30% stock Sigma Aldrich) 
125mM Tris-HCl, pH 6.8 
(Fisher Scientific) 
0.1% SDS (Fisher Scientific) 
1% (w/v) ammonium persulfate (Sigma 
Aldrich) 
0.2% TEMED (Sigma Aldrich) 
10% resolving gel 
10% acrylamide:bis-acrylamide 
375mM Tris-HCl, pH 8.8 
0.1% SDS 
1% (w/v) ammonium persulfate 
0.2% TEMED 
5x Tris-Glycine Running 
buffer 
125mM Tris-HCl 
950mM Glycine (Fisher Scientific) 
0.5% SDS 
Western 
Blotting 
10x Transfer buffer 
250mM Tris-HCl, 
1.5M Glycine 
10% Methanol (Fisher Scientific) 
5x TBS 
(Tris buffered Saline) 
100m M Tris-HCl 
2.5M NaCl (Fisher Scientific) 
pH 7.5 
TTBS 0.1% Tween-20 (VWR) in 1x TBS 
Stripping buffer 
62.5mM Tris-HCl, pH 6.7 
2% SDS 
0.78% -mercaptoethanol 
Table 2-3: Routinely used reagents in protein analysis 
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Antibody Target Species Company/Cat No Ig Type Concentration Ab diluent and incubation time 
EGFR Rabbit 
Cell Signalling 
(D38B1)/#4267 
Monoclonal 1:1000 
5% Marvel 
Overnight at 4ºC 
Phospho-EGFR Rabbit 
Cell Signalling 
Tyr 1068 (D7A5)/#3777 
Monoclonal 1:1000 
5% Marvel 
Overnight at 4ºC 
HER2 Rabbit 
Cell Signalling 
(D8F12)/#4290 
Monoclonal 1:1000 
5% Marvel 
Overnight at 4ºC 
Phospho-HER2 Rabbit 
Cell Signalling 
Tyr 1221/1222(6B12)/#2243 
Monoclonal 1:1000 
5% Marvel 
Overnight at 4ºC 
HER3 Rabbit 
Cell Signalling 
(D22C5)/#12708 
Monoclonal 1:1000 
5% Marvel 
Overnight at 4ºC 
Phospho-HER3 Rabbit 
Cell Signalling 
(Tyr1289) (21D3)/# 4791 
Monoclonal 1:1000 
5% Marvel 
Overnight at 4ºC 
AR Rabbit 
Santa Cruz 
N-20/ sc-816 
Polyclonal 1:1000 
5% Marvel 
Overnight at 4ºC 
Table 2-4: List of Antibodies and their conditions used routinely in western blotting
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Antibody Target Species Company/Cat No Ig Type Concentration Ab diluent and incubation time 
Phospho – AR 
(Ser 81) 
Rabbit 
Merck Millipore 
04-078 
Monoclonal 1:1000 
5% Marvel 
Overnight at 4ºC 
PARP 1/2 Rabbit 
Santa Cruz 
sc-7150 
Polyclonal 1:1000 
5% Marvel 
Overnight at 4ºC 
α – tubulin Mouse 
Sigma Aldrich 
T 9026 
Monoclonal 1:2000 
5% Marvel 
Overnight at 4ºC 
Histone H4 Rabbit 
AbCam 
Ab10158 
Polyclonal 1:1000 
5% Marvel 
Overnight at 4ºC 
AKT 1/2 Rabbit 
Santa Cruz 
sc-1619 
Polyclonal 1:1000 
5% Marvel 
Overnight at 4ºC 
Phospho- AKT 1/2/3 
(Ser 473) 
Rabbit 
Santa Cruz 
sc-7985 
Polyclonal 1:1000 
5% Marvel 
Overnight at 4ºC 
ERK 1/2 Mouse 
Santa Cruz 
sc-135900 
Monoclonal 1:500 
5% Marvel 
Overnight at 4ºC 
Table 2-5: List of Antibodies and their conditions used routinely in western blotting
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Antibody Target Species Company/Cat No Ig Type Concentration Ab diluent and incubation time 
Phospho – ERK1/2 Mouse 
Santa Cruz 
Sc-7383 
Monoclonal 1:200 
5% Marvel 
Overnight at 4ºC 
ERK5 Rabbit 
Cell Signalling 
#3372S 
Polyclonal 1:1000 
5% Marvel 
Overnight at 4ºC 
Phospho – ERK5 
Thr218/ Tyr220 
Rabbit 
Cell Signalling 
#3371S 
Monoclonal 1:1000 
5% Marvel 
Overnight at 4ºC 
PSA Rabbit 
Dako 
A0562 
Polyclonal 1:1000 
1% Marvel 
1hr at RT or Overnight at 4ºC 
Table 2-6: List of Antibodies and their conditions used routinely in western blotting
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2.8 siRNA transfections 
siRNAs against the target of interest were obtained from Sigma Aldrich. The 
oligonucleotides were obtained in duplexes where the antisense strand sequence was 
generated by the company’s software and is based on complementarity to the sense 
strand (Table 2-7). They were diluted in sterile diethylpyrocarbonate (DEPC) treated 
water to avoid contamination by RNase. Based on the stock concentration, the siRNA 
was diluted to a final working concentration of 25nM. Lipofectamine RNAiMax 
(Invitrogen) was used to facilitate the transfections. 3 µl of RNAiMax was used per 
microgram of siRNA. After determining the amount of siRNA required, a mastermix 
was made in basal medium and incubated for 30 minutes at room temperature. The cells 
were reverse transfected (adding siRNA first and then seeding cells slowly over it) in 
either full or steroid depleted medium. Efficiency of the siRNA was tested by 
monitoring the protein expression levels before and after transfection. 
2.9 Plasmid transfections 
Forward transfections were carried by estimating the amount of plasmid required for the 
experiment. 3 µl of the DNA transfection reagent -TransIT-LT1 Transfection Reagent 
(Mirus), was added per microgram of plasmid. A master mix was made in basal 
medium, incubated at room temperature for 30 minutes and then added drop wise onto 
previously seeded cells. 
2.10 Immunofluorescence 
Glass coverslips and forceps were sterilised by soaking in 100% ethanol for one hour. 
The coverslips were then allowed to dry by placing them against each well of a 6-well 
plate using forceps. Meanwhile, the cells required for the experiment were prepared. 
Once the coverslips were dry, the plate was slightly nudged to place the coverslips onto 
the well. The cells were seeded on top of the coverslips and left to attach. The next day, 
the cells were washed in PBS and either changed to full medium or starved in basal 
medium overnight. The next day, the cells were treated with Heregulin (20 ng/ml) for 2 
hours. The medium was then removed and the cells were washed with PBS following 
which they were fixed with warm 4% para-formaldehyde (Alfa Aesar) for 10 minutes at  
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Target Sequence of sense strand 
Scrambled 5´  UUCUCCGAACGUGUCACGU[dT][dT] 
HER3 
HER3-1 5´  AAGAGGAUGUCAACGGUUA[dT][dT] 
HER3-2 5´  GAAGACUGCCAGACAUUGA[dT][dT] 
HER3-3 5´  GCAGUGGAUUCGAGAAGUG[dT][dT] 
HER2 
HER2-1 5´  GGACGAAUUCUGCACAAUG[dT][dT] 
HER2-2 5´  GACGAAUUCUGCACAAUGG[dT][dT] 
HER2-3 5´  CUACAACACAGACACGUUU[dT][dT] 
Table 2-7: siRNA sequences 
37 ºC followed by treatment with chilled methanol at -20 ºC for a further 10 minutes for 
permeabilization. Unspecific binding was prevented by blocking with serum-free 
protein block (Dako) for 5 minutes followed by primary antibody incubation. 50 µl of 
antibody (HER2 (sc-33684) 1:300 and HER3 (Cell Signalling #12708) 1:300) was 
placed on parafilm, kept in a hydrated chamber and the coverslips were inverted onto 
the antibody and incubated at room temperature for 1 hour. The coverslips were then 
washed in PBS for 5 minutes (2x) and similarly incubated with 50 µl of 1:500 Alexa 
Fluor (Invitrogen) secondary antibody for 1 hour at room temperature in the dark to 
prevent bleaching of the fluorescent probe.  The species of the secondary antibody was 
either anti-mouse (488nm excitation) or anti-rabbit (633nm excitation) The coverslips 
were then washed in the dark with PBS for 5 minutes (3x) followed by one wash with 
distilled water for 5 minutes and then mounted onto glass slides using hard-set mountant 
with DAPI (Vectashield). The sides of the coverslips were sealed with clear nail varnish 
to prevent excess drying. The slides were then left to set in the dark at 4ºC.  The slides 
were viewed with a confocal fluorescent microscope (Leica TCS SP2 UV laser scanning 
microscope) under x63 oil immersion using lasers of appropriate wavelengths. Optical 
sections of 1 µm increments in the Z-axis were taken by scanning across the XY-axis 
and a Z series was reconstructed from individual images taken throughout the depth of 
the section.  
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2.11 Cytoplasmic–nuclear–chromatin extractions 
Cytoplasmic-nuclear extractions were carried out using the NE-PER nuclear and 
cytoplasmic extraction kit (ThermoScientific). 1x106 cells were seeded on 90mm petri 
dishes. After 24 hours, the medium was changed on respective samples to basal medium 
after a wash with PBS. Depending on the experiment, the cells were treated with or 
without appropriate inhibitory compounds overnight. The next morning, the cells were 
treated with Heregulin (20ng/ml) for 30 and 120 minutes. The cells were then pelleted 
down in either full medium or steroid depleted medium and they were then used to 
extract cytoplasmic and nuclear fractions following the protocol provided. 80X protease 
and phosphatase inhibitors stocks were made and appropriate amounts to get a final 
concentration of 1X were added to the extraction buffers to keep the proteins and their 
modifications from degrading. The pellets left behind were taken as the chromatin 
fractions and were dissolved in 50 µl of SDS (sodium dodecyl sulphate) sample buffer 
(125 mM Tris-HCl pH 6.8; 2% SDS; 10% glycerol, 10% β-mercaptoethanol, 0.01% 
bromophenol blue) and were then subjected to a 5 minutes sonication programme using 
a Bioruptor (Diagenode) which incorporated cycles of 30 seconds on and 30 seconds off 
at the ‘high’ setting. The extracts were probed for α-tubulin (cytoplasm), PARP 
(nucleus) and histone H4 (chromatin) to ensure equal loading of the samples and purity 
of the extracts.  
2.12 Plasmid vectors 
pIRES-Hyg, pIRES-Hyg-HER2, pIRES-Hyg-HER3 plasmids (Antibiotic selection- 
Hygromycin) were a kind gift from Dr. Maurizio Scaltriti (Memorial Sloan-Kettering 
Cancer Center, New York) (Scaltriti et al., 2007) and were used for transfections and as 
a template for the generation of lentiviral particles. 
MMP9-Luciferase construct (Antibiotic selection - Ampicillin) was obtained as a kind 
gift from Dr. D. Boyd (MD Anderson Cancer Centre, USA). The constructs contain 5′
-flanking fragments upstream to the transcription initiation start site that is linked to a 
luciferase reporter (Gum et al., 1996). 
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pFLAG-CMV-AR (Wild type; Antibiotic selection - Ampicillin) was a kind gift from 
Ralf Janknecht (Oklahoma University, Rochester, MN).(Gaughan et al., 2011)  
The pCMV (Antibiotic selection - Ampicillin) empty vector was used as a control for 
transfections and to ensure equal final amount of DNA used throughout the experiment 
carried out.(Gaughan et al., 2011) 
pCMV-β-gal (Antibiotic selection - Zeocin) was used as a control to normalise 
transfection efficiency.(Gaughan et al., 2011)  
2.13 Bacterial transformation and plasmid preparation 
NEB 5α E.coli competent cells (New England Biolabs) were used for routine plasmid 
transformations. The cells were thawed on ice after recovering from storage at -80 ºC. 1 
µl of plasmid (maximum concentration of 100 ng/µl) was then added to 25 µl of 
competent cells and mixed gently by pipetting followed by incubation on ice for 30 
minutes. The cells were then subjected to a heat shock at 42 ºC for 45 seconds using a 
water bath and immediately placed on ice for 2 minutes. 1ml of pre-warmed Luria-
Bertani (LB) media (10g/L tryptone, 5g/L yeast extract (Oxoid), 10g/L NaCl, pH 7.0) 
was then added to the cells and placed on a 37 ºC shaker for 1 hour at 200rpm. Cells 
were then spread out on LB agar plates (15g/L agar,10g/L tryptone, 5g/L yeast extract, 
10g/L NaCl, 20g/L pH 7.0) at different dilutions (10-100 µl and a concentrated sample 
after spinning the cells down on the highest speed for 1 minute) which contained the 
respective antibiotic for selection (Ampicillin 100 µg/ml, Zeocin 100 µg/ Kanamycin, 
50 µg/ml). The plates were incubated at 37 ºC overnight. 
The next day, the plasmid was prepared following instructions from the miniprep or 
maxiprep kit (Sigma Aldrich) for respective small scale and large scale preparations. 
Stocks of the culture were made by mixing equal volumes of bacterial culture and sterile 
glycerol in a cryovial and stored at -80 ºC.  
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2.14 Generation of stable over-expressing cell lines 
2.14.1 Lentivirus production 
The production of lentivirus was made by using the ViraPower lentiviral expression kit 
(Life Technologies) by following the manufacturer’s guidelines. 
Briefly, the full length gene of HER2 and HER3 was amplified from the pIRES-Hyg-
HER2, pIRES-Hyg-HER3 plasmids respectively. The primers were designed so that the 
forward primer contained a ‘CACC’ overhang before the transcription initiation site to 
permit directional cloning into the pENTR/ D- TOPO vector and the reverse primer was 
stopped just before the stop codon to ensure that the insert was in-frame with the V5 
epitope following recombination into the pLenti6/V5 DEST vector. (Note: The last 
amino acid of HER2 was changed to incorporate a methionine (ATG) instead of valine 
(GTG) and the second amino acid of HER3 was changed to glycine (GGG) instead of 
arginine (AGG). These changes were necessary to minimise the chance of the PCR 
product cloning in the opposite direction) (Table 2-8). The quality of the primers was 
checked using the online programme – PCR Primer Stats – Bioinformatics.Org. The 
PCR reaction was done by making a reaction mix as mentioned in Table 2-9. A 
negative control with water as template was used for each gene. The contents were 
mixed briefly and the PCR was carried out using the conditions mentioned in Table 
2-10 . The PCR product was run on an agarose gel to confirm the right product size. 
Gene Forward Primer Reverse Primer 
HER2 5’ CACCACCATGGAGCTGGCGG 3’ 5’CATTGGCACGTCCAGACC 3’ 
HER3 5’ CACCGTCATGGGGGCGAA 3’ 5’CGTTCTCTGGGCATTA 3’ 
Table 2-8: Primer sequences used for HER2 and HER3 amplification 
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Reagent Volume 
10x PFX reaction mix 5µl 
Forward primer (10 µM) 1.5 µl 
Reverse primer (10 µM) 1.5 µl 
Template DNA (100ng) 1 µl 
Accuprime Pfx DNA Polymerase 1 µl 
Sterile water 40 µl 
Table 2-9: PCR reaction mix 
Cycle Stage Cycles Temp Time 
Initial Denaturation 1 1 95 ºC 2 min 
Denaturation 
2 30 
95 ºC 15 sec 
Annealing 55 ºC 30 sec 
Extension 68 ºC 4min 10sec (1min/kb insert) 
Final extension 3 1 68 ºC 5 min 
Storage 4  4 ºC  
Table 2-10: PCR conditions 
Agarose gel electrophoresis 
1% agarose gel was made in TAE buffer (40mM Tris-HCl, 20mM acetic acid and 1mM 
EDTA). The sample was mixed with equal amounts of DNA loading dye and once 
loaded alongside a ladder, they were run at 100V in TAE buffer till the dye front 
reached two-thirds the length of the gel. The gel was stained with SYBR® Safe DNA 
gel stain (Life Technologies) and imaged under UV (Ultraviolet) light using a Gel 
Documentation System (BioRad). 
The manufacturer’s guidelines were followed and the PCR product was ligated to 
pENTR/ D-TOPO. The plasmid was then transformed into competent cells as 
mentioned in (2.13). Resistant colonies were selected using kanamycin, validated by 
agarose gel electrophoresis and Sanger sequencing using M13 forward and reverse 
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primers with an additional 4 primers per gene making sure the correct sequence of the 
gene was incorporated in the right direction. 
The HER2 and HER3 genes were transferred to the pLenti6/V5 DEST vector by 
allowing homologous recombination by combining the pENTR/ D-TOPO with the 
respective gene insert according to the manufacturer’s guidelines. The recombined 
plasmid was then transformed into Stbl3 competent E.coli cells as mentioned in (2.13). 
Resistant colonies were selected using ampicillin, validated by restriction digestion, 
agarose gel electrophoresis and Sanger sequencing using CMV forward and V5 reverse 
primers with an additional 4 primers per gene making sure the correct sequence of the 
gene was incorporated in the right direction. 
The viral particles were then produced in 293FT cells following the manufacturer’s 
guidelines by transfecting the verified pLenti6 clone along with the ViraPower 
packaging mix which contained the pLP1, pLP2, pLP/VSVG plasmids in an optimized 
mixture to facilitate viral packaging. The control pLenti6 plasmid containing the LACZ 
gene was provided in the kit and was also used to produce viral particles which was 
further used to produce a LACZ control cell line.  The protocol was followed after 
which the medium containing the virus was centrifuged at 500g for 15 minutes to pellet 
cells and debris. The supernatant was filtered using a Millex-HV 0.45µm PVDF filter. 
The viral particles were pelleted by ultracentrifugation at 20,000g for 4 hours at 4 ºC. 
The viral pellet was then re-suspended in 1ml of basal medium and 100 µl aliquots were 
stored at -80 ºC. 
The virus was then titrated on PC3 cells by seeding out the cells in a 6-well plate at 30% 
confluency. The following day, the viral stock was serially diluted in range from 10-2 
and 10-6 in a final volume of 1ml. After 24 hours, the medium was removed and 
replaced with fresh selection medium which contained Blasticidin (10µg/ml – 
predetermined concentration). The cells were cultured for 14 days replacing the 
selection medium every 3 days. The colonies formed were fixed with Carnoy’s fixative 
and stained with 1% crystal violet. The excess stain was removed by washing with tap 
water and the plates were allowed to air dry and the colonies were counted. The viral 
titre was determined using the following formula. 
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𝑉𝑖𝑟𝑎𝑙 𝑡𝑖𝑡𝑟𝑒 = 𝑚𝑒𝑎𝑛 𝑐𝑜𝑙𝑜𝑛𝑦 𝑛𝑢𝑚𝑏𝑒𝑟 x   
1
𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
 
Using a multiplicity of infection (MOI) of 0.001 for HER2, HER3 and LACZ, PC3 cells 
were transduced with the respective virus and grown in selection medium to establish 
the stably over-expressing cell lines. Western blotting was performed to validate the 
over-expression of HER2 and HER3. The cell lines were continuously maintained in 
selection medium. 
2.15 In-Vivo experiments 
Athymic CD1 nude mice (male; 6 weeks old) were purchased from Harlan UK and 
maintained under aseptic conditions with the use of a laminar air-flow unit. Experiments 
were carried out under a Home Office License alongside the UKCCCR guidelines and 
were approved and reviewed by the Local Animal Welfare Committee. The mice were 
given tap water and fed with a pelleted diet (SDS Ltd, R & M No.3) ad libatum. 
2.15.1 Xenografts 
A total of 1.1 x 107 cells of PC3-HER2, -HER3 and -LACZ in full medium were 
subcutaneously injected into the flanks of nude mice in a final volume of 50 µl (10 mice 
per cell line). The mice were inspected thereafter for signs of tumour development. The 
tumour sizes were measured 3 times a week with callipers and recorded. When the 
tumour size reached 10 x 10 mm or > 15 mm in one dimension, the animals were culled 
and the tumours were excised into full medium containing antibiotics (Penicillin 
100U/ml/Streptomycin 100µg/ml; Sigma Aldrich). The final tumour size was calculated 
by using the formula 
𝑙𝑒𝑛𝑔𝑡ℎ
2
∗ (𝑤𝑖𝑑𝑡ℎ)2 
 The tumours were then divided into 3 parts under sterile conditions and the tumour was 
stored in - 10% formalin (Fisher Scientific) for subsequent histological analysis, liquid 
nitrogen for protein analysis and the final third of the sample was washed in PBS and 
cut up into small pieces with the use of sterile scissors and forceps. The pieces were 
then transferred into an Erlenmeyer flask containing 10 ml of filter sterilised full 
medium which contained antibiotics and collagenase type I (200IU/ml; 6 mg in 10 ml; 
Worthington Biochemical Corporation). The tissue was digested overnight at 37 ºC on 
an orbital shaker at low speed. The next morning, the mixture was pipetted repeatedly 
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with sequentially smaller pipette tips and finally taken though a needle and syringe until 
a broth-like mixture was produced. The cells were spun down at 400g for 5 minutes. 
The supernatant was removed and the pellet was washed twice with PBS. The pellet 
was then re-suspended in 10ml of full medium containing antibiotics and was 
centrifuged at 1000 rpm for 1 minute. The epithelial cell pellet was then re-suspended in 
full medium containing antibiotics and cultured back as cell lines. Blasticidin was 
included in the medium to avoid growth of any mouse cells. 
2.16 Proliferation assays 
2.16.1 Colony formation assay 
1000-2000 cells/well were seeded onto a 6-well plate depending on the cell line and 
treated accordingly the next day depending on the experiment. The cells were allowed 
to form colonies over a period of 14 days after which the medium was removed and the 
cells were washed with PBS. The cells were fixed with Carnoy’s fixative (3:1 
Methanol: Acetic acid) for 1 minute and were allowed to dry. The colonies were then 
stained with 1% crystal violet and counted. 
2.16.2 Sulforhodamine B (SRB) assay 
This assay was performed on 96-well plates where 1000-2000 cells were seeded per 
well depending on the cell line in 90µl of normal growth medium using an Eppendorf 
repeater stream pipette. After 24 hours, the cells were treated with 10µl of 10x drug 
(final concentration 1x in total final volume of 100 µl) or DMSO or left untreated 
depending on the nature of the experiment. After 96 hours, the cells were fixed by 
adding 25µl of 50% ice cold trichloroacetic acid (TCA) for 1 hour at 4 ºC. The cells 
were washed with tap water, dried and 100µl of 0.4% SRB (w/v in 1% acetic acid) was 
added per well and left to stain the cells for 30 minutes at room temperature. The cells 
were then washed with 1% acetic acid to remove excess stain. After drying, the bound 
stain was dissolved by adding 100µl of 10mM Tris (pH 10.8) per well and placing on an 
orbital shaker for 30 minutes at room temperature. The absorbance was then measured 
at 570nm using the BioRad Model 680 microplate reader. 
2.16.3 Cell counts 
Cells were seeded at the required density in a 6-well plate and treated with appropriate 
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drugs depending on the experiment. After 96 hours, the cells were pelleted as mentioned 
in (2.6) and the pellet was re-suspended in 1ml of medium. The number of cells in each 
sample was counted and compared to the control sample. 
2.17 Cell migration and invasion assays 
The cell motility and metastatic potential of PC3 cells over-expressing either HER2 or 
HER3 were tested using the Boyden chambers.  The inserts were made up of PET 
(polyethylene terephthalate) membrane with a membrane pore size of 8µm. The inserts 
were coated with matrigel (composed of extracellular matrix proteins - laminin, 
collagen IV, heparan sulfate proteo-glycan and entactin) for invasion (Corning – Cat 
No. 354480) whereas the uncoated inserts were used to measure migration (Corning – 
Cat No. 353097). The experiment was carried out by placing the inserts in a 24-well 
culture plate. The invasion inserts were pre-treated with basal media prior to the 
experiment according to manufacturer instructions.  600µl of basal media with 
Heregulin (20ng/ml) with or without drug/DMSO was added per well and the inserts 
were placed on top. Depending on the experiment, the cells were not treated, pre-treated 
with drug or control in basal media for 16 hours. The cells were then collected in SDM 
and re-suspended in basal media with or without drug/DMSO. 3x104 cells were seeded 
in a final volume of 300µl in the upper chamber. The cells were allowed to migrate for 
48 hours at 37 ºC and 5% CO2. The cells that hadn’t migrated or invaded were removed 
from the upper part of the chamber by wiping the inside of the insert with a cotton bud. 
The membrane was then fixed with methanol for 30 minutes at -20 ºC, stained with 1% 
crystal violet and the excess stain was removed with tap water. The inserts were then 
allowed to air dry and the membrane was carefully removed from the insert with the 
help of a scalpel. The membrane was then mounted on glass slides (bottom side 
upwards) with the help of DPX mountant. The number of cells was counted using a 
light microscope at 20x magnification. The average number of cells from 8 random 
views per membrane was considered. Each arm of the experiment was tested in 
triplicate and the entire experiment was carried out three times. 
2.18 Luciferase assay 
When LNCaP-7B7 cells were used, the cells were seeded out in quadruplets per 
experimental arm using a 24-well plate. The next day the cells were either starved in 
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SDM for 3 days. For the HER2-3 signalling inhibition, the cells were either treated with 
DMSO, AZD8931 or Enzalutamide (as inhibition control for AR activity). Once the 
experiment was completed, the cells were washed with PBS and lysed using 50 µl of 1x 
reporter lysis buffer (Promega) /well. 10 µl of lysate from each well was transferred 
onto an opaque flat-bottomed 96-well plate.  The plate was then placed in the automated 
FLUOstar Omega (BMG Labtech) plate reader where 50 µl of Steady-Glo luciferase 
substrate (Promega) was injected per well, shaken for 5 seconds and the emitted 
luciferase counts per second was recorded.  The data was then normalised to the protein 
concentration per well by performing a BCA assay on the samples. The average values 
were then used to interpret the results. 
When PC3 cells were used, the cells were seeded out in quadruplets per experimental 
arm using a 24-well plate and were forward transfected (transfection after the cells have 
adhered) with the appropriate plasmids required for the experiment (HER2, HER3, 
MMP9, pCMV and -gal). The experiment was carried out accordingly and once 
completed, the cells were lysed in 1x reporter lysis buffer and luciferase activity was 
recorded as explained above. The results were normalised to the results of a -
galactosidase assay which would reveal transfection efficiency. Briefly, 10 µl of lysate 
from each well was transferred onto a 96-well plate and equal amount of -gal assay 
substrate (2mM MgCl2, 100 mM -mercaptoethanol, 1.33 mg/ml o-nitrophenyl--D-
galactopyranoside (ONPG) and 100 mM sodium phosphate buffer, pH 7.3) was mixed 
and incubated at 37 ºC for 5 minutes. ONPG (substrate of -galactosidase) is cleaved to 
galactose and o-nitrophenol to yield a pale yellow colour. The reaction was then stopped 
by adding 50 µl of 1M Na2CO3 and the absorbance was read at 415 nm using the 
BioRad Model 680 microplate reader. The average values were then used to interpret 
the results. 
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Chapter 3 Aberrant Expression of HER2 and HER3 in Human 
Prostate Cancer 
3.1 Introduction 
Early detection and diagnosis of prostate cancer have been very difficult due to the lack 
of clinical symptoms during disease development. Prostate cancer detection is 
traditionally achieved by performing digital rectal examination, PSA screening and 
histopathological analysis (Venderbos and Roobol, 2011). Due to the heterogeneity of 
the disease, the aggressiveness of the disease can vary from patient to patient. The use 
of biomarkers has helped with the detection and monitoring of the disease.  Prostate 
cancer biomarkers can be classed into different categories; namely diagnostic, 
prognostic, predictive, and pharmacodynamic markers respectively. Diagnostic markers 
help to differentiate between benign and cancerous cell types and the advancement of 
the disease can be evaluated by prognostic markers. As the name suggests, predictive 
biomarkers assess the patient’s response to the given treatment regiment. 
Pharmacodynamic biomarkers help to conclude an appropriate dosage of anticancer 
drug in the initial stages of therapy (Madu and Lu, 2010; Esfahani et al., 2015).  
The most common diagnostic, prognostic and predictive protein marker used in prostate 
cancer detection is prostate specific antigen (PSA). PSA screening has been a popular 
technique in the United States of America, as it is a non-invasive procedure and since its 
use, there has been a decrease in the number of metastatic patients at diagnosis (Cary 
and Cooperberg, 2013). Although being a prostate specific protein marker, PSA is not 
cancer specific.  Elevated PSA levels have been detected in patients with benign 
prostatic hyperplasia leading to false positive tests. The rather poor specificity and 
sensitivity of PSA to cancer have led to needless biopsies and wrong/over diagnosis 
along with overtreatment of dormant disease (Nogueira et al., 2010). Histopathological 
analysis helps to assess the aggressiveness of the cancer by assigning a Gleason grade to 
the cancer. The disease progression however differs between patients.  The disease may 
be inactive or slow progressing, having no significant effect on mortality in some 
patients, while other patients may possess an extremely aggressive form of the disease 
leading to tumour metastasis which plays a substantial role in cancer death (Siddiqui et 
al., 2004; Bickers and Aukim-Hastie, 2009).The limitations of the current biomarkers of 
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prostate cancer have created a sense of urgency and necessity for novel, reliable and 
specific molecular biomarkers that can enhance the detection and clinical monitoring of 
the disease. The current focus in biomarker research involves looking into deregulated 
signalling pathways in the cancer and identifying proteins that could be quantifiable. 
Such proteins and their regulated pathways can also serve as novel therapeutic targets 
along with their use of being diagnostic, prognostic and predictive markers of the 
disease. This kind of clinical screening will be additionally effective, as it will facilitate 
in providing the patients with appropriate and beneficial therapy, based on their 
individual molecular profiling. 
As explained in the introductory chapter, the deregulation of the PI3 Kinase and MAP 
Kinase signalling pathways due to the over-expression of EGFR, HER2 and HER3 has 
been linked to the progression of aggressive prostate cancer. Previous research has 
linked the over-expression of EGFR and HER2 to poor prognostic disease. However, 
the use of EGFR and HER2 inhibitors in prostate cancer has not shown any promise and 
suggests that HER3 could be compensating for the inhibition of EGFR and HER2 (Chen 
et al., 2011). As HER3 is a kinase dead receptor, it requires a dimerization partner to 
carry out its activity. The present study concentrates on the role of HER2-HER3 
heterodimer in prostate cancer, as it the most potent heterodimer when receptor 
phosphorylation and downstream signalling activity is considered (Jathal et al., 2011). 
This chapter focusses on analysing the expression of HER2 and HER3 in clinical 
samples by performing immunohistochemistry on “in-house” constructed tissue 
microarrays (TMAs). These TMAs consist of patient biopsy samples collected over the 
years and serve as valuable tools to investigate protein expression during various stages 
of prostate cancer. The cohort also consists of matched paired biopsy samples that are 
taken from the same patients during different points after their initial diagnosis and 
helps in comparing the protein expression alterations, pre- and post-therapy. There is 
limited available literature on using matched clinical samples and profiling protein 
expression changes. The recorded clinic-pathological data has been used to correlate the 
changes in protein expression to disease progression and patient survival. The 
expression of downstream signalling proteins and other prognostic markers in the 
clinical samples were also analysed. The chapter concludes by also observing the 
protein expression in prostate cancer cell line models that are routinely used in-vitro.  
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3.2 HER2 and HER3 show elevated expression in advanced prostate cancer and 
their expression can be associated with poor prognostic disease - Analysis of 
TMA1 
To evaluate the role of HER2 and HER3 in human prostate cancer, the expression levels 
of HER2 and HER3 in cancer samples was initially examined. This was done by 
performing immunohistochemistry on TMAs. The first TMA consisted of a collection 
of prostate cancer samples across a range of cancer stages taken from patients at the 
time of diagnosis. The results thus indicate the expression levels of the receptors prior to 
any anti-cancer treatment. BPH samples were also included in the TMA for comparison. 
Figure 3-1 is a representative picture of the sample cores of the TMA after performing 
immunohistochemistry. Once stained, the TMA was then scored for nuclear and 
cytoplasmic staining using the histoscore method (2.2.4). Briefly, the method considers 
the intensity of staining and the percentage of cells with the same intensity of staining 
across the sample. The score is calculated by using the formula: 
𝐻𝑖𝑠𝑡𝑜𝑠𝑐𝑜𝑟𝑒 = (1 x % 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ 𝑤𝑒𝑎𝑘 𝑠𝑡𝑎𝑖𝑛𝑖𝑛𝑔) + (2 x % 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ 𝑚𝑜𝑑𝑒𝑟𝑎𝑡𝑒 𝑠𝑡𝑎𝑖𝑛𝑖𝑛𝑔)
+ (3 x % 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ 𝑠𝑡𝑟𝑜𝑛𝑔 𝑠𝑡𝑎𝑖𝑛𝑖𝑛𝑔) 
This method provides a maximum score of 300 (100% cells with strong staining) and a 
minimum of 0 (100% cells with no staining), which makes the data quantifiable. These 
scores were then used with the available patient clinic-pathological data to infer the 
results. 
  
 68 
 
 
Figure 3-1: TMA cores showing cytoplasmic and nuclear staining for HER2 and 
HER3 by immunohistochemistry 
Briefly, the samples were deparaffinised and rehydrated. Antigen retrieval was 
performed in 0.01M sodium citrate buffer pH-6.0 using a decloaker. Endogenous 
peroxide activity was blocked by treating the samples with hydrogen peroxide. The 
samples were then incubated with HER2 and HER3 antibodies at 1:300 dilutions 
overnight at 4ºC. (Concentration validated by performing IHC on test TMA). The 
Menapath kit was used to complete the procedure. A positive (prostate cancer) and 
negative control (secondary antibody only) was included in the experiment.The stained 
slides were then scanned using the Aperio Scanscope CS system (Spectra Healthcare). 
The images were stored in a secure database. The samples were then scored as having 
low expression (0-100), moderate (100-200) and strong (200-300).(A,B) Representative 
BPH samples stained for HER3 showing weak diffused cytoplasmic and moderate 
nuclear staining. The stromal regions as indicated in the picture was not included in the 
scoring process. Cancer samples (C,D,E and F) were similarly scored for low, moderate 
and strong cytoplasmic and nuclear expression. 
  
 69 
 
 
Figure 3-1: TMA cores showing cytoplasmic and nuclear staining for HER2 and 
HER3 by immunohistochemistry 
Cancer samples (C,D,E and F) showing low, moderate and strong nuclear and diffused 
cytoplasmic expression as indicated. 
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3.2.1 Cytoplasmic and nuclear expression of HER2 and HER3 is significantly 
elavated in cancer samples when compared to benign samples 
The differences in expression between benign hyperplasia and cancer samples was 
compared. It was observed that both cytoplasmic and nuclear expression of HER2 and 
HER3 was increased significantly in patients with cancer and not in those with benign 
prostatic hyperplasia. It should be noted that there was no nuclear HER2 expression in 
patients who presented with benign disease (Figure 3-2).  
3.2.2 Cytoplasmic expression of HER3 is elavated with the grade of prostate cancer 
Further comparisons were made across different Gleason grades to observe any 
differential expressions of the receptors in the cellular compartments. The Gleason 
single grades of the samples present on the TMA were considered for the comparison. 
An increase in cytoplasmic HER3 expression, but not nuclear, was revealed with 
increase in Gleason grade. No change in expression was observed across cytoplasmic 
and nuclear HER2 (Figure 3-3). 
3.2.3 Cytoplasmic expression of HER2 and HER3 and nuclear expression of HER2 
is stronger with cancer stage 
The next comparison made was between the stages of the cancer, i.e. if the cancer was 
organ confined or locally invasive at diagnosis. Figure 3-4 shows the observed increase 
in both HER2 and HER3 cytoplasmic expression when the cancer was known to be 
locally invasive. There was also an increase in HER2 nuclear expression when the 
disease was found to be locally invasive. 
3.2.4 Cytoplasmic expression of HER2 is higher in patients who subsequently 
developed metastases after diagnosis 
The samples from the patients were collected by transurethral resection of the prostate 
(TURP). These samples, when obtained, were analysed to see if they were metastatic or 
not. Analysis of the patient records revealed that many patients developed metastases 
post diagnosis. Figure 3-5 and Figure 3-6 show the comparison of receptor expression 
between the cellular compartments upon attaining a metastatic condition.  It was 
observed that HER2 cytoplasmic expression was higher when patients developed 
subsequent metastases. However, no variation in receptor expression was observed in 
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the nuclear compartment with metastases at diagnosis or in patients who subsequently 
developed metastases. 
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Figure 3-2: Cytoplasmic and nuclear expression of HER2 and HER3 is significantly higher in cancer patients when compared to those with BPH 
This figure shows the significantly higher expression of both cytoplasmic (A) and nuclear (B) of HER2 and HER3 in cancer samples. Student t-test 
was performed on the experiments and * indicates statistical significance with p-value <0.05 when compared to the BPH samples. 
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Figure 3-3: Cytoplasmic expression of HER3 is significantly higher with the grade of prostate cancer 
This figure shows the significantly higher expression of cytoplasmic (A) HER3 with Gleason grade of prostate cancer. However, there was no 
significant change in HER2 cytoplasmic expression or nuclear expression of both HER2 and HER3 (B). One-way ANOVA was performed on the 
experiments and * indicates statistical significance with p-value <0.05 when compared to Gleason 3. 
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Figure 3-4: Cytoplasmic expression of HER2 and HER3 is higher with cancer stage 
This figure shows the significantly higher expression of cytoplasmic (A) HER2 and HER3 with cancer stage. There were also a significant changes in 
HER2 nuclear expression (B). Student t-test was performed on the experiments and * indicates statistical significance with p-value <0.05 when 
compared to organ confined disease. 
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Figure 3-5: Comparison of cytoplasmic and nuclear expression of HER2 and HER3 upon metastases on diagnosis 
This figure shows no significant increase of HER2 and HER3 in either of the cellular compartments when the cancer is metastatic at diagnosis. Student 
t-test was performed on the experiments to test for statistical significance. 
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Figure 3-6: Cytoplasmic expression of HER2 is significantly higher in patients who subsequently develop metastases after diagnosis 
This figure shows the significantly higher expression of cytoplasmic HER2 (A) in patients who subsequently develop metastasis after diagnosis. 
However, there was no significant change in HER3 cytoplasmic expression or nuclear expression of both HER2 and HER3 (B). Student t-test was 
performed on the experiments and * indicates statistical significance with p-value <0.05 when compared to metastases –ve samples.
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3.2.5 Strong HER2 and HER3 cytoplasmic expression correlates with poor patient 
survival 
Further comparisons were made to examine the effect of receptor expression on patient 
survival. Figure 3-7 and Figure 3-8 show the correlation of cytoplasmic HER2 and 
HER3 expression on patient survival. The expression levels were categorised into 3 
groups –low, moderate and strong expression.  Kaplan–Meier curves were plotted using 
the available patient survival data against the different receptor expression groups. 
Comparisons were also made by combining the low and moderate expression groups 
and significant differences were observed. 
3.2.6 Strong HER2 nuclear expression correlates with poor patient survival  
Similar comparisons were made for nuclear expression of HER2 and HER3. Only 
HER2 nuclear expression demonstrated a significant correlation with patient survival 
(Figure 3-9 and Figure 3-10).  
3.3 Continued analysis with additional clinical samples – combined analysis of 
TMA1 and TMA4 
It was noticed that certain groups in the analysis had very low patient numbers. A 
second TMA –“TMA4”, was added to the analysis to increase the sample size. Similar 
comparisons were made and Figure 3-11 shows that there is still a significant elevated 
expression of cytoplasmic and nuclear expression of HER2 and HER3 in cancer patients 
when compared to those with BPH. However, all the other comparisons showed no 
difference in cytoplasmic or nuclear expression of the receptors (Figure 3-12 and 
Figure 3-13). It should be noted that there was an overall higher expression of nuclear 
HER3 when compared to HER2, even though there were no significant differences with 
cancer grade and presence of metastases. 
  
  
 
Figure 3-7: Kaplan–Meier curves showing an inverse correlation of HER2 cytoplasmic expression on patient survival 
The staining of the receptors was grouped into low, moderate and strong expression and the available patient survival data was used to estimate the 
correlation of HER2 cytoplasmic expression on survival (A). Due to low patient number in the low expression group, a further comparison was made 
between combined low and moderate expression vs strong expression (B). This comparison shows a significant correlation of HER2 strong 
cytoplasmic expression on patient survival. 
  
 
Figure 3-8: Kaplan–Meier curves showing an inverse correlation of HER3 cytoplasmic expression on patient survival 
The staining of the receptors was grouped into low, moderate and strong expression and the available patient survival data was used to estimate the 
correlation of HER3 cytoplasmic expression on survival (A). A further comparison (similar to HER2 cytoplasmic expression) was made between 
combined low and moderate expression vs strong expression of HER3 (B). Both comparisons show a significant correlation of HER3 strong 
cytoplasmic expression on patient survival. 
  
 
Figure 3-9: Kaplan–Meier curves showing an inverse correlation of HER2 nuclear expression on patient survival 
The staining of the receptors was grouped into low, moderate and strong expression and the available patient survival data was used to estimate the 
correlation of HER2 nuclear expression on survival (A). A further comparison was made between combined low and moderate expression vs strong 
expression (B). Both comparisons show a significant correlation of HER2 strong nuclear expression on patient survival. 
  
 
Figure 3-10: Kaplan–Meier curves showing no correlation of HER3 nuclear expression on patient survival 
The staining of the receptors was grouped into low, moderate and strong expression and the available patient survival data was used to estimate the 
correlation of HER3 nuclear expression on survival (A). A further comparison was made between combined low and moderate expression vs strong 
expression (B). Both comparisons showed no significant correlation of HER3 nuclear expression on patient survival. 
  
  
   
Figure 3-11: Increased sample size (TMA1 and TMA4 together) shows cytoplasmic and nuclear expression of HER2 and HER3 is significantly 
higher in cancer patients when compared to those with BPH 
This figure shows the significantly higher expression in both cytoplasmic (A) and nuclear (B) of HER2 and HER3 in cancer samples. Student t-test 
was performed on the experiments and * indicates statistical significance with p-value <0.05 when compared to the BPH samples. 
  
  
 
Figure 3-12: Increased sample size (TMA1 and TMA4 together) does not show any significant changes in HER2 and HER3 expression with cancer 
grade or stage 
This figure shows the cytoplasmic and nuclear expression of HER2 and HER3 between cancer grades (A) or stage (B). One-way ANOVA was 
performed on the experiments to reveal if there was any statistical significance. It was observed that there were no significant changes of receptor 
expression within the groups 
  
  
 
Figure 3-12: Increased sample size (TMA1 and TMA4 together) does not show any significant changes in HER2 and HER3 expression with cancer 
stage 
This figure shows the cytoplasmic and nuclear expression of HER2 and HER3 between cancer stages (B). One-way ANOVA was performed on the 
experiments to reveal if there was any statistical significance. It was observed that there were no significant changes of receptor expression within the 
groups 
  
  
 
 
Figure 3-13: Increased sample size (TMA1 and TMA4 together) does not show any significant changes in HER2 and HER3 expression with 
metastases 
This figure shows the cytoplasmic and nuclear expression of HER2 and HER3 between patients who presented with or without metastases at diagnosis 
(A) Student t-test was performed on the experiments to reveal if there was any statistical significance. It was observed that there were no significant 
changes of receptor expression within these groups. 
  
 
Figure 3-13: Increased sample size (TMA1 and TMA4 together) does not show any significant changes in HER2 and HER3 expression with 
metastases 
This figure shows the cytoplasmic and nuclear expression of HER2 and HER3 between patients who presented without any metastases at diagnosis and 
those who developed subsequent metastases after diagnosis (B). Student t-test was performed on the experiments to reveal if there was any statistical 
significance. It was observed that there were no significant changes of receptor expression within these groups. 
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3.3.1 Patients presenting with low HER2 and strong HER3 cytoplasmic expression 
and those with low HER2 and strong HER3 nuclear expression have the 
poorest survival rates 
The analysis of the combined TMA cohort was continued by further correlations with 
the patient survival data. When HER2 cytoplasmic expression was analysed, it was 
observed that there was no significant correlations between HER2 expression and 
patient survival (Figure 3-14). However, analysis of HER3 expression revealed a 
significant inverse correlation of HER3 cytoplasmic expression on patient survival 
(Figure 3-15). 
The nuclear expression of HER2 and HER3 was similarly analysed. Patients had poorer 
survival rates with increased HER2 and HER3 nuclear expression (Figure 3-16 and 
Figure 3-17). However, it should be noted that there were very few patient numbers 
with strong nuclear HER2 expression. 
A final comparison was made to analyse the outcome of patient survival by analysing 
the co-expression of HER2 and HER3 (Figure 3-18). 
It was observed that patients who had low/moderate HER2 along with strong HER3 
cytoplasmic expression had the poorest survival rates when compared to the other 
groups. When the nuclear expression was considered, there were no patients who 
presented with both strong HER2 and HER3 expression and strong HER2 and 
low/moderate HER3 together. However, it was observed that patients who had low/ 
moderate HER2 along with strong HER3 nuclear expression had lower survival rates 
than patients who presented with low/ moderate expression of both HER2 and HER3. 
  
  
 
Figure 3-14: Kaplan–Meier curves showing the correlation of HER2 cytoplasmic expression on patient survival upon analysis of samples taken from 
2 TMAs  
The staining of the receptors was grouped into low, moderate and strong expression and the available patient survival data was used to estimate the 
correlation of HER2 cytoplasmic expression on survival (A). Due to low patient numbers in the low expression group, a further comparison was made 
between combined low and moderate expression vs strong expression (B). Both comparisons revealed no significant correlation of HER2 cytoplasmic 
expression on patient survival. 
  
 
Figure 3-15: Kaplan–Meier curves showing an inverse correlation of HER3 cytoplasmic expression on patient survival upon analysis of samples 
taken from 2 TMAs  
The staining of the receptors was grouped into low, moderate and strong expression and the available patient survival data was used to estimate the 
correlation of HER3 cytoplasmic expression on survival (A). Due to low patient numbers in the low expression group, a further comparison was made 
between combined low and moderate expression vs strong expression (B). Both comparisons revealed a significant correlation of HER3 cytoplasmic 
expression on patient survival. 
  
 
Figure 3-16: Kaplan–Meier curves showing an inverse correlation of HER2 nuclear expression on patient survival upon analysis of samples taken 
from 2 TMAs 
The staining of the receptors was grouped into low, moderate and strong expression and the available patient survival data was used to estimate the 
correlation of HER2 nuclear expression on survival (A). A further comparison was made between combined low and moderate expression vs strong 
expression (B). Both comparisons revealed a significant correlation of HER2 nuclear expression on patient survival. There were very few patients who 
presented with strong nuclear HER2 expression. 
  
 
Figure 3-17: Kaplan–Meier curves showing an inverse correlation of HER3 nuclear expression on patient survival upon analysis of samples taken 
from 2 TMAs 
The staining of the receptors was grouped into low, moderate and strong expression and the available patient survival data was used to estimate the 
correlation of HER3 nuclear expression on survival (A). A further comparison was made between combined low and moderate expression vs strong 
expression (B). The second comparisons revealed a significant correlation of strong HER3 nuclear expression on patient survival. 
  
 
Figure 3-18: Kaplan–Meier curves showing an inverse correlation of HER2 and HER3 differential expression on patient survival upon analysis of 
samples taken from 2 TMAs 
The staining of the receptors was grouped into 4 groups for combined cytoplasmic expression of HER2 and HER3 as indicated in the figure (A). The 
available patient survival data was used to estimate the correlation of their combined expression on patient survival. This analysis revealed that patients 
who expressed low /moderate levels of HER2 along with strong levels of HER3 had the worst outcome. For the combined nuclear expression, only 2 
groups could be formed due to limited sample number (B). This analysis revealed that patients who had low HER2 along with strong HER3 nuclear 
expression showed a significant decrease in their survival rates.   
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3.3.2 Patients who developed castrate resistant prostate cancer presented with 
higher nuclear HER3 expression along with a loss of PTEN expression 
A separate TMA – “TMA5”, was considered and the expression of HER2, HER3, 
tumour suppressor gene – PTEN and pAKT - the downstream protein of HER2 and 
HER3 signalling pathway, were analysed. This TMA was of particular interest because 
it consisted of matched paired samples i.e. samples taken from the same patient before 
and after they received treatment. The pairs were divided into 3 groups – hormone naïve 
group which consisted of patients who had not received any treatment; hormone 
sensitive group which consisted of patients who had received androgen withdrawal 
therapy and were sensitive and continued to be sensitive to the treatment and the 
castrate resistant group, which consisted of patients who received treatment but had 
relapsed and presented with castrate resistant prostate cancer. There were no significant 
differences in receptor expression between the hormone naïve and hormone sensitive 
groups (Figure 3-19). However, the analysis revealed a significant increase in HER3 
nuclear expression in patients who developed castrate resistant disease (Figure 3-20). 
The groups were also analysed for the loss of PTEN expression. It was observed that in 
the castrate resistant group 33.33% of samples had loss of PTEN which was a 
significant increase from the hormone sensitive group (6.25%) and hormone naïve 
group (4.35%) (Figure 3-21). However, no change in pAKT was observed between the 
three groups (Figure 3-22). 
The analysis of the clinical samples proves that HER2 and HER3 expression plays a 
crucial role in advanced prostate cancer and inhibiting its signalling activity could help 
in cancer regression. 
 
  
 
Figure 3-19: HER2 and HER3 expression does not change between matched patients who belonged to the treatment naïve group vs those who were 
sensitive to treatment 
 (A, B) There was no significant change in cytoplasmic and nuclear expression of HER2 and HER3 in matched samples from patients who were 
screened at an early and later stage. These patients had not received any treatment.   
  
 
Figure 3-19:  HER2 and HER3 expression does not change between matched patients who belonged to the treatment naïve group vs those who were 
sensitive to treatment (C, D) There was no significant change in the receptor expression in matched samples from patients who were screened before 
treatment and after they showed signs of being sensitive to the treatment. 
  
 
Figure 3-20: HER3 cytoplasmic and nuclear expression is significantly higher in matched patients who relapsed after being sensitive to therapy 
  
 (A) There was a significant change in cytoplasmic expression of HER3 in matched samples taken from patients who were screened after they received 
treatment and after they relapsed following treatment. (B) There was a significant change in nuclear HER3 expression in matched samples taken from 
patients who were screened after they were sensitive to treatment and after they relapsed following treatment. Student t-test was performed on the 
experiments and * indicates statistical significance with p-value <0.05 when compared to the treatment sensitive group. 
 
Figure 3-21: PTEN loss is observed in patients who become sensitive to treatment and in those who relapse after receiving treatment. 
  
 (A) There was no significant change in PTEN expression in matched samples from patients who were screened for prostate cancer at different stages. 
These patients had not received any treatment.  However, a reduction in PTEN expression was observed in matched samples from patients who were 
screened before treatment and after they showed signs of being sensitive to the treatment (B) and in samples who eventually relapsed (C). Student t-test 
was performed on the experiments and * indicates statistical significance with p-value <0.05 when compared to the treatment naïve and sensitive group 
respectively. (Staining performed by Luke Martinson). 
 
 
Figure 3-21: PTEN loss is observed in patients who become sensitive to treatment and in those who relapse after receiving treatment. 
Representative patient samples showing strong expression of PTEN while they were sensitive to treatment (D) and reduced expression when they 
relapsed with aggressive disease (E) (Staining performed by Luke Martinson).  
  
 
 
Figure 3-22: There is no change on pAKT levels in matched paired patient samples between the treatment naïve, treatment sensitive and relapsed 
groups. 
pAKT levels were screened in matched paired samples between 3 groups of patient samples – naïve group consisted of patients who were screened at 
different time points after being diagnosed with prostate cancer (A); Naïve/sensitive group consisted of samples from patients who hadn’t received any 
treatment and then who showed sensitivity to the treatment (B) and the sensitive / relapsed group which consisted of patients samples that were 
sensitive to treatment but subsequently relapsed with aggressive prostate cancer (C). There were no significant changes in pAKT levels in all the 3 
groups. (Staining performed by Luke Martinson)..
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3.4 Validating the expression of HER2 and HER3 in prostate cancer cell lines 
After analysing the expression in clinical samples, the validation of receptor expression 
was continued in prostate cancer cell lines that were to be used in this project. The cell 
lines used were LNCaP and their derivative cell lines LNCaP–AI. The androgen –
independent LNCaP–AI cell line was established by growing LNCaP cells in steroid 
depleted conditions and is used as a model of prostate cancer under androgen 
withdrawal conditions. Both the cell lines showed good levels of expression with and 
without Heregulin stimulation (Figure 3-23). 
 
Figure 3-23: Expression of HER2 and HER3 in prostate cancer cell lines 
The cells were seeded out in full medium (FM). The next day, the cells were washed 
with PBS and the media were changed on the control and treatment arms of the 
experiment to basal medium (BM) to starve the cells. After an overnight incubation, the 
cells were treated with Heregulin (HRG; 20 ng/ml) for 15 minutes after which the cells 
were lysed in RIPA buffer and the lysates were analysed for HER2 and HER3 
expression by western blotting. The above result is a representation of 2 repeats. 
3.5 Cellular localisation of HER2 and HER3 
Having observed the nuclear localisation of these receptors in the clinical samples, the 
finding was further investigated in-vitro and the LNCaP cell line was used for 
validation. It was observed that when the cells were treated with Heregulin, both HER2 
and HER3 translocated to the nucleus. This finding was confirmed by 
immunofluorescence (Figure 3-24) and western blotting (Figure 3-25). 
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Figure 3-24: HER2 and HER3 translocate to the nucleus with Heregulin stimulation 
LNCaP cells were seeded out in full medium on sterile coverslips. The next day, the 
relevant arms of the experiment were starved in basal medium overnight followed by 
treatment with Heregulin (HRG; 20 ng/ml) for 2 hours. The cells were then fixed onto 
the coverslips with 4% paraformaldehyde and permeabilized using chilled methanol. 
This was followed by blocking the cells with serum-free protein block, to avoid 
unspecific binding of primary antibody. The cells were incubated with the respective 
primary antibodies for 1 hour at room temperature. After the incubation, the cells were 
washed with PBS, followed by incubation with appropriate Alexa-Fluor secondary 
antibodies for another hour at room temperature. The cells were finally washed with 
PBS and mounted on the glass slides using Vectashield mountant containing DAPI to 
stain the nucleus. The images were observed under confocal microscope using Z-stack 
imaging taking of sections of 1 micron thickness. Appropriate secondary only negative 
controls were used to ensure specificity. The above result is a representation of 2 repeats 
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Figure 3-25: Total and phosphorylated forms of HER2 and HER3 translocate to the 
nucleus after Heregulin stimulation 
LNCaP cells were seeded out in full medium. The following day, the medium was 
changed to basal medium on the control and the samples to be treated with Heregulin. 
After starving the cells overnight, the cells were treated with Heregulin (HRG; 20 
ng/ml) for 30 minutes and 2 hours as indicated. The cells were then lysed and the 
cytoplasmic and nuclear compartments of the cells were then separated by following the 
protocol of the extraction kit. The lysates were then analysed for cytoplasmic (A) and 
nuclear (B) protein expression by western blotting. α-tubulin and PARP were used as 
controls for the cytoplasmic and nuclear compartments, respectively. The result 
revealed that Heregulin aided the total and active forms of the receptors to shuttle into 
the nucleus. The above result is a representation of 2 repeats
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3.6 HER2 and HER3 translocate to the nucleus and is also present in the 
chromatin fraction upon Heregulin stimulation 
The presence of these receptors in the nuclear compartment was further investigated. 
The remaining chromatin samples, extracted from the above experiment, were analysed 
by western blotting, using appropriate controls. Upon analysis it was observed that 
HER2 and HER3 were present in the chromatin fraction upon Heregulin stimulation 
(Figure 3-26). 
  
Figure 3-26: HER2 and HER3 shows association with chromatin upon Heregulin 
treatment 
LNCaP cells were seeded out in full medium. The following day, the medium was 
changed to basal medium on the control and the samples to be treated with Heregulin. 
After starving the cells overnight the cells were treated with Heregulin (HRG; 20ng/ml) 
the following day for 30 minutes and 2 hours. The cells were then lysed and the 
cytoplasmic and nuclear compartments of the cells were then separated by following the 
protocol of the extraction kit. The insoluble pellet left behind was sonicated in laemmli 
buffer. The chromatin samples were then analysed for the presence of total HER2 and 
HER3 and their phosphorylated forms by western blotting. α-tubulin and histone H4 
were used as controls. The result revealed that Heregulin aided the total and active 
forms of the receptors to be associated with the chromatin. The above result is a 
representation of 2 repeat 
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3.7 Discussion 
There is an essential need for reliable and specific biomarkers that can differentiate 
between benign and aggressive prostate disease. The use of the historic biomarker, PSA, 
has resulted in over-dosing and treatment due to its lack of specificity, as it is present in 
both normal and diseased prostate cells (Crawford et al., 2014). There has been a 
significant amount of research carried out to identify new, more specific biomarkers for 
prostate disease and its different stages. Due to the variability of disease between 
patients, it would be useful to screen patients for biomarkers before, during and after 
therapy. The patient’s individual molecular profile can then be used to monitor and 
direct the patient towards more appropriate and beneficial therapies. 
Prostate cancer progression has been linked to various mechanisms as explained earlier 
in the introductory chapter. The role of HER3 in prostate cancer is still poorly 
understood and the available data on clinical samples is not consistent and reveals some 
contradictions. For example, Koumakpayi et al. (2006) have observed higher nuclear 
HER3 in hormone-refractory disease, whereas Carlsson et al. (2013) have observed a 
downregulation in HER3 expression in prostate metastases. Since this project is 
focussed on the role of HER2 and HER3 expression and signalling in prostate cancer, 
an initial screen for these receptors was performed using clinical samples. 
Immunohistochemistry was performed using tissue microarrays that consisted of benign 
and prostate cancer samples. The recorded patient data was used to draw correlations 
between the protein expression and disease. The stained TMAs were scored for 
cytoplasmic and nuclear expression using the histoscore method, which made the data 
quantifiable. 
Upon analysis, a significant increase in both cytoplasmic and nuclear expression of 
HER2 and HER3 was observed in cancer samples when compared to BPH samples 
(Figure 3-11). When the expression between different Gleason grades, cancer stages 
(Figure 3-12) and the presence of metastasis (Figure 3-13) was considered, it was 
observed that there was no significant differences between HER2 and HER3 expression. 
However, there remained a higher nuclear expression of HER3 in advanced and 
metastatic disease. The data of TMA1 alone revealed significant differences between 
the cytoplasmic HER2 and HER3 expression in all these groups (Figure 3-3, Figure 
3-4, Figure 3-5 and Figure 3-6). Upon close analysis of the data in these groups, it was 
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observed that the additional samples had stronger expression of receptor expression in 
groups that were previously seen to have low expression. Also, the additional TMA did 
not result in adding equal number of patient data to all the groups to be analysed. Hence 
it will be interesting to continue the expression analysis by adding the appropriate 
number of patient samples (based on a power calculations) in each data set to ensure 
equal sample distribution leading to a more accurate correlation of the data sets. The 
available patient records were used to correlate HER2 and HER3 cytoplasmic and 
nuclear expression with patient survival. When the independent cytoplasmic scores 
were considered, only strong HER3 expression significantly correlated with poor patient 
survival (Figure 3-15). Both HER2 and HER3 strong nuclear expression significantly 
correlated with survival outcome (Figure 3-16). However, it must be noted that there 
were very few patients who presented with high nuclear HER2.  
The data from the matched paired patient samples suggests the importance of HER3 
expression in advanced disease. In the treatment naïve group, the data suggests a trend 
to increasing nuclear HER3 expression as the disease progresses. A similar trend in 
increasing cytoplasmic and nuclear HER3 expression was observed in patients who 
showed sensitivity to treatment (Figure 3-19). Interestingly, there was a significant 
increase in both cytoplasmic and nuclear HER3 in patients who relapsed from the 
treatment (Figure 3-20). This result provides new insight to one of the many 
mechanisms adopted by advanced disease to survive and evolve. Another such 
mechanism, the reduction of the tumour suppressor gene PTEN, has been previously 
observed and described in prostate cancer (McMenamin et al., 1999; Squire, 2009). The 
results herein are in agreement with these findings with the observation of a significant 
reduction in PTEN expression in patients who subsequently relapsed with a more 
aggressive disease after being sensitive to treatment. (Figure 3-21). PTEN loss has also 
been researched for its use as a predictive biomarker and could be useful and analysis of 
clinical samples has shown some direct correlation of PTEN loss and disease 
aggressiveness (Ahearn et al., 2016). However there were no changes in the pAKT 
expression between the matched-paired samples used in this study (Figure 3-22). Upon 
analysis of the patient pairs it was seen that majority of the samples did not have a 
complete PTEN loss suggesting that the activation of this pathway could still be 
regulated and hence not resulting in a dramatic increase in pAKT. Saying this, the 
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expression of pAKT was still strong between all the groups suggesting that the pathway 
remains active in aggressive disease. 
When co-expression of HER2 and HER3 was evaluated, patients who presented with 
low HER2 along with strong HER3 cytoplasmic expression had the worst prognosis. 
Similarly, patients who co-expressed low levels of nuclear HER2 along with strong 
nuclear HER3 showed poorer survival rates (Figure 3-18). There has been no previous 
published data analysing the co-expression of HER2 and HER3 expression in prostate 
cancer and correlating it to patient survival. The results obtained from this study using 
clinical material, suggests that these receptors, particularly HER3, could play an 
important role in advanced prostate cancer. 
The observed data from the clinical samples encouraged the analysis of the expression 
of these receptors in-vitro. Two prostate cancer cell lines that serve as models to study 
the different stages on prostate cancer were used. LNCaP and their derivative LNCaP-
AI typically represent androgen dependent and androgen-independent prostate cancer. 
Upon analysis using western blotting, it was observed that these receptors show 
substantial co-expression of HER2 and HER3 (Figure 3-23). An upregulation of 
receptor expression was also observed upon Heregulin treatment suggesting that the 
activation of the signalling pathways could be causing stabilisation of the receptors. It 
will be interesting to study the stabilisation mechanisms for these receptors in prostate 
cancer. The nuclear expression of HER2 and HER3 was also investigated in-vitro after 
observing their expression in clinical samples. LNCaP cells were stimulated with 
Heregulin and analysed for HER2 and HER3 expression using immunofluorescence. It 
was observed that both HER2 and HER3 are translocated to the nucleus when they are 
activated (Figure 3-24). This finding was validated by analysing the different protein 
expression, in the different cell compartments, by performing nuclear-cytoplasmic 
extractions. Both the total and active phosphorylated forms of HER2 and HER3 were 
present in the cytoplasm and nucleus upon activation by the addition of Heregulin 
(Figure 3-25). The study of nuclear HER2 and HER3 has been quite limited and very 
little data exists of their presence in prostate cancer cell lines. Koumakpayi et al. (2006) 
observed an increased presence of nuclear HER3 in AR-positive cell lines and 
suggested a link to AR regulation. There have been reports in other cancers suggesting 
that these receptors could be acting as transcription factors for key survival and 
proliferation genes (Xie and Hung, 1994; Wang et al., 2004). To investigate these 
findings further in prostate cancer, chromatin extraction was performed. It was observed 
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that upon Heregulin treatment, there was increased association of these receptors to 
chromatin (Figure 3-26). The active phosphorylated forms of HER2 and HER3 were 
also found to be associated with chromatin. The presence of the active forms in the 
nucleus and them being bound to chromatin is a novel finding using a prostate cancer 
cell line. 
The data presented in this chapter validates the expression of HER2 and HER3 in 
prostate cancer and also brings new insight to their role in the advancement and 
sustenance of the disease. The analysis of patient samples has suggested that the disease 
progression is reliant on HER2 and HER3 signalling and can be significantly correlated 
to poor prognosis. The presence of these receptors in the nucleus also provides an 
interesting avenue for further research. The investigation was continued by focussing on 
the functionality of these receptors in prostate cancer and these findings are discussed in 
the next chapter. 
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Chapter 4 The Association of HER2 and HER3 Over-expression and 
Aggressive Prostate Cancer 
4.1 Introduction 
The development of prostate cancer is commonly a slow process and can take several 
years to progress (Freedland et al., 2005). The tumour initially originates in the prostate 
gland due to increased proliferation of prostate cells and can eventually invade 
surrounding organs like the seminal vesicles, bladder and urethra. As the cancer 
progresses, the proliferating cells make use of the blood and lymphatic system to reach 
distal sites in the body and causing the disease to affect other organs which include 
liver, lungs and bones (Lynch and Lynch, 1996; Jin et al., 2011). Prostate cancer is 
initially treated by surgery or radiotherapy and more progressive disease is then treated 
by androgen –withdrawal therapy. However, the latter treatment is only temporarily 
effective as the disease progresses and attains a more aggressive nature, causing the 
cancer to recur. One of the causes that has been associated with cancer relapse is the 
disruption in cell signalling pathways within the cancer microenvironment (Culig et al., 
1994; Lonergan and Tindall, 2011). There have been many signalling pathways that 
have been associated with the advancement of prostate cancer including the MAP 
Kinase and the PI3 Kinase pathways (da Silva et al., 2013). 
MAP Kinase and PI3 Kinase pathways are known for their role in assisting tumour 
growth and metastasis in many types of cancer (Dhillon et al., 2007). The MAP Kinases 
have been known to regulate various intracellular process including gene expression, 
cell differentiation and cell growth. The MAPK/ERK pathway is known to be activated 
by receptor tyrosine kinases such as EGFR, HER2 and HER3. This activation then leads 
to a signalling cascade causing the downstream protein ERK to become phosphorylated 
which in turn leads to the activation of a variety of transcription factors that control cell 
proliferation, differentiation and migration (Yarden, 2001). The PI3K/AKT pathway can 
also be activated by EGFR, HER2 and HER3 amongst other RTKs and cytokine 
receptors. The functioning pathway leads to the activation of AKT which then regulates 
other transcription factors similarly assisting in cell survival and proliferation (Manning 
and Cantley, 2007).  
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Signalling through the EGFR, HER2 and HER3 receptors and their roles in regulating 
the MAP Kinase and PI3 Kinase pathways has been an interesting subject for research 
and has led to a deeper understanding of their molecular signatures. These receptors can 
be activated by a variety of ligands as explained in section 1.6.2. Upon ligand binding, 
the receptors change their conformation which assists in the formation of homodimers 
or heterodimers. The receptors then propagate the downstream signalling process by the 
transphosphorylation of the dimers. Amongst all the HER receptors, HER2 is the 
favoured partner for dimerization (Graus-Porta et al., 1997). The association of HER2 
and HER3 forms the most potent heterodimer combination as HER2 allows a slow rate 
of ligand disassociation and receptor internalisation and HER3 allows the most efficient 
cross phosphorylation of the receptors and creates docking sites for the recruitment of 
downstream signalling components. Signalling via these receptors is prolonged and 
causes enhanced cellular responses such as proliferation, migration and invasion 
(Zaczek et al., 2005; Baselga and Swain, 2009).  
As previously described, the androgen receptor plays a crucial role in prostate cancer 
development and progression. Various theories, including the outlaw pathway, suggest 
that signalling mediated via receptor tyrosine kinases have a significant effect on AR 
activity in prostate cancer. Previous research has associated the over-expression of 
EGFR and HER2 with poor prognostic disease in many cancers, including prostate 
cancer. However, therapies targeting these receptors haven’t been successful. HER3 has 
since become an attractive area of interest and research in other malignancies has 
suggested a link to the receptor’s over-expression and acquiring therapeutic resistance 
(Sergina et al., 2007; Jiang et al., 2012). 
One of the crucial processes required for the malignant transformation of solid tumours 
includes tumour cell migration and invasion and, as mentioned above, is regulated by 
different signalling pathways. The degradation of the extracellular matrix is an essential 
step in achieving metastasis (Jin et al., 2011). Proteinases such as matrix 
metalloproteinases (MMPs) help in the degradation of the surrounding extracellular 
matrix and assist tumour progression. Previous studies have revealed that deregulated 
signalling pathways have led to increased MMP expression (Overall and Lopez-Otin, 
2002).  
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The data collected from the previous chapter has shown increased expression of both 
HER2 and HER3 in advanced prostate cancer. Particularly, the observed increased 
expression of HER3 in advanced disease has warranted further investigation. This 
chapter focusses on understanding the activity and the functional importance of the 
HER2-HER3 heterodimer in prostate cancer.  For this study, the expression levels of 
both these receptors have been manipulated by creating relevant cell line models and 
they have been assessed and validated by using a range of functional assays that are 
used in monitoring key cellular processes in metastatic disease 
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4.2 Transient over-expression of HER2 and HER3 increases downstream 
signalling of PI3 Kinase and MAP Kinase pathways 
The analysis of prostate cancer tissue samples and cell lines shows that HER2 and 
HER3 are over-expressed in this disease. To investigate their role in the disease, HER2 
and HER3 stably over-expressing cell lines were established from PC3 cells, an AR 
negative prostate cancer cell line, expressing low levels of these proteins. It also has low 
activation of MAP Kinase and PI3 Kinase pathways hence serves as a good model to 
study the activation of these pathways when HER2 and HER3 are overexpressed. The 
empty vector lane shows relatively low levels of HER2 and HER3 expression which are 
increased by transfection of HER2 and HER3 plasmids (Error! Reference source not 
ound.). 
 
Figure 4-1: Validation of expression of HER2 and HER3 in PC3 cells 
PC3 cells were forward transfected either with empty vector, pIRES-HER2, pIRES-
HER3 or pIRES-HER2 and pIRES-HER3 plasmids together in full medium for 72 
hours. Empty vector was used as a control and to ensure equal plasmid concentration (2 
µg) was added to each experimental arm. The cells were then lysed in RIPA buffer and 
analysed for HER2 and HER3 expression levels The above figure is a representation of 
2 repeats. 
The downstream effects of HER2 and HER3 over-expression were further investigated 
upon Heregulin stimulation. It was observed that both the MAP Kinase and PI3 Kinase 
pathways showed increased signalling activity (Figure 4-2). 
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Figure 4-2: HER2 and HER3 over-expression causes increased signalling of MAP 
Kinase and PI3 Kinase pathways 
PC3 cells were forward transfected either with empty vector, pIRES-HER2, pIRES-
HER3 or pIRES-HER2 and pIRES-HER3 plasmids together in full medium. Empty 
vector was used as a control and to ensure equal plasmid concentration (2 µg) was 
added to each experimental arm. The following day the cells were starved overnight in 
basal medium followed by 15 minutes of Heregulin (HRG; 20 ng/ml) treatment. The 
cells were then lysed in RIPA buffer and analysed for HER2 and HER3 expression 
levels along with pERK5 and pAKT levels to observe the activity of MAP Kinase and 
PI3 Kinase pathways, respectively. Increased expression of both pERK5 and pAKT 
indicated increased signalling of their pathways caused by the over-expression of HER2 
and HER3 The above figure is a representation of 2 repeats. 
4.3 Generation of HER2 and HER3 over-expressing cell lines 
4.3.1 Lentivirus production 
Lentiviral particles containing HER2 and HER3 were produced as mentioned in 2.14.1.  
Briefly, HER2 and HER3 were amplified from pIRES plasmids using a forward primer 
that contains at 5’ – CACC overhang sequence to promote directional cloning into the 
pENTR/D-TOPO vector and it was ensured that the sequence did not contain the stop 
codon to retain the sequence in-frame with the C-terminal V5 tag following 
recombination into pLenti6/V5-DEST vector.  HER2 and HER3 amplification was 
verified by agarose gel electrophoresis and sequencing (Figure 4-3 (A)). Primers were 
designed to verify the gene sequence by referring to The National Center for 
Biotechnology Information (NCBI) database. HER2 (NCBI Reference Sequence - 
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M11730.1) amplicon was confirmed to be 3869 bp and HER3 (NCBI Reference 
Sequence - NM_001982.3) as 4097 bp in size. 
 
 Figure 4-3: Confirmation of PCR and cloning by agarose gel electrophoresis 
(A) PCR amplicons of HER2 and HER3 along with their respective negative controls 
were run and visualised on a 1% agarose gel (B) The HER2 and HER3 amplicons were 
cloned into the pENTR/D-TOPO vector. The transformed clones (lanes1-9) were run on 
an agarose gel and the positive clones (Lane 3) were selected and used for further 
analysis. 
After cloning into the pENTR/D-TOPO vector, positive clones were identified by 
agarose gel electrophoresis (Figure 4-3 (B)) and were then mini-prepped and the 
directional cloning and gene sequence was confirmed by Sanger gene sequencing by 
using primer sequences that covered the entire gene.  A confirmed clone was then 
incubated with the pLenti6/V5-DEST vector to clone the gene from the pENTR/D-
TOPO vector by homologous recombination.  Clones were transformed, selected by 
antibiotic selection, mini-prepped and confirmed by agarose gel electrophoresis, 
restriction digestion (Figure 4-4) and Sanger sequencing. The correct clone was then 
used to generate viral particles. 
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Figure 4-4: Confirmation of directional cloning by restriction digestion.  
The sequences of the gene and the vector were analysed for restriction sites using the 
online tool restriction mapper. 1µg of pLenti6/V5-DEST with the insert was then 
digested using the restriction enzyme XhoI according to the guidelines. Successful 
digestion would yield 3 fragments of sizes 8016bp, 2460bp and 587bp if the insert was 
integrated in the correct direction as seen above. 
4.4 Profiling established cell lines 
The titre for the virus was established and PC3-LACZ, -HER2 and -HER3 lines were 
generated as mentioned in (2.14). Briefly, the respective viruses were transduced to PC3 
cells with the same MOI and the transduced cells were selected by Blasticidin antibiotic 
selection. 
4.4.1 Validating HER2 and HER3 expression in the established stable cell lines 
The V5 antibody was first validated to detect the over-expressed proteins. Whole cell 
lysates were analysed by western blotting using the V5 antibody. However, the antibody 
presented with a non-specific band in the non-transduced sample at approximately the 
same size of the HER2 and HER3 proteins as seen in Figure 4-6. For this reason, only 
total HER2 and HER3 antibodies have been used to investigate the protein expression in 
the over-expressing cell lines. Over-expression of HER2 and HER3 was confirmed in 
the cell lines (Figure 4-7) after which the cells were analysed to check for any 
functional differences. 
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Figure 4-5: Schematic of lentiviral production using the pLenti expression system 
(Invitrogen)   
 118 
 
Figure 4-6: Western blot using the V5 antibody.  
PC3 cells were transduced with increasing amounts of HER3 lentivirus. The next day 
the medium was changed and the cells were allowed for grow for another 24 hours after 
which the cells were lysed in RIPA buffer and analysed by western blotting. 
Unfortunately, this antibody could not be used in subsequent experiments as the non-
transduced sample presented with a non-specific band at approximately the same size of 
HER2 and HER3.  
 
Figure 4-7: Western blot analysis confirming over-expression of HER2 and HER3. 
Over-expressing cell lines were seeded out in 6-well plates. The next day, the medium 
was changed with selection medium and the cells were allowed to grow for 24 hours 
after which they were lysed in RIPA buffer and the whole cell lysates were analysed for 
total HER2 and HER3 expression The above figure is a representation of 2 repeats. 
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4.4.2 HER2 and HER3 over-expression leads to increased PI3 Kinase and MAP 
Kinase signalling 
Potential functional changes due to the increased expression of HER2 and HER3 were 
analysed by observing the changes in their signalling pathways. The cell lines were 
treated with Heregulin and the downstream proteins of the PI3 Kinase and MAP Kinase 
pathways were analysed. An increase in pAKT and pERK5 levels was observed in the 
over-expressing cell lines (Figure 4-8) suggesting that these cell lines maintain higher 
signalling activity that are controlled by HER2 and HER3. 
 
Figure 4-8: HER2 and HER3 over-expression leads to increased PI3 Kinase and 
MAP Kinase signalling. 
PC3-LACZ, -HER2 and -HER3 over-expressing lines were seeded out in full medium. 
The following day, the cells were starved overnight in basal medium and the next day 
they were treated with Heregulin (HRG; 20ng/ml) for 15 minutes. The cells were then 
lysed in RIPA buffer and the lysates were analysed for protein expression using western 
blotting. The figure shows the over-activation of both HER2 and HER3 along with that 
of pERK5 and pAKT. The above figure is a representation of 2 repeats. 
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4.4.3 HER2 and HER3 over-expression leads to increased cell growth 
Any changes in cell growth due to expression of HER2 and HER3 were analysed by 
performing SRB assays. The PC3-LACZ line was used as a control. The analysis 
revealed increased cell growth in HER2 and HER3 over-expressing cell lines (Figure 
4-9). This result was further validated by performing cell count changes over 96 hours 
of proliferation (Figure 4-10). 
 
Figure 4-9: HER2 and HER3 over-expression causes increased cell growth 
Briefly, the different cell lines were seeded out in a 96-well plates.  The cells were 
allowed to grow for 96 hours in full medium after which the cells were fixed with 
chilled 50% trichoroacetic acid (TCA) for 1 hour at 4 ºC. The cells were then washed 
with tap water, dried and stained with 0.4% SRB in 1% acetic acid for 30 minutes at 
room temperature. Excess staining was prevented by rinsing the cells in 1% acetic acid. 
The retained dye on the cells was then dissolved in 10mM Tris (pH 10.8) and the 
absorbance was recorded at 570nm. The experiment was repeated 3 times and the data 
was normalised to PC3-LACZ. Student t-test was performed on the experiment and * 
indicates statistical significance with p-value <0.05 when compared to the control 
LACZ line. 
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 Figure 4-10: HER2 and HER3 over-expression causes increased cell proliferation 
Briefly, 100,000 cells of each cell line were seeded in full medium on a 6-well plate. 
The following day, the medium was changed to selection medium and the cells were left 
to grow for 96 hours. The cells from each cell line were then counted using a 
haemocytometer. Each cell line was counted 3 times and the experiment was performed 
3 times. The changes in proliferation were calculated using GraphPad Prism. Student t-
test was performed on the experiments and * indicates statistical significance with p-
value <0.05 when compared to the control LACZ line. 
4.4.4 HER2 and HER3 over-expression leads to an increase in cell migratory 
potential 
Since HER2 and HER3 are over-expressed in advanced prostate cancer, it was 
hypothesised that these proteins could have an impact on cell migration. To test this 
hypothesis, the association between the differential expression of HER2 and HER3 and 
matrix metallopeptidase 9 (MMP-9) was investigated. 
Matrix metallopeptidase 9 (MMP-9) 
MMP-9 belongs to the family of proteases called matrix metalloproteinase (MMP). 
These proteins are involves in breaking down the extracellular matrix. Their activity has 
been linked with cancer, immunological and cardiovascular diseases. In cancer, they 
initiate tumour migration, invasion and angiogenesis by degrading the extracellular 
matrix and collagen IV in the basement membrane (Groblewska et al., 2012). 
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4.4.5 HER2 and HER3 over-expression increases MMP-9 transcription  
The activity of MMP-9 was assessed by a luciferase reporter assay. This was performed 
by using a construct that had the luciferase gene linked downstream to the MMP-9 
promoter. PC3 cells were used for this experiment and they were transfected with either 
empty vector as control or HER2 and HER3 plasmids. MMP-9 transcription was found 
to be increased in the presence of HER2, HER3 and both receptors (Figure 4-11). 
 
Figure 4-11: HER2 and HER3 increases MMP-9 promoter activity 
PC3 cells were seeded out in quadruplets per experimental arm using a 24-well plate 
and were forward transfected with 100 ng of MMP9, 50 ng of gal and 300 ng of HER2 
and HER3. pCMV empty vector was used for the control and to ensure equal amounts 
of plasmid were added to all the experimental arms. The cells were then starved in basal 
medium overnight and treated with Heregulin (20 ng/ml) for 24 hours to activate HER2 
and HER3 receptors. The cells were then lysed and luciferase substrate was added. The 
emitted luciferase counts were measured using a plate reader. A -Gal assay was 
performed on the same samples and the data obtained was used to normalise for 
luciferase activity. Student t-test was performed on the experiments and * indicates 
statistical significance with p-value <0.05 when compared to the empty vector control. 
MMP-9 promoter activity was increased in the presence of HER2, HER3 and both 
receptors. 
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This was further investigated by performing migration assays using Boydon chambers 
(2.17). PET (polyethylene terephthalate) membrane inserts with a pore size of 8 µm 
were used. The cells were seeded at the top of the chamber and allowed to migrate 
towards the chemoattractant which was placed in the bottom compartment of the 
chamber. The result revealed that the over-expressing lines did possess higher migratory 
potential compared to the control LACZ control cell line (Figure 4-12). 
 
Figure 4-12: HER2 and HER3 over-expression causes an increase in cell migration 
The over-expressing stable cell lines were used for performing migration assays using 
Boydon chambers. PET membrane inserts with a pore size of 8 µm was used. 600 µl of 
basal medium with Heregulin (20 ng/ml) was added per well and the inserts were placed 
on top. 3x104 cells were seeded in a final volume of 300 µl in the upper chamber. The 
cells were allowed to migrate for 48 hours. The cells that hadn’t migrated were removed 
using a cotton bud and the cells that had migrated were fixed on the membrane using 
methanol, stained with crystal violet, mounted on a slide and counted. Each arm of the 
experiment and the entire experiment itself was performed in triplicate and normalised 
to the control LACZ line. Student t-test was performed on the experiment and * 
indicates statistical significance with p-value <0.05. 
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4.4.6 HER2 and HER3 over-expression leads to an increase in cell invasion 
potential 
Potential changes to the cell’s invasion capability due to the increased activity of HER2 
and HER3 were also investigated. The experiment was similarly conducted, except that 
the Boyden chambers were coated with matrigel containing extracellular matrix proteins 
to mimic in-vivo conditions (2.17). As expected, the experiment proved that HER2 and 
HER3 over-expression can correlate to an increase in cell invasion potential, when 
compared to the LACZ control line (Figure 4-13). 
 
Figure 4-13: HER2 and HER3 over-expression increases cell invasion potential 
The over-expressing stable cell lines were used for performing invasion assays using 
Boydon chambers. PET membrane inserts with a pore size of 8 µm was used. The 
chambers were coated with matrigel. 600 µl of basal medium with Heregulin (20 ng/ml) 
was added per well and the inserts were placed on top. 3x104 cells were seeded in a final 
volume of 300 µl in the upper chamber. The cells were allowed to migrate for 48 hours 
the cells that hadn’t invaded were removed using a cotton bud and the cells that had 
invaded were fixed on the membrane using methanol, stained with crystal violet, 
mounted on a slide and counted. Each arm of the experiment and the entire experiment 
itself was performed in triplicate and normalised to the control LACZ line. Student t-
test was performed on the experiment and * indicates statistical significance with p-
value <0.05. 
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4.5 Validating HER2 and HER3 functionality in-vivo 
After observing the increase in proliferation, migration and invasion the next step 
involved validating the findings of the differentially functional cell lines in-vivo. 
Athymic CD1 nude mice were injected with either PC3-LACZ, -HER2 or -HER3 over-
expressing cell lines, used for the formation of xenografts (2.15.1). The in-vivo 
experiment revealed no differences in tumour size between the cell lines (Figure 4-14). 
 
Figure 4-14: in-vivo experiment revealing growth rates of xenografts established from 
different cell lines 
10 mice were used per experimental arm. A total of 1.1 x 107 cells of PC3-HER2, -
HER3 and -LACZ cell lines in full medium were subcutaneously injected into the flanks 
of the athymic CD1 nude mice in a final volume of 50 µl (10 mice per cell line). The 
mice were inspected thereafter for signs of tumour development. The tumour sizes were 
measured 3 times a week with callipers and recorded. The study was stopped as soon as 
the tumours reached a size of 10 x 10 mm or > 15 mm in one dimension.  The tumour 
volume was calculated by using the following formula  
𝑙𝑒𝑛𝑔𝑡ℎ
2
∗ (𝑤𝑖𝑑𝑡ℎ)2 
 
The resected tumours were used for further analysis. A mixed population of tumours 
was used to establish cell lines (2.15.1). Blasticidin was incorporated in the media to 
prevent the culture of mouse cells. The tumours were also fixed appropriately and were 
used to validate protein expression through immunohistochemistry and western blotting. 
The cell lines established from the xenografts were used to confirm the over-expression 
of the receptors.  The expression was compared in two different conditions. The first 
condition was comparing the expression of HER2 and HER3 in their normal growth 
medium i.e. full medium (FM). The other condition involved starving the cells in basal 
medium overnight followed by Heregulin stimulation.  Interestingly, differential 
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expression was only observed when the cells were treated with Heregulin (Figure 
4-15). 
 
Figure 4-15: Differential expression of HER2 and HER3 under +/- Heregulin 
stimulated conditions in cell lines established from xenografts 
The cells were seeded down in full medium and either left alone or starved in basal 
medium overnight and treated with Heregulin (HRG; 20ng/ml) for 15 minutes. The cells 
were then lysed in RIPA buffer and analysed for HER2 and HER3 expression by 
western blotting. The above result is a representation of 2 repeats 
The proliferation assays were also performed as described before, on the xenograft cell 
lines to observe if there was any variability before and after implantation. From the 
results obtained (Figure 4-16) it was noted that the cells behaved differently post 
implantation as there was no increased proliferation in the HER2 and HER3 over-
expressing cell lines as seen before. 
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Figure 4-16: Proliferation assays revealing no significant change in proliferation in the 
PC3-LACZ, -HER2 and -HER3 over-expressing cell lines which were established from 
xenografts 
(A) The xenograft cell lines were seeded on 96-well plates in selection medium. The 
cells were allowed to grow for 96 hours after which the cells were fixed with chilled 
50% TCA for 1 hour at 4 ºC. The cells were then washed with tap water, dried and 
stained with 0.4% SRB in 1% acetic acid for 30 minutes at room temperature. The cells 
were then rinsed in 1% acetic acid to remove excess dye. The dye on the cells were 
dissolved in 10mM Tris (pH 10.8) and the absorbance was recorded at 570nm. The 
experiment was repeated 3 times and the student t-test performed on the data. There 
were no significant differences compared to the control LACZ line.  
(B) 100,000 cells of each cell line were seeded in full medium on a 6-well plate. The 
following day, the medium was changed to selection medium and the cells were left to 
grow for 96 hours. The cells from each cell line were then counted using a 
haemocytometer. Each cell line was counted 3 times and the experiment was performed 
3 times. The changes in proliferation were calculated using GraphPad Prism. Student t-
test was performed on the experiments. There were no significant differences compared 
to the control LACZ line. 
The initial profiling experiments were performed in normal growth conditions (Figure 
4-9, Figure 4-10). However, the cells from the xenografts showed no over-expression in 
normal growth conditions (Figure 4-16).  These differences were further investigated in 
resected tumours. It was observed that the tumours had varied sizes and hence it was 
chosen to analyse the smallest and the largest tumours obtained from the different cell 
line xenografts. 
IHC analysis revealed that the larger tumours had stronger expression of HER2 and 
HER3 (Figure 4-17 and Figure 4-18). There was also strong nuclear staining of HER3 
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in the larger tumours. This finding led to an investigation of potential differences in the 
downstream targets of HER2 and HER3 signalling.  The same tumour samples were 
stained for pAKT as an indicator of active PI3-Kinase signalling. The result indicated 
that the pathway was more active in the larger tumours which was correlated to the high 
expression of HER2 and HER3 (Figure 4-19). 
 
Figure 4-17: Expression of HER2 in xenografts of different sizes  
Immediately after extraction, the xenografts were fixed overnight in 10% formalin 
buffered to pH–7. They were then embedded in paraffin blocks after they were trimmed 
and processed in graded ethanol and xylene using the routine processing and embedding 
equipment.  Sections of 5μm thickness were cut using a standard microtome and placed 
onto slides. IHC was performed for HER2 on the sections as mentioned in (2.2.4). 
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Figure 4-18: Expression of HER3 in xenografts of different sizes  
Immediately after extraction, the xenografts were fixed overnight in 10% formalin 
buffered to pH–7. They were then embedded in paraffin blocks after they were trimmed 
and processed in graded ethanol and xylene using the routine processing and embedding 
equipment.  Sections of 5μm thickness were cut using a standard microtome and placed 
onto slides. IHC was performed for HER3 on the sections as mentioned in (2.2.4). 
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Figure 4-19: Expression of pAKT in xenografts of different sizes  
Immediately after extraction, the xenografts were fixed overnight in 10% formalin 
buffered to pH–7. They were then embedded in paraffin blocks after they were trimmed 
and processed in graded ethanol and xylene using the routine processing and embedding 
equipment.  Sections of 5μm thickness were cut using a standard microtome and placed 
onto slides. IHC was performed for pAKT on the sections as mentioned in (2.2.4). 
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4.6 HER2 and HER3 over-expression increases AR activity and expression 
4.6.1 AR activity increases through HER2-HER3 mediated signalling 
The LNCaP-7B7 cell line was used to test the effect of HER2 and HER3 signalling on 
AR activity. This cell line was derived from the LNCaP cell line and stably over-
expresses the luciferase gene downstream the PSA promoter (2.3.2) which can be used 
to measure promoter’s activity. The FM and the SDM treated samples were compared 
to ensure that the cells were starved by observing the decrease in the PSA promoter’s 
activity (Figure 4-20 (A)). The same experiment was conducted using the LNCaP-AI 
7B7 cell line. This cell line was established from the LNCaP-AI cell line that grows in 
steroid depleted media. A luciferase gene downstream to the PSA promoter was 
similarly incorporated in this cell line and was used as a model to investigate the effect 
of HER2 and HER3 signalling on AR activity in androgen independent disease. The 
results revealed increased activity of PSA promoter with Heregulin treatment in both 
androgen dependent (Figure 4-20 (B)) and independent cell lines (Figure 4-20 (C)). 
 
Figure 4-20: HER2-HER3 mediated signalling increases AR promoter activity  
(A) LNCaP-7B7 cells were seeded out in 24-well plates and starved in SDM for 3 days 
as a control for AR activity. After starvation, the cells were lysed in reporter lysis buffer 
and luciferase substrate was added to measure the luciferase activity. The luciferase 
counts per second were measured using the plate reader. The data was normalised to the 
protein concentration per well by performing a BCA assay. 
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Figure 4-20: HER2-HER3 mediated signalling increases AR promoter activity 
(B) LNCaP-7B7 cells were starved as described above, followed by Heregulin (HRG; 
20ng/ml) treatment for 16 hours. The cells were then lysed and analysed as explained.  
(C) For LNCaP-AI 7B7 cells, the cells were seeded out in their normal growth medium 
(SDM) and treated with Heregulin (HRG; 20ng/ml) for 16 hours the next day. The cells 
were similarly lysed and analysed.  
Student t-test was performed on all the experiments and * indicates statistical 
significance with p-value <0.05. 
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To prove that this activity was indeed through the AR, the cells were also treated with 
the drug Enzalutamide, an AR antagonist.  Minimal activity of the PSA promoter was 
observed when the cells were treated with Enzalutamide (Figure 4-21). 
 
Figure 4-21: The effect of Heregulin on the PSA promoter acts through the androgen 
receptor.  
The cells were seeded out in 24-well plates, starved in SDM for 3 days. 16 hours prior 
to Heregulin treatment, the cells were treated with either Enzalutamide (ENZ) (10 µM) 
or DMSO as control.  The cells were then treated with Heregulin (HRG; 20ng/ml) for 
an additional 16 hours. The cells were then lysed in reporter lysis buffer and luciferase 
substrate was added to measure the luciferase activity. The luciferase counts per second 
were measured using the plate reader. The data was normalised to the protein 
concentration per well by performing a BCA assay (2.7.2).  Student t-test was 
performed on the experiment and * indicates statistical significance with p-value <0.05. 
4.6.2 AR expression increases with HER2 and HER3 mediated signalling  
An investigation of the effect of HER2 and HER3 on androgen receptor was continued 
by transiently over-expressing HER2 and HER3 in the AR-negative PC3 cells. These 
cells were then transfected with equal amounts of the androgen receptor and the changes 
in protein expression under androgen and Heregulin stimulation were observed (Figure 
4-22(A)). AR expression increased in the presence of DHT and Heregulin. This finding 
was further verified by transfecting the AR in the PC3-HER2 and -HER3 over-
expressing cell lines, using the PC3-LACZ cell line as a control (Figure 4-22 (B)). 
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Figure 4-22: AR expression increases in the presence of Heregulin and low levels on 
androgens 
(A) PC3 cells were seeded down in full medium and transfected with equal amounts of 
AR, empty vector control, HER2 and HER3.  The final amount of plasmid going into 
each arm was consistent and was balanced using the empty vector. The cells were then 
starved in SDM for 3 days after which they were treated with either 1nM DHT alone or 
with both DHT and Heregulin (HRG; 20ng/ml) for 24 hours. The cells were then lysed 
in RIPA buffer and AR protein expression was analysed using western blotting. (B) In 
this experiment equal amount of androgen receptor was transfected between the 
different over-expressing cell lines and the difference in its expression was observed 
under similar conditions as mentioned above. The above figure is a representation of 2 
repeats.  
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4.7 Discussion 
There have been many signalling pathways implicated in the malignant transformation 
of prostate cancer. The findings of the previous chapter, i.e. the observed over-
expression of HER2 and HER3 in patient samples, suggests that the activation of these 
receptors could be leading to sustained signalling of their regulated pathways, thus 
ultimately leading to favourable conditions for tumour growth and survival. The 
analysis of the clinical samples also revealed that differential expression of HER2 and 
HER3 could be associated with the varied survival outcomes of the patients. Hence, it 
was deemed relevant to establish an appropriate model to study the individual effects of 
these receptors. For this purpose, the PC3 cell line was chosen as it expresses low levels 
of HER2 and HER3. It is also a cell line that can be easily transfected and this was 
verified with the use of HER2 and HER3 plasmids as seen in Error! Reference source 
ot found.. This experiment validated that the expression levels of HER2 and HER3 
could be individually manipulated in PC3 cells. The downstream effects of this 
increased expression were also investigated and it was noted that upon Heregulin 
stimulation both the MAP Kinase (pERK5) and the PI3 Kinase (pAKT) pathways were 
activated as seen in Figure 4-2. The same samples were also analysed for pERK1/2 but 
there was no expression detected even in the HER2 and HER3 overexpressed cells 
leading to evaluating the activation of the pathway by looking at pERK5 instead. It 
would have been useful to have a pERK1/2 positive control to establish any problems 
with the antibody used. This experiment also revealed that the cells expressing high 
amounts of HER3 led to the strongest activation of both the above mentioned signalling 
pathways. 
However, transient over-expression of proteins isn’t stable for long periods of time and 
the number of gene copies incorporated per cell can differ. Hence it was opted to 
establish stable over-expressing cell lines by transducing PC3 cells with lentivirus 
containing HER2, HER3 or the control LACZ gene. This method allowed for the stable 
integration of the gene into the cells and also for the selection of only the over-
expressing cells by Blasticidin antibiotic selection. Since the virus was titred and the 
multiplicity of infection (MOI) was <1, it can be assumed that the cells that over-
express these proteins have incorporated only a single copy of the gene making them a 
more robust model for investigation. The virus was made and titred as explained in 
2.14.1. Figure 4-3 and Figure 4-4 show that the genes were successfully incorporated 
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into the plasmid which was then packaged to produce the respective viral particles. The 
established cell lines were maintained in Blasticidin selection medium and it was 
observed that the cells did not present with any morphological changes. The V5 tag 
could not be used to detect the over-expressing proteins, as an unspecific band was 
detected even in non-transduced cells (Figure 4-6). So, the over-expression of the 
receptors was validated by using the total HER2 and HER3 antibodies, as seen in 
Figure 4-7. The downstream changes were also analysed and it was observed that both 
the MAP Kinase and PI3 Kinase pathways were similarly upregulated between the 
over-expressing cell lines (Figure 4-8). This result validated the outcomes of the 
transient over-expression experiment but it however did not reveal any differential 
abilities between HER2 and HER3. This could be due to the fact that the basal levels of 
the partner receptors are also upregulated in the cell lines allowing for similar levels of 
downstream activity to be established.  
The cell lines were further used to validate any functional differences. The first set of 
experiments was used to study the effect of HER2 and HER3 over-expression on cell 
proliferation. SRB assays and cell counts were performed and it was observed that both 
the HER2 and HER3 over-expressing cell lines showed significant differences in the 
rates of cell proliferation (Figure 4-9, Figure 4-10). Since the over-expression of these 
receptors has been observed in advanced disease, the potential effects on cell migration 
and invasion were also investigated. Matrix metalloproteinases are a family of proteins 
that have been known to play a key role in normal physiological processes, but also in 
diseases such as cancer. MMPs in cancer mainly facilitate tumour migration and 
invasion by breaking down the extracellular matrix and hence enabling cells to establish 
new colonies of growth. These proteins have been investigated and have been known to 
be over-expressed and activated in many types of cancers (Egeblad and Werb, 2002). In 
this study, the transcriptional regulation of MMP-9 was investigated by transiently over-
expressing HER2 and HER3 in PC3 cells. A luciferase reporter construct that consisted 
of the MMP-9 promoter was also transfected to analyse its transcriptional activation 
upon activation of HER2 and HER3 mediated signalling. The result showed that the 
presence of both HER2 and HER3 led to the highest transcriptional activation of MMP-
9. It was also observed that both the receptors could individually upregulate MMP-9 
transcriptional activity (Figure 4-11). Migration and invasion assays with the use of 
Boyden chambers were further performed to validate this finding. For this experiment, 
the stable over-expressing cell lines were used and receptor activation was ensured with 
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the treatment of Heregulin. It was observed that both the HER2 and HER3 over-
expressing cell lines showed increased cell migratory and invasion potential when 
compared to the control LACZ cell line (Figure 4-12 and Figure 4-13). Interestingly, 
the HER3 cell line seemed to possess a stronger potential when compared to the HER2 
over-expressing cell line. The profiling of the cell lines however showed that the 
downstream signalling pathways were not different between the lines. This suggests a 
potential role of nuclear HER3 acting as a transcription factor in the upregulation of 
MMP-9 and should be investigated further. 
These results suggested that the established cell line models could be further used to 
investigate the role of HER2 and HER3 in prostate cancer progression. An in-vivo study 
was considered to study the rate of xenograft formation with the use of the stable over-
expressing cell lines. Analysing the results in this manner gives would provide 
additional information about the cells behaviour as they will be growing in a more 
physiologically relevant environment, i.e, by interacting with the surrounding tissues 
that could aid their survival by providing them with the necessary proliferative signals. 
These environments are currently being studied in-vitro with the use of 3D cultures and 
ex-vivo cultures. For this study, athymic CD1 nude mice were used and 10 mice were 
used per experimental arm. The cells were injected into the flank of the mice and the 
xenograft formation was regularly monitored as mentioned in (2.15.1). The mice were 
sacrificed when the xenograft reached a size of 10 x 10 mm or > 15 mm in one 
dimension. From Figure 4-14 it was observed that there were no significant changes in 
the xenograft formation between the over-expressing cell lines and the control LACZ 
cell line. The resected xenografts were used for further analysis. Although the calliper 
measurements of the xenografts indicated they had reached their maximum permissible 
size , it was observed that this measurement could not be correlated with the resected 
tumours. This suggested that the implantation in the mice was variable leading to 
irregular xenograft formation. The tumours once resected were found to be quite cystic 
and hence difficult to measure. The resected xenografts were collected under sterile 
conditions and were used for further profiling. The cell lines established from the 
xenografts were grown in Blasticidin selection medium and hence ensured that they 
were not contaminated with mouse cells. Protein lysates from these cell lines were 
collected after culturing the cells in their normal growth conditions and when they were 
treated with Heregulin. Interestingly, it was observed that HER2 and HER3 expression 
was significantly increased only with Heregulin treatment (Figure 4-15). This result 
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suggests that there was improper Heregulin stimulation in-vivo thus leading to 
inadequate expression and activity of HER2 and HER3. The proliferation of these cell 
lines was also investigated by performing SRB assays and cell counts which revealed no 
significant changes (Figure 4-16). The xenografts were also analysed for protein 
expression by immunohistochemistry. Since the sizes of the resected tumours were 
different, comparisons of protein expression were made between a small and large 
xenograft taken from each cell line. A downstream mark for pAKT was also included in 
the analysis. Figure 4-17, Figure 4-18 and Figure 4-19 show that the larger sized 
tumours had more expression of HER2, HER3 and pAKT. This finding indirectly 
suggests that HER2 and HER3 expression and its ability to activate the downstream 
signalling can be linked to tumour formation and growth. Staining these samples with 
Ki67 would be indicative if the cells possess increased proliferative capabilities between 
the LACZ, HER2, HER3 cell lines. It would also be useful to analyse these samples by 
performing some H and E staining to observe the pathology of the tumours. As the 
tumour samples were not validated by H and E it is quite difficult to draw and 
conclusions from the IHC analysis. Lysing the frozen tissue material and analysing it 
for protein expression would also give additional information about the protein 
expression in the xenografts. Since these cell lines showed a pronounced effect of cell 
migration and invasion, it would also be useful to perform the in-vivo experiments by 
intravenously implanting the cells and performing a lung colony formation assay. It 
would also be useful to carry out a smaller pilot study using these alternative assays to 
ensure success rates and then carry out a larger study to observe any significant 
changes. 
The next set of experiments performed was to interpret the effects of HER2 and HER3 
on the androgen receptor (AR). The AR is known to be the driver of prostate cancer and 
its over-expression and activity have been extensively researched. The development of 
the aggressive form of androgen-independent prostate cancer as discussed in Feldman 
and Feldman (2001) has been established as a benchmark review, and since has led to 
further investigations for the greater understanding of the disease. In the review, the 
‘outlaw pathway’ is one of the mechanisms suggested for attaining androgen 
independence wherein the AR can be activated by growth factors such as  insulin-like-
growth factor -1 (IGF-1) and epidermal growth factor (EGF) and also by receptor 
tyrosine kinases like HER2.  In this study, the effect of HER2-HER3 mediated 
signalling on the AR was initially investigated by using a luciferase reporter assay. The 
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LNCaP-7B7 cell line was used which stably expresses a PSA-luciferase construct. Since 
PSA is an AR regulated gene, the use of this cell line serves as an appropriate model to 
study AR activity.  The functioning of the cell line was validated by starving the cells in 
steroid depleted medium and as expected, it was observed that the transcriptional 
activity of PSA was reduced (Figure 4-20 (A)).  These cells were then stimulated with 
Heregulin under appropriate conditions and it was observed that activated HER2 and 
HER3 caused an increase in PSA transcriptional activity (Figure 4-20 (B)). A similar 
result was obtained when the LNCaP-AI 7B7 cell line was used. This cell line grows in 
androgen deprived conditions and hence serves as a model for androgen-independent 
prostate cancer (Figure 4-20 (C)).  To prove that these changes are occurring through 
the activity of the androgen receptor, the cells were treated with the anti-androgen drug 
Enzalutamide and treated with Heregulin. Upon drug treatment, it was observed that 
PSA transcriptional activity was inhibited thus proving that the influence of HER2 and 
HER3 signalling on androgen receptor’s activity (Figure 4-21).  
After validating the role of HER2 and HER3 mediated signalling on AR’s activity, the 
investigation was continued to observe the effect of differential expression of HER2 and 
HER3 on AR protein expression. Since the differential expression on the receptors was 
observed in advanced prostate cancer, the experiment was designed to mimic those 
conditions. In advanced disease, patients are usually treated by androgen ablation which 
ultimately leads to the low levels of androgens to be present in circulation. For the 
experiment, PC3 cells were used and transfected with equal amounts of AR along with 
either HER2 or HER3 or both the receptors. An empty vector control was also used. 
From Figure 4-22 (A) it was observed that AR expression was increased in the 
presence of low levels of androgens and Heregulin, particularly in the presence of 
HER3 and hence strongly suggests that HER2-HER3 mediated signalling plays a crucial 
role in maintaining the AR levels and its activity in advanced prostate cancer. To 
validate this finding, the experiment was repeated in the stable over-expressing cell 
lines. The result similarly revealed the enhanced expression of the AR upon HER2-
HER3 activation (Figure 4-22 (B). 
The findings of this chapter provide a better understanding of these receptors in prostate 
cancer. The analysis of the differential expression of these receptors along with their 
downstream effects – particularly the migration, invasion and AR expression studies, 
have suggested that HER3 over-expression could be leading to enhanced and prolonged 
signalling activity that is more efficient in sustaining the disease.  The study of the 
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expression and activity of HER2 and HER3 in clinical samples and in-vitro models 
provided sufficient data to continue this study by investigating their potential as drug 
targets 
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Chapter 5 Demonstrating the Therapeutic Potential of HER2-HER3 
Heterodimer Inhibition  
5.1 Introduction 
Signalling pathways within the cell are highly regulated to maintain the equilibrium of 
important processes including cell proliferation, differentiation and cell death. Many of 
these vital processes are maintained by receptor tyrosine kinases (RTKs). Receptor 
tyrosine kinases and their properties have been extensively studied and their role in cell 
signalling activation and regulation has been well established. These receptors can 
transform into oncogenic proteins and trigger tumourigenesis when they acquire 
mutations or become structurally altered (Gschwind et al., 2004). This phenomenon has 
been observed in many solid tumours including cancers of the breast, prostate, colon 
and lung. Many types of inhibitors have been clinically developed and examined since 
the identification of RTKs as therapeutic targets and these inhibitors are known as 
tyrosine kinase inhibitors (TKIs). Numerous small molecule inhibitors (SMIs) and 
monoclonal antibodies (mAbs) have been developed in recent years and have 
transformed the therapeutic options for malignant diseases. Focussing on the EGFR 
family, many such inhibitors have been developed with the intention to inhibit their 
activity and cause tumour regression. Since these proteins have been shown to be 
oncogenic across a variety of tissues, the targeted therapies have been used in clinical 
trials in different malignancies but with varied outcomes. For example, Trastuzumab, a 
monoclonal antibody against HER2, has been more successful in the treatment of HER2 
positive breast cancer when compared to HER2 positive prostate cancer (Jathal et al., 
2011). The next approach taken in the TKI development involved designing drugs that 
targeted two members of the protein family to overcome the disadvantages of single-
agent targeted therapy. This resulted in the use of TKIs such as Lapatinib – which is a 
small-molecule inhibitor against the EGFR and HER2 receptors. However, phase II 
clinical trials using Lapatinib in early stage and metastatic prostate cancer were 
unsuccessful (Sridhar et al., 2010). The dual receptor inhibition has been reasoned to be 
unsuccessful due to the ability of the cancer cell to sustain active signalling by the 
upregulation of alternative receptors. This upregulation can lead to more active 
heterodimer or homodimer formation and safeguard the continual signalling of the pro-
survival pathways. This mechanism is also linked to enabling the cancer to become drug 
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resistant; a major setback commonly faced in targeted therapy (Sergina et al., 2007). 
Re-sensitising cells to existing cancer therapy is a strategy currently being investigated 
for prostate cancer treatment and has been addressed with the use of pan-inhibitors. Pan-
inhibitors such as Canertinib and Dacomitinib, which target EGFR, HER2 and HER4 
are currently being investigated in the treatment of melanoma and non-small cell lung 
cancers (Djerf Severinsson et al., 2011; Enting and Spicer, 2012). However, these drugs 
aren’t used in prostate cancer treatment as HER4 hasn’t been known to have a role in 
prostate cancer development and has in fact not been detected in prostate cancer tissues 
and cell lines (Grasso et al., 1997). A recently developed pan-inhibitor from 
AstraZeneca – AZD8931, is designed to target the kinase activity of EGFR, HER2 and 
HER3 (Hickinson et al., 2010). Its role is currently being investigated in breast cancer 
and other solid tumours (Tjulandin et al., 2014). However, there is no data available 
regarding the use of this inhibitor in prostate cancer. 
The clinical and in-vitro analyses of HER2-HER3 expression and their mediated 
signalling in this study have revealed supporting information and justifies its potential 
as therapeutic targets. This chapter focusses on profiling the use of the novel pan-
inhibitor-AZD8931 in prostate cancer along with investigating the role of HER3 in 
acquiring drug resistance. 
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5.2 AZD8931-pan EGFR family inhibitor 
Use of AZD8931 
The inhibitor was obtained from AstraZeneca and was reconstituted and stored 
according to the guidelines. Briefly, a 30mM stock was made in DMSO which was 
stored at -80 ºC and was used to make further stocks of lower concentrations.  Working 
aliquots were stored at -20 ºC and frequent freeze-thaw cycles were avoided to ensure 
the stability of the compound was maintained. 
5.3 AZD8931 reduces and colony forming ability in prostate cancer cell lines 
LNCaP and LNCaP–AI cell lines were used to estimate the LC50 values of AZD8931 by 
performing colony forming assays. The assay analyses the ability of cells to form 
colonies in the presence of drug. The reduction in the number of colonies formed over a 
period of time would indicate the reduction in cell survival. This method was chosen for 
its sensitivity as it can estimate a more accurate LC50 of the drug as opposed to SRB 
assays that estimates cell growth The analysis revealed that AZD8931 reduced cell 
proliferation in both the androgen dependent and independent cell lines (Figure 5-1). 
The respective LC50 concentration was used for all the subsequent experiments. 
 
      
  
 144 
 
     
 
Figure 5-1: Colony forming assay revealing AZD8931 reduces cell survival in 
prostate cancer cell lines 
LNCaP and AI cell lines (A and B respectively) were seeded in 6-well plates at low 
densities (2000 cells) and treated with respective drug doses the next day. The cells 
were allowed to grow for 14 days in full medium to form colonies after which they were 
fixed using Carnoy’s fixative and stained with crystal violet. The colonies were counted 
(C) and the reduction in proliferation and the LC50 values were calculated using 
GraphPad Prism. Student t-test was performed on the experiments and * indicates 
statistical significance with p-value <0.05 when compared to the control DMSO. 
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5.4 AZD8931 reduces HER2 and HER3 translocation to the nucleus and reduces 
their activity in the cellular and nuclear compartments 
In the previous chapter, it was shown that Heregulin activates HER2 and HER3 and 
their active forms along with the respective full length receptors were detected in the 
cytoplasm and nuclear cell compartments. After estimating the LC50 values, the action 
of AZD8931 on the receptor nuclear translocation was investigated. From Figure 5-2 it 
was observed that with AZD8931 treatment, LNCaP cells retained the total receptors in 
the cytoplasm and their presence in the nucleus was reduced suggesting that AZD8931 
can inhibit the nuclear translocation of HER2 and HER3.  It was also observed that 
AZD8931 reduced the presence of the active forms in the nucleus. 
5.5 AZD8931 reduces HER2 and HER3 association with chromatin 
After observing the reduction of HER2 and HER3 nuclear translocation upon AZD8931 
treatment, the investigation of the compound was continued by analysing its ability to 
inhibit chromatin association of these receptors. In Chapter 3, it was shown that 
Heregulin treatment enhances chromatin association of HER2 and HER3 (Figure 3-26).  
The insoluble chromatin pellets collected after nuclear and cytoplasmic extractions were 
dissolved in 1X SDS sample buffer and sonicated to reduce the viscosity due to their 
high chromatin content. Histone H4 was used as a positive control for the chromatin 
fractions and α-tubulin as a negative control. Figure 5-3 shows that AZD8931 reduces 
the association of the total and active forms of HER2 and HER3 to chromatin. 
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Figure 5-2: AZD8931 reduces nuclear translocation of total and phosphorylated 
forms of HER2 and HER3 
LNCaP cells were seeded out in full medium. The following day, the medium was 
changed to full medium or basal medium and the indicated sample was pre-treated with 
3 µM AZD8931 (LC50). The cells were then treated with Heregulin (HRG; 20ng/ml) the 
following day for 2 hours after which the cells were lysed and the cytoplasmic and 
nuclear compartments of the cells were separated (by following the extraction kit 
protocol). The lysates were then analysed for cytoplasmic (A) and nuclear (B) protein 
expression by western blotting. α-tubulin and PARP were used as controls for the 
cytoplasmic and nuclear compartments respectively. The result revealed that AZD8931 
reduced the translocation of the total and active forms of HER2 and HER3 into the 
nucleus. 
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Figure 5-3: AZD8931 reduces total and phosphorylated forms of HER2 and HER3 
from associating to chromatin 
LNCaP cells were seeded out in full medium. The following day, the medium was 
changed to full medium or basal medium and the indicated sample was pre-treated with 
3 µM AZD8931 (LC50). The cells were then treated with Heregulin (HRG; 20ng/ml) the 
following day for 2 hours after which the cells were lysed and the cytoplasmic and 
nuclear compartments of the cells then separated by following the protocol of the 
extraction kit. The insoluble chromatin fraction was solubilised by sonicating the pellet 
in 1X SDS sample buffer. Histone H4 and α-tubulin were used as controls to ensure the 
purity of the chromatin samples. The result revealed that AZD8931 reduced the 
association of total and active forms of HER2 and HER3 to chromatin in the presence of 
Heregulin. 
5.6 AZD8931 reduces activity of EGFR family and their signalling pathways 
LNCaP cells were used to study the effects of Heregulin and AZD8931 on EGFR, 
HER2, HER3 and their downstream signalling pathways. The cells were stimulated with 
Heregulin with or without the presence of AZD8931. Figure 5-4 shows that the drug 
reduced the activity of EGFR, HER2 and HER3 along with downstream marks of the 
PI3 Kinase and MAP Kinase pathways. A reduction in phosphorylation of AR was also 
observed in the presence of AZD8931. 
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Figure 5-4: AZD8931 reduces the activity of EGFR family along with their 
downstream targets including AR in LNCaP cells 
The cells were seeded down in full medium, starved in basal medium and treated with 
or without drug (using LNCaP LC50 – 3 µM) overnight. Equal amounts of DMSO were 
added to the untreated samples to ensure that any variation observed was due to the drug 
alone. The following day, the cells were treated with Heregulin (HRG; 20ng/ml) for 15 
minutes after which the cells were lysed in RIPA buffer and analysed by western 
blotting. 
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5.7 AZD8931 reduces AR activity 
In the previous chapter it was seen that HER2 and HER3 increased the activity of 
androgen receptor (Figure 4-20) in the LNCaP-7B7 cell line. The cell line contains a 
chromosomally integrated PSA-luciferase promoter, thus enabling the analysis of AR 
activity on the transcription of its downstream targets like PSA. The same experiment 
was repeated along with AZD8931. DMSO was added as a control to the untreated 
samples. Figure 5-5 (A) shows that the activity of AR is reduced by the effect of 
AZD8931.  This was also seen in the LNCaP-AI 7B7 cell line which grows in androgen 
independent conditions (Figure 5-5 (B)). To validate that HER2 and HER3 inhibition 
mediated the reduction in PSA promoter activity, the experiment was repeated by 
inhibiting HER2 and HER3 by using respective siRNAs for protein knockdown. The 
siRNAs were first validated by western blotting (Figure 5-6 (A)) and were then used on 
the LNCaP–7B7 cell line. Figure 5-6 (B) shows that the reduction of HER2 and HER3 
levels results in the reduction of AR activity. 
 
Figure 5-5: AZD8931 reduces AR promoter activity   
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Figure 5-5: AZD8931 reduces AR promoter activity 
LNCaP-7B7 cells were seeded out in quadruplets per experimental arm, using a 24-well 
plate. The cells were then starved in SDM for 3 days. 16 hours prior to the starvation 
period, the cells were treated with either DMSO or AZD8931 (3 µM AZD8931-LC50) 
after which the cells were treated with Heregulin (HRG; 20ng/ml) for another 16 hours. 
When the LNCaP-AI 7B7 cell line was used, the cells were seeded out in their normal 
growth medium (SDM) and the cells were pre-treated with AZD8931 the next day 
followed by 16h of Heregulin stimulation. The cells were then lysed in reporter lysis 
buffer and luciferase substrate was added to measure the luciferase activity. The 
luciferase counts per second were measured and the data was normalised to the protein 
concentration per well by performing a BCA assay. Student t-test was performed on the 
experiment and * indicates statistical significance with p-value <0.05. The data showed 
that AZD8931 reduces Heregulin stimulated AR activity in both LNCaP–7B7 (A) and 
LNCaP-AI 7B7 cell lines (B). 
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Figure 5-6: Knockdown of HER2 and HER3 using siRNA shows similar effect to 
that of AZD8931 
(A) HER2 and HER3 siRNAs were validated using western blotting. LNCaP cells were 
seeded out in full medium in a 6-well plate. The next day, the cells were transfected 
with respective siRNAs so that the final concentration on the cells was 25nM. A 
scrambled siRNA sequence (SCR) was used as a control. The knockdown was 
performed for 96 hours after which the cells were lysed in RIPA buffer and protein 
expression was analysed using western blotting. The figure shows that the siRNAs are 
specific and reduce their targeting protein levels. 
(B) The validated siRNAs were used on the LNCaP-7B7 cell line which was previously 
used to measure PSA promoter activity. HER2 and HER3 knockdown was performed 
similarly as mentioned above except the transfections were done in SDM for 96 hours 
after which the cells were treated with Heregulin (HRG; 20ng/ml) for 16 hours. The 
luciferase activity was then measured and the data was analysed as previously 
described. Student t-test was performed on the experiment and * indicates statistical 
significance with p-value <0.05. The figure shows that the reduction of HER2 and 
HER3 protein levels reduces Heregulin stimulated AR activity. 
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5.8 AZD8931 reduces cell migratory and invasion potential 
The effects of AZD8931 on cell migratory and invasion potential were also 
investigated. In the previous chapter it was seen that HER2 and HER3 increased cell 
migration (Figure 4-11 and Figure 4-12) and invasion (Figure 4-13). The same 
experiment was repeated along with the pre-treatment with AZD8931 prior to Heregulin 
stimulation. DMSO was added as a control to the untreated samples. Figure 5-7 
revealed that AZD8931 reduced the activity of MMP9. This was further validated by 
performing migration and invasion assays using the HER2 and HER3 over-expressing 
cell lines. AZD8931 reduced both the cell migratory and invasion potential of these 
cells (Figure 5-8). 
 
Figure 5-7: AZD8931 reduces HER2 and HER3 induced MMP9 activity 
MMP-9 expression is reduced in the presence of AZD8931. PC3 cells were seeded out 
in quadruplets per experimental arm using a 24-well plate and were forward transfected 
with 100ng of MMP9, 50ng of gal and 300ng of HER2 and HER3. pCMV empty 
vector was used for the control and to ensure equal amounts of plasmid were added to 
all the experimental arms.  The cells were allowed to transfect for 24 hours after which 
the cells were starved in basal medium with or without treatment of 3 µM AZD8931 
(LC50) for 16 hours. DMSO was added as a control to the untreated samples. The cells 
were then treated with Heregulin (HRG; 20ng/ml) for 16 hours after which the cells 
were lysed in 1x reporter lysis buffer and the luciferase activity was recorded. The data 
was normalised to the results of a -galactosidase assay that revealed transfection 
efficiency. Student t-test was performed on the experiment and * indicates statistical 
significance with p-value <0.05. 
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Figure 5-8: AZD8931 reduces cell migratory and invasion potential 
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Figure 5-8: AZD8931 reduces cell migratory and invasion potential 
The over-expressing stable cell lines were used for performing migration and invasion 
assays using Boydon chambers (A and B). PET membrane inserts with a pore size of 
8µm was used. The invasion chambers were coated with matrigel. 600µl of basal 
medium with Heregulin (20ng/ml) and 3 µM AZD8931 (LC50). /DMSO was added per 
well and the inserts were placed on top. The cells were pre-treated with drug or DMSO 
in basal medium for 16 hours. The cells were then collected in SDM and re-suspended 
in basal medium with drug/DMSO. 3x104 cells were seeded in a final volume of 300µl 
in the upper chamber. The cells were allowed to migrate/invade for 48 hours The cells 
that hadn’t migrated/invaded were removed using a cotton bud and the cells that had 
migrated were fixed on the membrane using methanol, stained with crystal violet, 
mounted on a slide and counted. Each arm of the experiment and the entire experiment 
itself was done in triplicate and normalised to the control LACZ line. Student t-test was 
performed on the experiment and * indicates statistical significance with p-value <0.05. 
Figure C is a representation of the stained migration/invasion inserts containing the cells 
of the 3 respective cell lines – before and after AZD8931 treatment. 
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5.9 Comparative experiments using Lapatinib 
Lapatinib – another TKI that targets only 2 members of the EGFR family – EGFR and 
HER2 was used to compare the sensitivity of AZD8931. The preliminary experiment 
performed was to compare the effect on proliferation in prostate cancer cell lines. 
Colony forming assays were similarly performed using the LNCaP and the LNCaP-AI 
cell lines and it was observed that the cell lines were more sensitive to Lapatinib than 
AZD8931 (Figure 5-9).  
However, the use of Lapatinib has been unsuccessful in prostate cancer clinical trials 
and suggests that the cancer may have attained other mechanisms in overcoming 
inhibition. This was investigated through the establishment of Lapatinib resistant cell 
lines. 
 
     
Figure 5-9: Lapatinib reduces cell proliferation in prostate cancer cell lines   
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Figure 5-9: Lapatinib reduces cell proliferation in prostate cancer cell lines 
LNCaP and LNCaP-AI (A and B, respectively) were seeded in 6-well plates at low 
densities (2000 cells) and treated with indicated doses of Lapatinib the next day. The 
cells were allowed to grow for 14 days to form colonies after which they were fixed 
using Carnoy’s fixative and stained with crystal violet. The colonies were counted and 
the reduction in proliferation and the LC50 values were calculated using GraphPad 
Prism. Student t-test was performed on the experiments and * indicates statistical 
significance with p-value <0.05 when compared to the control DMSO. 
5.9.1 Establishing Lapatinib resistant cell line 
Lapatinib sensitive cell lines inhibit the activity of HER3 by inhibiting the activity of its 
preferred partner HER2. However, previous research in different cancer cell lines has 
shown that Heregulin induces Lapatinib resistance by increasing HER3 expression 
(Sato et al., 2013). However, there is very little literature that explains the mechanisms 
of Lapatinib resistance in prostate cancer. Therefore a Lapatinib resistant cell line was 
established using the LNCaP cell line. Briefly, the cells were grown in increasing doses 
of Lapatinib over a period of 3 months. The maximum concentration of drug that could 
be used was 5 µM as higher doses had very poor solubility.  
5.9.2 The presence of lapatinib in lapatinib resistant cells does not affect their 
survival 
Cell survival assays were first performed to test the resistance. Colony forming assays 
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were performed on both - Lapatinib sensitive and resistant LNCaP cell lines. Figure 
5-10 shows that there was no reduction in survival in the Lapatinib resistant lines in the 
presence of Lapatinib. 
Cell proliferation was then evaluated by performing SRB assays. This showed that the 
Lapatinib resistant lines had reduced proliferation in the presence of drug (Figure 5-11 
(A)). However, the overall proliferation was still higher compared to the Lapatinib 
sensitive lines. An additional experiment was performed with the use of live cell 
imaging for the analysis of cell proliferation using the Incucyte incubator. This is an 
incubator in which cells can be grown and the cell confluence can be regularly 
monitored by taking live images, which can then be analysed from time zero to observe 
any changes in proliferation. The result showed that the resistant lines grew slower in 
the presence of Lapatinib (Figure 5-11 (B)). 
 
Figure 5-10: Colony forming assay showing Lapatinib resistant lines growing in the 
presence of drug 
LNCaP–Lapatinib resistant and sensitive lines were seeded in 6-well plates at low 
densities (2000 cells) and treated with indicated doses of Lapatinib the next day. The 
cells were allowed to grow for 14 days to form colonies after which they were fixed 
using Carnoy’s fixative and stained with crystal violet. The colonies were counted and 
the reduction in proliferation and the LC50 values were calculated using GraphPad 
Prism. Student t-test was performed on the experiments and * indicates statistical 
significance with p-value <0.05 when compared to the control DMSO. 
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Figure 5-11: Lapatinib resistant cell line has reduced proliferation in the presence of 
Lapatinib 
(A) LNCaP and Lapatinib resistant cell lines were seeded on 96-well plates and the next 
day were treated with or without 5 µM Lapatinib. The cells were allowed to grow for 96 
hours after which the cells were fixed with chilled 50% TCA for 1 hour at 4 ºC. The 
cells were then washed with tap water, dried and stained with 0.4% SRB in 1% acetic 
acid for 30 minutes at room temperature. The cells were then rinsed in 1% acetic acid to 
remove excess dye. The dye on the cells was dissolved in 10mM Tris (pH 10.8) and the 
absorbance was recorded at 570nm. The experiment was repeated 3 times and student t-
test was performed on the experiment. * indicates statistical significance with p-value 
<0.05 when compared to the control – LNCaP Lapatinib sensitive line.  
(B) Lapatinib resistant lines were seeded out in 12-well plates and treated with or 
without Lapatinib the next day. The cells were placed in the Incucyte incubator for 96 
hours. The captured images were analysed using the Incucyte software. The software 
analysed the changes in well confluence from time zero till 96 hours.  The fold change 
in cell confluence was then plotted on a graph to observe any changes. The result 
revealed that the cells are not dependant on Lapatinib for their growth. 
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5.9.3 EGFR, HER2 and HER3 over-expression and activity leads to Lapatinib 
resistance which can be abrogated by AZD8931 
The cell line was further investigated to establish the mechanism of reaching Lapatinib 
resistance. The expression of EGFR, HER2 and HER3 was compared between the 
parental LNCaP cell line and the Lapatinib resistant cell line in their normal growth 
conditions. Figure 5-12 (A) shows that the Lapatinib resistant cell line has a profound 
increase in EGFR and HER3 protein expression. There did not appear to be a substantial 
increase in HER2 protein expression in the Lapatinib resistant line.  
However, when the active form of the receptor was considered, HER2 was still active in 
the resistant line upon Heregulin stimulation. The increased over-expression of EGFR 
and HER3 would suggest the maintenance of the pHER2 levels in the resistant line. The 
active forms of EGFR and HER3 were also observed in the resistant line when they 
were treated with Heregulin. The activity of these receptors was reduced in the parental 
LNCaP cell line when treated with Lapatinib (Figure 5-12 (B)). The observations of the 
resistant cell line still being responsive to Heregulin and the increased activity of EGFR, 
HER2 and HER3 suggest that the PI3Kinase and MAP Kinase signalling pathways are 
maintained, eventually aiding cell survival and creating drug resistance. This sustained 
activation of the receptors was abrogated with the treatment of AZD8931. 
 
Figure 5-12: Lapatinib resistant lines remain Heregulin responsive and AZD8931 
reduces this response. 
(A) LNCaP and Lapatinib resistant cell lines were grown in FM for 24 hours. The 
Lapatinib resistant lines were grown in 5 µM Lapatinib. After 24 hours, the cells were 
lysed in RIPA buffer and the whole cell lysates were analysed for protein expression 
using western blotting. The figure shows the Lapatinib resistant cell line have an 
increase in EGFR, HER2 (slight increase) and HER3 expression when compared to the 
parental LNCaP cell line.   
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Figure 5-12: Lapatinib resistant lines remain Heregulin responsive and AZD8931 
reduces this response. 
(A) LNCaP and Lapatinib resistant cell lines were seeded out in FM. The next day, 
fresh medium containing Lapatinib (5 µM) was added to the resistant cell line and the 
parental cell line was supplemented with fresh medium alone. After 24 hours, the cells 
were lysed in RIPA buffer and the whole cell lysates were analysed for protein 
expression using western blotting. The figure shows the Lapatinib resistant cell line 
have an increase in EGFR, HER2 (slight increase) and HER3 expression when 
compared to the parental LNCaP cell line.  
(B) Lapatinib resistant cells were seeded down in full medium and starved in basal 
medium overnight and treated with or without drug (Lapatinib – 1 µM, AZD8931 – 3 
µM) overnight. Same amount of DMSO was added to the untreated samples to ensure 
that any variation seen was due to the drug alone. The following day, the cells were 
treated with Heregulin (HRG; 20ng/ml) for 15 minutes after which the cells were lysed 
in RIPA buffer and analysed by western blotting. The figure shows that the Lapatinib 
resistant cell line is still responsive to Heregulin and shows active forms of EGFR, 
HER2 and HER3. This effect can be abrogated with the use of AZD8931. 
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5.9.4 AZD8931 is more effective in abrogating HER2-HER3 mediated signalling 
when compared to Lapatinib. 
The previous experiments conducted in this study have suggested that the differential 
expression of HER2 and HER3 and their mediated signalling could be creating 
advantageous conditions for the progression of prostate cancer. An experiment was 
conducted to establish the effect of AZD8931 in cells exhibiting these conditions whilst 
comparing the action of Lapatinib. It was observed that the presence of HER2 and 
HER3 together activated both the PI3 Kinase and the MAP Kinase pathways and this 
was confirmed by the increased presence of activated AKT and ERK5 respectively 
(Figure 5-13). This enhanced activity was reduced by the addition of both Lapatinib 
and AZD8931. However, it was observed that the AZD8931 exhibited a more 
pronounced inhibition of the activated pathways. 
 
Figure 5-13: AZD8931 is more effective in inhibiting MAP Kinase and PI3 Kinase 
signalling in cells differentialy expressing HER2 and HER3. 
PC3 cells were forward transfected either with empty vector, pIRES-HER2, pIRES-
HER3 or pIRES-HER2 and pIRES-HER3 together in full medium. Empty vector was 
used as a control and to make sure equal amounts of plasmid (2µg) were added to each 
experimental arm. The following day the cells were starved overnight in basal medium 
along with the indicated drug treatment (1 µM Lapatinib and 3 µM AZD8931) and this 
was followed the next day by 15 minutes of Heregulin (HRG; 20ng/ml) treatment to 
ensure receptor activation. The cells were then lysed in RIPA buffer and analysed for 
HER2 and HER3 expression levels along with pERK5 and pAKT levels to observe the 
activity of MAP Kinase and PI3 Kinase pathways, respectively. Increased expression of 
both pERK5 and pAKT indicated increased signalling of their pathways caused by the 
over-expression of HER2 and HER3. The addition of both Lapatinib and AZD8931 
reduced the activities of the signalling pathways with AZD8931 showing the more 
prominent effect. 
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5.10 Discussion 
Current research in the field of prostate cancer treatment is focussing on the potential 
benefits of patient stratification, based on their molecular profiling. This would provide 
useful information and reveal the survival mechanisms the cancer has utilised which 
could then be targeted using appropriate drugs. One of the mechanisms the cancer 
employs for survival is the over-expression of receptor tyrosine kinases that have a role 
in regulating signalling pathways that are important for cell survival and proliferation. 
This study so far has profiled a few mechanisms that can lead to the progression of 
prostate cancer with the over-expression of HER2 and HER3 and suggests the potential 
for these receptors to be therapeutic targets. The novel inhibitor AZD8931 has been 
used in this study and observes the effects of pan-inhibition of EGFR, HER2 and HER3 
in prostate cancer. 
Since this drug hasn’t been used in prostate cancer before, an initial proliferation assay 
was performed to estimate the LC50 drug concentration using different prostate cancer 
cell lines that represent androgen dependent and androgen independent prostate cancer. 
The LNCaP-AI cell line was the most sensitive cell line upon AZD8931 treatment and 
validates that EGFR, HER2 and HER3 play a crucial role in maintaining cell survival in 
an androgen-independent environment (Figure 5-1).  
The treatment of AZD8931 also influenced the expression and activity of HER2 and 
HER3 in the different compartments of the cell. The nuclear expression of HER2 and 
HER3 was observed in clinical samples and their translocation into the nucleus upon 
activation and being recruited to chromatin has been demonstrated in Chapter 3 
(Figure 3-18, Figure 3-24, Figure 3-25 and Figure 3-26). The use of AZD8931 
resulted in a dramatic inhibition of the expression and activity of HER2 and HER3 in 
the nuclei of LNCaP cells (Figure 5-2 (B)). However, when the cytoplasmic 
compartment was considered, the total and active forms of HER2 were not reduced, 
suggesting that they are retained in the cytoplasm (Figure 5-2 (A)). The chromatin 
fraction was also investigated and revealed a reduction in the active and total bound 
receptors with AZD8931 treatment (Figure 5-3). Since the presence of these forms of 
the receptor is remarkably reduced in the starved cells and the AZD8931 treated cells, it 
suggests that phosphorylation of these receptor plays a key role in their recruitment to 
chromatin. The role of these receptors as transcription factors is still not fully 
understood in prostate cancer. The reduced ability of HER2 and HER3 to bind to 
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chromatin upon AZD8931 would suggest that their role in prostate cancer sustenance 
could also be inhibited and needs to be investigated further.  
The next set of experiments focussed on the effect of AZD8931 on HER2 and HER3 
mediated signalling. The experiments performed in the previous chapters revealed that 
the activation of the PI3 Kinase and MAP Kinase pathways depended on the differential 
expression of HER2 and HER3. However, these experiments were performed in the AR 
negative PC3 cell line. The activation of the signalling pathways and the inhibitory 
effects of AZD8931 was tested in the AR positive LNCaP cell line. The activation of 
the receptors using Heregulin showed an increase in the phosphorylation of EGFR, 
HER2 and HER3 along with the downstream proteins including AKT and ERK. 
However, this activation was abrogated with the addition of AZD8931 (Figure 5-4). It 
was also observed that AR was phosphorylated at Serine 81, a site known for positively 
regulated the activity of the receptor (Coffey and Robson, 2012).  This observation also 
validated the luciferase reporter data in Chapter 4 (Figure 4-20) which showed the 
increase in the transcription of PSA, which is an AR regulated gene. The addition of 
AZD8931 also reduced the phosphorylation of the AR and the reduction in its activity 
was further validated by using the LNCaP-7B7 and LNCaP–AI 7B7 cell lines (Figure 
5-4 and Figure 5-5), where the transcriptional activity of PSA was also supressed. The 
experiment was also repeated using siRNA targeting HER2 and HER3. The specificity 
of the siRNA was verified by the addition of the respective siRNAs on LNCaP cells, for 
96 hours, and the expression of HER2 and HER3 was compared using western blotting. 
The siRNAs proved to be specific as it did not knockdown its respective partner 
receptor. It was observed that the PSA transcription was reduced with the inhibition of 
either partner of the HER2 and HER3 heterodimer, thus revealing the importance of 
their signalling in regulating the androgen receptor (Figure 5-6). 
The inhibition of the HER2-HER3 signalling axis also exposed various functional 
consequences. The treatment with AZD8931 reduced the ability of the cells to migrate 
and invade as seen in Figure 5-7 and Figure 5-8 and indicates the benefit of using a 
pan-inhibitor against the EGFR family in advanced prostate cancer.  
The use of other tyrosine kinase inhibitors such as Lapatinib has largely been 
unsuccessful in prostate cancer treatment (Sridhar et al., 2010; Whang et al., 2013). 
This study investigated Lapatinib resistance and the resistant cell lines were first 
validated. Figure 5-11 showed that the cells has reduced proliferation in the presence of 
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drug but overall had higher proliferation when compared to the Lapatinib sensitive 
LNCaP cells. The experiment would be more informative if comparisons were made 
using LNCaP sensitive cells with and without the presence of drug. An over-expression 
of EGFR and HER3 receptors was also observed in the LNCaP-Lapatinib resistant cell 
line suggesting their role in overcoming EGFR and HER2 inhibition (Figure 5-12). The 
cells also retained their ability to be responsive to Heregulin treatment. Increased 
activity of EGFR suggests that the EGFR-HER3 heterodimers and their mediated 
signalling could be assisting in cell survival even in the presence of drug. The addition 
of AZD8931 inhibited the activities of EGFR, HER2 and HER3 in the Lapatinib 
resistant cell line and provided initial evidence of restoring drug sensitivity (Figure 
5-12). AZD8931 also seemed to inhibit the downstream phosphorylation of MAP 
Kinase and PI3 Kinase signalling pathways more efficiently when compared to 
Lapatinib (Figure 5-13).  This experiment used the drug concentration (LC50) that was 
estimated in LNCaP cell lines. These concentrations were used as they were quite low 
and showed fewer signs of cell toxicity but were still in excess of the IC50 
concentrations (Table 5-1). A comparison of the data by using a drug concentration 
after estimating the LC50 values in PC3 cells for both AZD8931 and Lapatinib would be 
more appropriate. Quantification of the respective western blots can also reveal the 
extent of downregulation of the phosphorylation of EGFR, HER2 and HER3.  
Table 5-1: IC50 values of EGFR, HER2 and HER3 with AZD8931 and Lapatinib 
AZD8931 has been shown to be more potent in inhibiting the phosphorylation of 
EGFR, HER2 and HER3 (Hickinson et al., 2010) 
  
Compound Name EGFR (IC50) HER2 (IC50) HER3 (IC50) 
AZD8931 4 nmol/L 3 nmol/L 4 nmol/L 
Lapatinib 33 nmol/L 9 nmol/L 13 nmol/L 
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Compound Name Maximum tolerated 
dose (MTD), mg 
Cmax (Peak serum 
concentration), µg/mL 
AZD8931 240 1.46 
Lapatinib 1600 2.13 
Table 5-2: Pharmacokinetics of AZD8931 and Lapatinib 
The available Phase I clinical data was used to compare the pharmacokinetic parameters 
of AZD8931 and Lapatinib (Burris et al., 2005; Tjulandin et al., 2014) 
In summary, the over-expression of the EGFR, HER2 and particularly HER3 can lead to 
enhanced cell signalling events that are important for cell survival, proliferation, 
migration and invasion. Table 5-1 and Table 5-2 show the available pharmacokinetics 
data for Lapatinib and AZD8931. AZD8931 is more sensitive in inhibiting the activities 
of EGFR, HER2 and HER3. The phase I studies using AZD8931 were done in a range 
of solid tumours but did not include patients who had prostate cancer. It would be 
interesting to correlate the maximum tolerated dose (MTD) to the dose used this study. 
It will be useful to perform a clinical trial using AZD8931 in prostate cancer patients 
and see if they respond well at the MTD. The data collected in this project validates the 
importance of these receptors in prostate cancer and indicates that HER3 mediated 
signalling to be crucial in driving these functions especially in advanced and drug 
resistant disease. The inhibition of HER3 along with its dimerization partners HER2 and 
EGFR signifies the strong potential of the use of a pan-inhibitor for the treatment of 
advanced prostate cancer.
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Chapter 6 General Discussion 
Prostate cancer is the most commonly diagnosed cancer in men in Australia, Europe and 
the USA (Jemal et al., 2011). The UK holds the 15th place in Europe for mortalities 
caused by prostate cancer, the highest being Lithuania (CancerResearchUK). Despite 
the improvement in our knowledge of prostate cancer, management of the disease 
remains a challenge. The normal functioning of the prostate and the majority of its 
malignancies are regulated by androgens. Of those cases unsuitable for curative 
treatments, an initial favourable response is observed in 80% with the use of androgen 
withdrawal therapy alone, however a more aggressive form of the disease inevitably 
develops and, whereas previously termed “androgen-independent” disease, is now 
known as castration-resistant prostate cancer (CRPC) (Kirby et al., 2011). Patients who 
present with metastatic CRPC have a poor prognosis and it has been estimated that they 
have a mean survival of 16-18 months (Tilki and Evans, 2014). Castrate resistant 
prostate cancer remains a therapeutic challenge and recent research in the past decade 
has focussed on targeting the androgen receptor and its signalling with the development 
of drugs such as Abiraterone acetate and Enzalutamide. The metastatic disease is also 
treated by chemotherapeutic agents such as Docetaxel and Cabazitaxel. However, the 
use of the above mentioned therapies has generated many clinical questions. Firstly, the 
unavailability of a reliable biomarker for AR-targeted therapies is challenging for 
clinicians in deciding treatment plans that are beneficial to patients and the optimal 
sequence of administering these therapies remains unknown.  Additionally, regardless 
of effective blockade of androgen receptor biosynthesis and signalling, the cancer 
continues to progress (Tran et al., 2009; de Bono et al., 2011; Fizazi et al., 2012) and 
suggests that the cancer employs alternative mechanisms for the development and 
maintenance of castrate resistant disease. 
One such mechanism is the up-regulation of growth and survival pathways by the over-
expression of receptor tyrosine kinases (RTKs). RTKs and their activity are highly 
controlled in normal cells. However, this regulation is lost in transformed cells and 
RTKs present with abnormal activity. This phenomenon has been observed in many 
human cancers including breast, gastrointestinal and non-small-cell lung cancers 
(Gschwind et al., 2004). This study has focussed on the tyrosine kinases belonging to 
the EGFR family. The EGFR family consists of 4 member receptors – EGFR, HER2, 
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HER3 and HER4. Their structure typically constitutes of a ligand binding region, a 
transmembrane region and a cytoplasmic tyrosine kinase domain. The activation of 
these receptors is controlled by the expression of their ligands.  These ligands all belong 
to the EGF- related peptide growth factor family and are produced as transmembrane 
precursors that are then cleaved by proteolysis forming the soluble growth factors. 
Ligand binding facilitates signalling by the formation of specific homodimers and 
heterodimers that subsequently activate the cytoplasmic tyrosine kinase domains of the 
receptor by cross-phosphorylation of the tyrosine residues in the tail zone of each 
receptor (Hynes and MacDonald, 2009). These phosphorylation events enable the 
recruitment of specific downstream signalling molecules which can initiate the 
signalling cascade. However, HER2 and HER3 differ in their properties and possess a 
non-functional ligand binding domain and tyrosine kinase domain, respectively. They 
can hence be activated only after heterodimerization with other activated receptors.  
However, the HER2-HER3 heterodimer is the most effective combination for the 
downstream activation of signalling pathways. Once active, these receptors are involved 
in various cellular processes including cell proliferation, differentiation and migration 
(Graus-Porta et al., 1997; Olayioye et al., 2000; Hynes and Lane, 2005). 
The starting point of this study was to validate the expression of HER2 and HER3 using 
prostate cancer patient material. An increase in HER2 and HER3 expression was 
observed by performing immunohistochemistry on formalin fixed prostate cancer 
samples. The samples were scored for the cytoplasmic and nuclear expression of HER2 
and HER3. A total of 195 patient samples spread between two microarrays was 
analysed. The analysis of the samples revealed that both HER2 and HER3 cytoplasmic 
and nuclear expression increased in prostate cancer samples when compared to benign 
disease (Figure 3-11). However, upon analysis of samples from different Gleason 
grades and stages of cancer, it was observed that there were no significant variations in 
HER2 and HER3 expression. Interestingly, an overall high expression of nuclear HER3 
was observed (Figure 3-12 and Figure 3-13). A significant correlation of increased 
protein expression with Gleason grade and different stages of cancer was observed 
when the samples of the first TMA was considered and suggests that further analysis 
with more patient material might be beneficial (Figure 3-3 and Figure 3-4). The 
insufficient sample size could also be due loss of samples from the TMA. The 
construction of a TMA involves selecting the appropriate tissues for analysis and 
embedding representative cores to the recipient paraffin wax block according to a pre-
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designed layout. However, due to the variations of availability of the required tissues, 
the final depth of the embedded samples tends to be unequal in the TMA leading 
ultimately to a loss of the limited samples. Further loss of samples also occurs as the 
samples are processed through the stages of antigen retrieval and various wash steps 
involved in the protocol for immunohistochemistry. The limited and inconsistent 
availability of patient follow-up data led to varied sample numbers in the groups 
compared. Hence further analysis of the groups with increased sample size would be 
beneficial for a conclusive result. It would be useful to collect appropriate number of 
patient samples in each group to ensure equal distribution of samples for a more robust 
comparison and to observe any statistical significance. That being said, the preliminary 
results obtained in this study agree with other research findings. Previous reports have 
shown an increase of HER2 and HER3 expression in prostate cancer samples across all 
Gleason grades (Ahmad et al., 2011). Nuclear HER3 has also been detected in advanced 
prostate cancer samples and has been linked to poor prognosis (Koumakpayi et al., 
2006). This study also revealed that the differential expression of HER2 and HER3 
could be related to patient survival. Patients who presented with low levels of HER2 
along with high levels of HER3, both in the cytoplasm and nucleus died significantly 
quicker hence suggesting an important role of HER3 expression in disease advancement 
(Figure 3-18). The role of HER3 was further strengthened with the analysis of 
matched-paired patient samples. A total of 69 matched patient samples were analysed 
for the changes in expression of HER2 and HER3 as they progressed with the disease. 
The samples were spread across three groups – the hormone naïve group did not receive 
any androgen–deprivation therapy and biopsy samples from these patients were 
collected at an initial stage and at a later stage of their disease. The hormone sensitive 
group consisted of samples taken from patients before they received androgen–
deprivation therapy and at a later stage when they were still sensitive to the treatment. 
The final relapsed group consisted of samples that were taken from patients who were 
sensitive to treatment and eventually relapsed with aggressive disease. Upon analysis, 
an upregulation of HER3 cytoplasmic and nuclear expression was observed in the 
relapsed patients (Figure 3-20) enforcing the hypothesis of this study that HER3 could 
be playing a crucial role in the progression and sustenance of metastatic castrate 
resistant prostate cancer. A reduction in the tumour suppressor gene PTEN was also 
observed in the treatment sensitive and relapsed samples although no changes was 
observed in the downstream pAKT levels. (Figure 3-21 and Figure 3-22). On closer 
observation of the data there did not seem to be a complete loss of PTEN suggesting the 
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remaining regulatory role of the tumour suppressor gene. This could be resulting in 
prevention of increased activation of AKT however still sustaining its activity. Loss of 
PTEN expression for tumour development and progression is observed in many types of 
cancers including prostate cancer (Squire, 2009). This mechanism ensures sustained cell 
signalling by enabling the activation of AKT.  Also, the presence of six consensus 
phosphotyrosine sites at the C-terminal region of HER3 help in the binding of the SH2 
domain of PI3 K thus implicating its critical role in the activation of the PI3 Kinase-Akt 
pathway (Jiang et al., 2012). This suggests that the PI3 Kinase pathway is constitutively 
active in advanced prostate cancer and the upregulation of HER3 expression is playing a 
role in this activation. 
The presence of nuclear HER2 and HER3 expression in patient biopsy samples led to 
the investigation of their expression and cellular translocation in-vitro using the LNCaP 
cell line. Upon activation, both HER2 and HER3 translocated to the nucleus and this 
was confirmed by western blotting and immunofluorescence (Figure 3-24 and Figure 
3-25).  In the nucleus it was also observed that these receptors bind to chromatin upon 
activation (Figure 3-26). The nuclear expression of EGFR family members has been 
previously reported. The presence of EGFR in the nucleus has been widely studied and 
it has been implied to function as a transcription factor acting on chromatin remodelling 
as well as DNA repair (Nowsheen and Yang, 2012; Dittmann et al., 2013). In prostate 
cancer, nuclear EGFR activity has been shown to promote bone metastasis by 
upregulating the transcription factor TWIST1 and downregulating the expression of the 
miRNA, miR-1 (Chang et al., 2015). Studies in breast cancer have revealed that nuclear 
HER2 activates the transcription of COX2 gene (Wang et al., 2004). Studies reporting 
the presence of nuclear HER3 are limited and also indicate roles of regulating gene 
transcription. Research performed on various cancer types reveals that HER3 
localisation and its outcome seems to be dependent on the cancer type and stage. For 
instance, non-small cell lung cancer (NSCLC) mainly exhibits cytoplasmic HER3 
expression. However, the nuclear expression of HER3 is associated with metastatic 
disease and overall poor survival (Jiang et al., 2012). Interestingly, patients with uveal 
melanoma show increased survival rates with the presence of nuclear HER3 expression 
(Trocme et al., 2012). In prostate cancer, the presence of nuclear HER3 has been linked 
to advanced disease and poor outcome (Koumakpayi et al., 2006). Even though research 
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in other cancers suggest transcriptional regulatory roles of HER2 and HER3 in the 
nucleus, these findings need to be further investigated and validated in prostate cancer.  
The significance on the outcome on patient survival due to the differential expression of 
HER2 and HER3 in the clinical samples led to further in-vitro investigation. The study 
was done in PC3 cells that allowed the study of the differential expression of HER2 and 
HER3 and served as an appropriate model. It was observed that the downstream 
activation of both the PI3 Kinase and MAP Kinase pathways was substantially 
increased with HER3 over-expression and this effect was seen both by transient and 
stable over-expression of HER2 and HER3 (Figure 4-2 and Figure 4-8). The transient 
over-expression of HER2 and HER3 together in cells should have been confirmed by 
using plasmids that had different antibiotic selection or with plasmids that incorporated 
different fluorescent tags. This would enable the selection of cells overexpressing both 
HER2 and HER3 and would confirm the downstream effects. The study also showed 
that this differential over-expression and increased signalling activity led to the increase 
in cell growth, migration and invasion (Figure 4-9, Figure 4-10, Figure 4-11, Figure 
4-12 and Figure 4-13). It should be noted that the cell growth assays is a measure of 
total protein content after 72 hours and does not reflect any discrepancies caused during 
the setting up of the experiment (time zero). It would hence be informative to repeat 
these experiments with an additional control for data normalisation. EGFR expression 
and signalling through the AKT pathway have been previously reported to positively 
regulate MMP9 activity in non-small cell lung cancer (Pei et al., 2014). This study 
shows the significance of HER3 mediated signalling and its ability to increase the cell 
migratory and invasion potential and coincides with the expression profiles of the 
analysed patient material. Unfortunately, an attempt to study the downstream effects of 
this differential expression and activity through the observation of the growth of in-vivo 
xenografts was unsuccessful. Although the measurements of the final tumour sizes 
indicated that there was no change in growth rate, the resected tumours were of different 
sizes and suggested improper implantation of the PC3-LACZ, -HER2 and -HER3 over-
expressing cell lines. The analysis of the resected tumour cells revealed no change in 
cell proliferation amongst the different cell lines (Figure 4-16). However, the 
expression of HER2 and HER3 increased with Heregulin stimulation, though not when 
they were grown in full media in-vitro, suggesting that there was improper Heregulin 
stimulation to the cells in the in-vivo setting (Figure 4-15). The analysis of the resected 
tumours also revealed that the tumours of larger sizes had stronger expression of HER2, 
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HER3 and downstream regulatory protein pAKT indirectly suggesting that the 
expression and activation of HER2 and HER3 are necessary for tumour growth (Figure 
4-19). It will beneficial to perform additional in-vivo experiments to study the increased 
migration and invasion potential of the over expressing cell lines. Experiments such a 
lung colony forming assay would be a more appropriate model to study these effects. It 
would also be beneficial to perform a preliminary study to ensure success rates and then 
power the study accordingly. 
The differential expression observed in the patient samples along with the observations 
from the in-vitro studies suggest an important role of HER2-HER3 signalling in prostate 
cancer progression. The androgen receptor has been established as the key regulatory 
protein in driving prostate cancer and its deregulated expression and activity is the main 
event in establishing and maintaining advanced castrate resistant prostate cancer (Kahn 
et al., 2014). As previously described (1.5.1) there are many theories describing the 
mechanisms of deregulation of AR expression and activity.  The effect of the cross talk 
between AR and other signalling pathways is of particular interest. This effect was 
investigated by observing changes in the expression of prostate specific antigen, which 
is an AR target gene. Luciferase reporter assays confirmed the upregulation of PSA 
promoter activity upon activation of HER2-HER3 signalling in both androgen 
dependent and androgen independent cell lines (Figure 4-20). The involvement of the 
androgen receptor activity was proven by the reduction in PSA promoter activity upon 
treatment with AR antagonist Enzalutamide in the presence of HER2-3 activity (Figure 
4-21). The differential expression and activity of HER2 and HER3 also increased AR 
protein expression in the presence of low levels of androgens (Figure 4-22). Previous 
research in prostate cancer has investigated the role of the EGFR family signalling in 
prostate cancer. Traish and Morgentaler (2009) demonstrated that EGFR levels are 
regulated in an androgen dependent manner in prostate cancer. This over-expression of 
EGFR has been associated with stabilisation of the sodium/glucose co-transporter 1 
(SGLT1) helping with cell survival by meeting the energy demand (Weihua et al., 
2008). EGFR has also been reported to be involved in chromatin remodelling and DNA 
repair (Dittmann et al., 2013) and proves to be a novel avenue for further research in 
prostate cancer. Research by Mellinghoff et al. (2004) resulted in an important article 
on prostate cancer signalling, adding to the limited knowledge on the impact of kinase 
signalling on the androgen receptor in prostate cancer. Their work showed that HER2 
mediated signalling enhanced the ability of the AR to bind to its respective androgen 
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responsive elements. Hsu et al. (2011) further showed that increased HER2 expression 
led to the stability of androgen receptor in an androgen independent environment.  The 
inhibition of the PI3 Kinase pathway led to an increase in AR stability and 
transcriptional activity by the upregulation of HER2-HER3 mediated signalling and was 
reported by Carver et al. (2011). The EGFR-HER2-HER3 signalling can contribute to 
the positive regulation of the AR through multiple pathways. EGF mediated signalling 
has been reported to phosphorylate the AR at Tyr534 through the activity of Src kinase 
(Liu et al., 2010). Nuclear EGFR can also be implicated in the regulation of the AR as it 
enhances the expression of Aurora A kinase, which in turn has been shown to activate 
the AR by phosphorylation at sites Tyr282 and Tyr293 (Hung et al., 2008; Shu et al., 
2010). HER2-HER3 mediated signalling also can also enhance AR activity through the 
activity of Ack1 (activated cdc42-associated kinase). Ack1 once activated can 
phosphorylate the AR at Tyr267 and enable its function (Liu et al., 2010). The activity 
of the MAP Kinase pathway by EGFR-HER2-HER3 signalling can also activate S6 
ribosomal kinase that has been previously implicated with AR regulation and prostate 
cancer growth (Whitworth et al., 2012). These findings all suggest the important roles 
played by these receptors in the progression of androgen independent prostate cancer. 
However, the inhibition of these receptors has been unsuccessful in prostate cancer 
treatment as the therapeutic agents used were designed only against one or two 
members of the EGFR family (Morris et al., 2002; Lara et al., 2004; Ziada et al., 2004; 
Canil et al., 2005; Guerin et al., 2008).  
The above findings led to the investigation of the use of AZD8931, a pan-EGFR family 
inhibitor from AstraZeneca. The compound has been tested predominantly in breast, 
lung and head and neck cancers and is currently in phase II clinical trials for solid 
tumours (Hickinson et al., 2010; Barlaam et al., 2013; Tjulandin et al., 2014). However, 
prostate cancer has not been included in these studies and the data presented in this 
project are the novel and preliminary findings of the outcomes of AZD8931 in an in-
vitro setting. The LC50 concentrations for the compound were first established by 
performing colony forming assays. The androgen dependent LNCaP cell line and the 
androgen independent LNCaP-AI cell line were used for comparison. Interestingly, the 
androgen-independent cell line was more sensitive to the compound with a LC50 
concentration of 0.78 µM when compared to the androgen dependent cell line, which 
had a concentration of 2.82 µM (Figure 5-1) and adds to the theory of the EGFR family 
playing a key role in androgen independent disease. After observing this effect on cell 
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survival, the investigation was continued by observing the nuclear translocation of 
HER2 and HER3. Treatment with AZD8931 demonstrated retention of the total HER2 
and HER3 in the cytoplasm (Figure 5-2 (A)) and this was confirmed by observing the 
reduced expression of both the total and activated forms of HER2 and HER3 in the 
nucleus (Figure 5-2 (B)). This was then further analysed and a reduced presence of 
these receptors and their active forms bound to chromatin was observed (Figure 5-3). 
The role of the nuclear expression of these receptors needs further investigation, 
however this result suggests that the inhibitory role of the compound can act against any 
positive regulatory functions of these receptors. The compound was then tested against 
the activity of the downstream signalling cascades in the LNCaP cell line. The treatment 
with AZD8931 reduced the activation of EGFR, HER2 and HER3 in the presence of the 
activating ligand, Heregulin. There were no observed reductions in the total levels of 
these receptors. The reduction of the receptors’ activities led to the reduction in both the 
MAP Kinase and PI3 Kinase signalling pathways and this was confirmed by the 
reduction in the pERK and pAKT levels, respectively. Similar to the EGF receptors, no 
reduction was observed in the total levels of ERK and AKT. The effect on the androgen 
receptor was also established by the presence of lower active site - serine 81 
phosphorylation on the androgen receptor upon AZD8931 treatment (Figure 5-4). The 
reduction in AR activity was further validated by luciferase reporter assays with the use 
of the LNCaP-7B7 and LNCaP-AI-7B7 cell lines that stably express the PSA-luciferase 
promoter. The initially shown positive effect of HER2-HER3 mediated signalling on 
AR activity was lowered with the addition of AZD8931 (Figure 5-5). This effect of 
AZD8931 was also verified with the use of siRNA (Figure 5-6). The reduction in the 
activity of downstream signalling cascades along with that of the AR led to the 
exploration of these outcomes on cell migration and invasion potential. It was observed 
that the expression of matrix metalloproteinase MMP9 was reduced with the treatment 
of AZD8931 (Figure 5-7). The migration and invasion assays performed with the use of 
the compound also proved to effectively reduce these cellular processes (Figure 5-8).  
The final part of this study included the study of tyrosine kinase inhibitor resistance in 
prostate cancer focussing on the EGFR family. As previously mentioned, the use of the 
dual kinase inhibitor, Lapatinib, has been largely unsuccessful in prostate cancer 
treatment (Sridhar et al., 2010; Whang et al., 2013). The current studies suggest that the 
signalling activities of EGFR and HER2 were still being carried out with the partnering 
of HER3. This was addressed by comparing the effect of Lapatinib between LNCaP and 
LNCaP-AI cell line proliferation. It was observed that the androgen independent cell 
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line had a higher LC50 concentration (Figure 5-9).This could be contribute to the lack of 
success of Lapatinib is CRPC. Previous profiling of this cell line showed an overall 
higher expression of HER3 (Figure 3-23) and higher sensitivity to AZD8931 (Figure 
5-1), hence further validating the role of HER3 mediated signalling in androgen 
independent disease. The added role of this signalling in drug resistance was tested 
using the LNCaP-Lapatinib resistant cell line. The cell line developed acquired 
resistance to Lapatinib upon gradual dose escalation and once established was 
continuously maintained in normal growth medium with a final Lapatinib concentration 
of 5µM. The cell line was then profiled for its resistance and it was shown through 
colony forming assays that the cells were able to grow in different concentrations of 
Lapatinib (from 0-5µM), unlike the sensitive parental cell line (Figure 5-10). The 
resistance cell line was however had a reduced rate of cell proliferation when grown in 
the presence of the drug. However, this rate of proliferation was still significantly higher 
when compared to the LNCaP sensitive cells thus proving its resistance (Figure 5-11). 
When the protein expression was analysed, an increased expression of EGFR and HER3 
was observed. The resistant cells were also still responsive to Heregulin, demonstrating 
a clear increase in pEGFR levels. The addition of AZD8931 efficiently reduced the 
effect of active EGFR, HER2 and HER3 receptors in the Lapatinib resistant cell line 
(Figure 5-12). The final experiment in this study was to compare the effects of both 
Lapatinib and AZD891 in HER2 and HER3 differentially expressing cells. PC3 cells 
were transiently over-expressed with either HER2, HER3 or both receptors together as 
previously described and showed increased MAPK and PI3 Kinase pathway activation 
with HER3 over-expression. The addition of Lapatinib reduced the PI3 Kinase pathway 
activation but the MAP Kinase pathway remained active with HER3 over-expression. 
However, AZD8931 demonstrated better activity in reducing both of these downstream 
signalling pathways, even in the presence of high HER3 levels (Figure 5-13). This 
suggests that pan-inhibiton of the receptors could be more effective in patients that 
show differential expression of HER2 and HER3. However, since these receptors are 
expressed and play a role in a variety of tissues in the body, the implications of pan-
inhibition should be considered. However, the phase I trial using AZD8931 in other 
solid tumours showed that the compound was well tolerated at a maxium dose of 240 
mg and had minor side effects like diarrhea and acne (Tjulandin et al., 2014). A trial 
including prostate cancer patients having differential strong expression of HER2 and 
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HER3 could be more informative. It would also be interesting to study AZD8931 
resistance and then subsequently study the effect of appropriate combination therapies. 
The results from this study sheds more light towards the understanding of the role of 
HER2-HER3 mediated signalling in advanced prostate cancer. The validation of the 
presence of the these receptors in the nucleus and their being associated to chromatin, 
along with its inhibition with the use of AZD8931, stimulates many questions regarding 
the roles played by these receptors in prostate cancer progression and drug resistance. 
Investigation of transcription regulatory roles of these receptors by performing ChIP-
sequencing would be a good starting point for further studies. Research in breast cancer 
has revealed that upon androgen stimulation, AR and FOXA1, a transcriptional 
regulator also over-expressed in prostate cancer, binds to HER3 gene regulatory regions 
upon androgen stimulation (Ni et al., 2011). On similar lines, the regulatory roles of AR 
on HER3 expression is reported to be lost in castrate resistant prostate cancer by the loss 
of its regulatory effect on Nrdp1, an E3 ubiquitin ligase that is known to target HER3 
for degradation (Chen et al., 2010). Further investigation of these receptors’ 
transcriptional regulation, intracellular translocation and recycling mechanisms may 
unveil more deregulated mechanisms in advanced prostate cancer and could serve as 
new targets for therapeutic intervention.  The differential expression of these receptors 
has revealed the importance of HER3 in advanced prostate cancer. The clinical data, 
along with the in-vitro analysis show increased activity of both the MAP Kinase and 
PI3 Kinase pathways. The role of HER3 in predominantly activating the PI3 Kinase 
pathway is well established. Patients samples analysed in this study suggests that this 
pathway is still active in aggressive disease due to the loss of PTEN expression, along 
with the upregulation of HER3 cytoplasmic and nuclear expression. Since the PI3 
Kinase pathway is critical for cell survival, it’s over activity has been linked to drug 
resistance. However, the inhibition of this pathway in prostate cancer has had limited 
success due to the upregulation of HER2-3 mediated signalling and dual pathway 
inhibition has been suggested for better anti-tumour activity (Carver et al., 2011). The 
combination of AKT inhibition along with the inhibition of EGFR-HER2-HER3 
mediated signalling has proven effective in reducing breast cancer tumour growth 
(Crafter et al., 2015) and suggests its use in prostate cancer treatment could be 
beneficial.  Signalling through the EGFR family has also been linked to tumour cells 
acquiring drug resistance, in particular as the result of the recently described, critical 
role of HER3 mediated signalling (Dey et al., 2015). For example, a recent study in 
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prostate cancer has shown that modulating the amounts of EBP1 – HER3 binding 
protein, affected Lapatinib sensitivity (Awasthi et al., 2015).  The work in this project 
on Lapatinib resistance further validates the role of HER3 in prostate cancer and the 
study is currently being continued by performing a wider screen for deregulated 
mechanisms with the use of a reverse phase protein array (RPPA). Another recently 
published article this September on breast cancer research showed that the targeting of 
nuclear HER2 inhibited the cells from acquiring and also overcoming Trastuzumab 
resistance, suggesting a similar mechanism could be useful in prostate cancer treatment 
(Cordo Russo et al., 2015). Interest also lies in linking the HER2-HER3 mediated 
signalling and AR as the driver of therapeutic resistance in prostate cancer. The 
combined use of the anti-androgen drug Enzalutamide along with Lapatinib has 
revealed enhanced anti-tumour activity in castrate resistant prostate cancer by inhibiting 
the activity of YB-1, a transcription factor regulated by AKT, and this factor in turn 
positively regulates HER2 expression (Shiota et al., 2015).  YB-1 has been reported to 
be over-expressed in prostate cancer and has been linked to resistant and advanced 
disease progression (Shiota et al., 2011). Interestingly, studies in non-small cell lung 
cancer have shown that the inhibition of YB-1 led to a depletion in HER3 levels 
(Kashihara et al., 2009), suggesting a potential novel regulatory mechanism in prostate 
cancer which requires further exploration.  Current research in our group has also 
confirmed an increase in HER2 and HER3 levels in an Enzalutamide resistant cell line 
(established in house) and these changes in expression are being investigated by gene 
microarray.  Figure 6-1 shows the summary of the findings of this project. The data 
collected from this project, along with the recent published findings, suggest that the 
simultaneous inhibition of EGFR, HER2 and HER3, perhaps in combination with 
androgen receptor blockade or more recently identified targets such as YB-1, could lead 
to an enhanced, prolonged delay to drug resistant / castrate resistant disease, and 
ultimately improve mortality rates in advanced prostate cancer.  
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Figure 6-1: Diagram summarising the findings of this PhD project 
The activity of EGFR/HER2/HER3 receptors activate the downstream MAP Kinase and PI3 Kinase signalling pathways that regulate a diverse range 
of cellular processes like migration and invasion that are beneficial for tumour growth. The receptors also translocate to the nucleus and can regulate 
the transcription of genes that can support tumour growth and can also help in attaining drug resistance. Targeting EGFR, HER2 and HER3 suggests a 
novel strategic approach in the treatment of advanced prostate cancer, whose growth is dependent on these receptors.  
Bibliography 
179 
Bibliography 
Abate-Shen, C. and Shen, M.M. (2000) 'Molecular genetics of prostate cancer', Genes & 
Development, 14(19), pp. 2410-2434. 
Ablin, R.J. and Haythorn, M.R. (2009) 'Screening for prostate cancer: Controversy? 
What controversy?', Current Oncology, 16(3), pp. 1-2. 
Abrahamsson, P.A. (1999) 'Neuroendocrine differentiation in prostatic carcinoma', 
Prostate, 39(2), pp. 135-48. 
Acevedo, V.D., Gangula, R.D., Freeman, K.W., Li, R., Zhang, Y., Wang, F., Ayala, 
G.E., Peterson, L.E., Ittmann, M. and Spencer, D.M. (2007) 'Inducible FGFR-1 
activation leads to irreversible prostate adenocarcinoma and an epithelial-to-
mesenchymal transition', Cancer Cell, 12(6), pp. 559-71. 
Adams, J. (1853) 'The case of scirrhous of the prostate gland with corresponding 
affliction of the lymphatic glands in the lumbar region and in the pelvis', Lancet, 1, pp. 
393-393. 
Aggarwal, B.B. (2000) 'Tumour necrosis factors receptor associated signalling 
molecules and their role in activation of apoptosis, JNK and NF-kappaB', Ann Rheum 
Dis, 59 Suppl 1, pp. i6-16. 
Ahearn, T.U., Pettersson, A., Ebot, E.M., Gerke, T., Graff, R.E., Morais, C.L., Hicks, 
J.L., Wilson, K.M., Rider, J.R., Sesso, H.D., Fiorentino, M., Flavin, R., Finn, S., 
Giovannucci, E.L., Loda, M., Stampfer, M.J., De Marzo, A.M., Mucci, L.A. and Lotan, 
T.L. (2016) 'A Prospective Investigation of PTEN Loss and ERG Expression in Lethal 
Prostate Cancer', J Natl Cancer Inst, 108(2). 
Ahmad, I., Patel, R., Singh, L.B., Nixon, C., Seywright, M., Barnetson, R.J., Brunton, 
V.G., Muller, W.J., Edwards, J., Sansom, O.J. and Leung, H.Y. (2011) 'HER2 
overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer', Proc 
Natl Acad Sci U S A, 108(39), pp. 16392-7. 
Amin M, K.A., Tazeen N, Yasoob M , (2010) 'Zonal Anatomy of Prostate', Annals, 
16(3), pp. 138-142. 
Ammirante, M., Luo, J.L., Grivennikov, S., Nedospasov, S. and Karin, M. (2010) 'B-
cell-derived lymphotoxin promotes castration-resistant prostate cancer', Nature, 
464(7286), pp. 302-5. 
Ang, J.E., Olmos, D. and de Bono, J.S. (2009) 'CYP17 blockade by abiraterone: further 
evidence for frequent continued hormone-dependence in castration-resistant prostate 
cancer', British Journal of Cancer, 100(5), pp. 671-675. 
Attard, G., Richards, J. and de Bono, J.S. (2011) 'New strategies in metastatic prostate 
cancer: targeting the androgen receptor signaling pathway', Clin Cancer Res, 17(7), pp. 
1649-57. 
Bibliography 
180 
Awasthi, S., Ezelle, H., Hassel, B.A. and Hamburger, A.W. (2015) 'The ErbB3-binding 
protein EBP1 modulates lapatinib sensitivity in prostate cancer cells', Mol Cell 
Biochem, 405(1-2), pp. 177-86. 
Azad, A.A., Volik, S.V., Wyatt, A.W., Haegert, A., Le Bihan, S., Bell, R.H., Anderson, 
S.A., McConeghy, B., Shukin, R., Bazov, J., Youngren, J., Paris, P., Thomas, G., Small, 
E.J., Wang, Y., Gleave, M.E., Collins, C.C. and Chi, K.N. (2015) 'Androgen Receptor 
Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance 
in Castration-Resistant Prostate Cancer', Clin Cancer Res, 21(10), pp. 2315-24. 
Barlaam, B., Anderton, J., Ballard, P., Bradbury, R.H., Hennequin, L.F., Hickinson, 
D.M., Kettle, J.G., Kirk, G., Klinowska, T., Lambert-van der Brempt, C., Trigwell, C., 
Vincent, J. and Ogilvie, D. (2013) 'Discovery of AZD8931, an Equipotent, Reversible 
Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors', ACS Med Chem Lett, 
4(8), pp. 742-6. 
Baselga, J. and Swain, S.M. (2009) 'Novel anticancer targets: Revisiting ERBB2 and 
discovering ERBB3', Nature Reviews Cancer, 9(7), pp. 463-475. 
Ben-Shlomo, Y., Evans, S., Ibrahim, F., Patel, B., Anson, K., Chinegwundoh, F., 
Corbishley, C., Dorling, D., Thomas, B., Gillatt, D., Kirby, R., Muir, G., Nargund, V., 
Popert, R., Metcalfe, C. and Persad, R. (2008) 'The Risk of Prostate Cancer amongst 
Black Men in the United Kingdom: The PROCESS Cohort Study', European Urology, 
53(1), pp. 99-105. 
Bennett, N.C., Gardiner, R.A., Hooper, J.D., Johnson, D.W. and Gobe, G.C. (2010) 
'Molecular cell biology of androgen receptor signalling', International Journal of 
Biochemistry and Cell Biology, 42(6), pp. 813-827. 
Berger, R., Lin, D.I., Nieto, M., Sicinska, E., Garraway, L.A., Adams, H., Signoretti, S., 
Hahn, W.C. and Loda, M. (2006) 'Androgen-dependent regulation of Her-2/neu in 
prostate cancer cells', Cancer Research, 66(11), pp. 5723-5728. 
Bickers, B. and Aukim-Hastie, C. (2009) 'New molecular biomarkers for the prognosis 
and management of prostate cancer--the post PSA era', Anticancer Res, 29(8), pp. 3289-
98. 
Bland, J.M. and Altman, D.G. (2004) 'The logrank test', BMJ : British Medical Journal, 
328(7447), pp. 1073-1073. 
Blobel, C.P. (2005) 'ADAMs: key components in EGFR signalling and development', 
Nat Rev Mol Cell Biol, 6(1), pp. 32-43. 
Brand, T.M., Iida, M., Li, C. and Wheeler, D.L. (2011) 'The nuclear epidermal growth 
factor receptor signaling network and its role in cancer', Discov Med, 12(66), pp. 419-
32. 
Brawer, M.K. (2005) 'Prostatic Intraepithelial Neoplasia: An Overview', Reviews in 
Urology, 7(Suppl 3), pp. S11-S18. 
Brogden, R.N. and Faulds, D. (1995) 'Goserelin. A review of its pharmacodynamic and 
pharmacokinetic properties and therapeutic efficacy in prostate cancer', Drugs Aging, 
6(4), pp. 324-43. 
Bibliography 
181 
Brooke, G.N. and Bevan, C.L. (2009) 'The role of androgen receptor mutations in 
prostate cancer progression', Curr Genomics, 10(1), pp. 18-25. 
Brown, C.J., Goss, S.J., Lubahn, D.B., Joseph, D.R., Wilson, E.M., French, F.S. and 
Willard, H.F. (1989) 'Androgen receptor locus on the human X chromosome: regional 
localization to Xq11-12 and description of a DNA polymorphism', Am J Hum Genet, 
44(2), pp. 264-9. 
Brown, E.J., Beal, P.A., Keith, C.T., Chen, J., Shin, T.B. and Schreiber, S.L. (1995) 
'Control of p70 s6 kinase by kinase activity of FRAP in vivo', Nature, 377(6548), pp. 
441-6. 
Burgess, A.W. (2008) 'EGFR family: structure physiology signalling and therapeutic 
targets', Growth Factors, 26(5), pp. 263-74. 
Burris, H.A., Hurwitz, H.I., Dees, E.C., Dowlati, A., Blackwell, K.L., O'Neil, B., 
Marcom, P.K., Ellis, M.J., Overmoyer, B., Jones, S.F., Harris, J.L., Smith, D.A., Koch, 
K.M., Stead, A., Mangum, S. and Spector, N.L. (2005) 'Phase I Safety, 
Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible 
Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily 
Pretreated Patients With Metastatic Carcinomas', Journal of Clinical Oncology, 23(23), 
pp. 5305-5313. 
Cai, C., Portnoy, D.C., Wang, H., Jiang, X., Chen, S. and Balk, S.P. (2009) 'Androgen 
receptor expression in prostate cancer cells is suppressed by activation of epidermal 
growth factor receptor and ErbB2', Cancer Research, 69(12), pp. 5202-5209. 
Cai, C.Q., Peng, Y., Buckley, M.T., Wei, J., Chen, F., Liebes, L., Gerald, W.L., Pincus, 
M.R., Osman, I. and Lee, P. (2008) 'Epidermal growth factor receptor activation in 
prostate cancer by three novel missense mutations', Oncogene, 27(22), pp. 3201-10. 
Callewaert, L., Van Tilborgh, N. and Claessens, F. (2006) 'Interplay between two 
hormone-independent activation domains in the androgen receptor', Cancer Res, 66(1), 
pp. 543-53. 
CancerResearchUK (Prostate cancer - UK incidence) Prostate cancer - UK incidence. 
Available at: 
http://info.cancerresearchuk.org/cancerstats/types/prostate/incidence/#source1. 
Canil, C.M., Moore, M.J., Winquist, E., Baetz, T., Pollak, M., Chi, K.N., Berry, S., 
Ernst, D.S., Douglas, L., Brundage, M., Fisher, B., McKenna, A. and Seymour, L. 
(2005) 'Randomized phase II study of two doses of gefitinib in hormone-refractory 
prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group', 
J Clin Oncol, 23(3), pp. 455-60. 
Cao, Y., Nimptsch, K., Shui, I.M., Platz, E.A., Wu, K., Pollak, M.N., Kenfield, S.A., 
Stampfer, M.J. and Giovannucci, E.L. (2015) 'Prediagnostic plasma IGFBP-1, IGF-1 
and risk of prostate cancer', Int J Cancer, 136(10), pp. 2418-26. 
Carlsson, J., Shen, L., Xiang, J., Xu, J. and Wei, Q. (2013) 'Tendencies for higher co-
expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph 
node metastases compared with corresponding primary tumors', Oncology Letters, 5(1), 
pp. 208-214. 
Bibliography 
182 
Carpenter, C.L., Auger, K.R., Chanudhuri, M., Yoakim, M., Schaffhausen, B., 
Shoelson, S. and Cantley, L.C. (1993) 'Phosphoinositide 3-kinase is activated by 
phosphopeptides that bind to the SH2 domains of the 85-kDa subunit', J Biol Chem, 
268(13), pp. 9478-83. 
Carpenter, G., Lembach, K.J., Morrison, M.M. and Cohen, S. (1975) 'Characterization 
of the binding of 125-I-labeled epidermal growth factor to human fibroblasts', J Biol 
Chem, 250(11), pp. 4297-304. 
Carrion-Salip, D., Panosa, C., Menendez, J.A., Puig, T., Oliveras, G., Pandiella, A., De 
Llorens, R. and Massaguer, A. (2012) 'Androgen-independent prostate cancer cells 
circumvent EGFR inhibition by overexpression of alternative HER receptors and 
ligands', Int J Oncol, 41(3), pp. 1128-38. 
Carver, B.S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, 
S., Arora, V.K., Le, C., Koutcher, J., Scher, H., Scardino, P.T., Rosen, N. and Sawyers, 
C.L. (2011) 'Reciprocal feedback regulation of PI3K and androgen receptor signaling in 
PTEN-deficient prostate cancer', Cancer Cell, 19(5), pp. 575-86. 
Cary, K.C. and Cooperberg, M.R. (2013) 'Biomarkers in prostate cancer surveillance 
and screening: past, present, and future', Ther Adv Urol, 5(6), pp. 318-29. 
Casaletto, J.B. and McClatchey, A.I. (2012) 'Spatial regulation of receptor tyrosine 
kinases in development and cancer', Nat Rev Cancer, 12(6), pp. 387-400. 
Chandrasekar, T., Yang, J.C., Gao, A.C. and Evans, C.P. (2015) 'Mechanisms of 
resistance in castration-resistant prostate cancer (CRPC)', Translational Andrology and 
Urology, 4(3), pp. 365-380. 
Chang, Y.S., Chen, W.Y., Yin, J.J., Sheppard-Tillman, H., Huang, J. and Liu, Y.N. 
(2015) 'EGF Receptor Promotes Prostate Cancer Bone Metastasis by Downregulating 
miR-1 and Activating TWIST1', Cancer Res, 75(15), pp. 3077-86. 
Chattopadhyay, A., Vecchi, M., Ji, Q., Mernaugh, R. and Carpenter, G. (1999) 'The role 
of individual SH2 domains in mediating association of phospholipase C-gamma1 with 
the activated EGF receptor', J Biol Chem, 274(37), pp. 26091-7. 
Chen, C.D., Welsbie, D.S., Tran, C., Baek, S.H., Chen, R., Vessella, R., Rosenfeld, 
M.G. and Sawyers, C.L. (2004) 'Molecular determinants of resistance to antiandrogen 
therapy', Nat Med, 10(1), pp. 33-9. 
Chen, L., Mooso, B.A., Jathal, M.K., Madhav, A., Johnson, S.D., van Spyk, E., 
Mikhailova, M., Ripoll, A.Z., Xue, L., Vinall, R.L., deVere White, R.W. and Ghosh, 
P.M. (2011) 'Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen 
withdrawal by suppressing ErbB3', Clinical cancer research : an official journal of the 
American Association for Cancer Research, 17(19), pp. 6218-6228. 
Chen, L., Siddiqui, S., Bose, S., Mooso, B., Asuncion, A., Bedolla, R.G., Vinall, R., 
Tepper, C.G., Gandour-Edwards, R., Shi, X., Lu, X.H., Siddiqui, J., Chinnaiyan, A.M., 
Mehra, R., White, R.W.D., Carraway Iii, K.L. and Ghosh, P.M. (2010) 'Nrdp1-mediated 
regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not 
castrate-resistant prostate cancer cells', Cancer Research, 70(14), pp. 5994-6003. 
Bibliography 
183 
Chen, M., Nowak, D.G. and Trotman, L.C. (2014) 'Molecular Pathways: PI 3-Kinase 
Pathway Phosphatases as Biomarkers for Cancer Prognosis and Therapy', Clinical 
cancer research : an official journal of the American Association for Cancer Research, 
20(12), pp. 3057-3063. 
Chen, N., Ye, X.-C., Chu, K., Navone, N.M., Sage, E.H., Yu-Lee, L.-Y., Logothetis, 
C.J. and Lin, S.-H. (2007) 'A secreted isoform of ErbB3 promotes osteonectin 
expression in bone and enhances the invasiveness of prostate cancer cells', Cancer 
research, 67(14), pp. 6544-6548. 
Cimino, S., Favilla, V., Russo, G.I., Galvano, F., Li Volti, G., Barbagallo, I., Giofre, 
S.V., D'Orazio, N., A, D.I.R., Madonia, M. and Morgia, G. (2014) 'Oxidative stress and 
body composition in prostate cancer and benign prostatic hyperplasia patients', 
Anticancer Res, 34(9), pp. 5051-6. 
Cleutjens, K.B.J.M., van Eekelen, C.C.E.M., van der Korput, H.A.G.M., Brinkmann, 
A.O. and Trapman, J. (1996) 'Two Androgen Response Regions Cooperate in Steroid 
Hormone Regulated Activity of the Prostate-specific Antigen Promoter', Journal of 
Biological Chemistry, 271(11), pp. 6379-6388. 
Coffey, K. and Robson, C.N. (2012) 'Regulation of the androgen receptor by post-
translational modifications', Journal of Endocrinology, 215(2), pp. 221-237. 
Cohen, S. (1962) 'Isolation of a mouse submaxillary gland protein accelerating incisor 
eruption and eyelid opening in the new-born animal', J Biol Chem, 237, pp. 1555-62. 
Cordo Russo, R.I., Beguelin, W., Diaz Flaque, M.C., Proietti, C.J., Venturutti, L., 
Galigniana, N., Tkach, M., Guzman, P., Roa, J.C., O'Brien, N.A., Charreau, E.H., 
Schillaci, R. and Elizalde, P.V. (2015) 'Targeting ErbB-2 nuclear localization and 
function inhibits breast cancer growth and overcomes trastuzumab resistance', 
Oncogene, 34(26), pp. 3413-28. 
Courtney, K.D., Corcoran, R.B. and Engelman, J.A. (2010) 'The PI3K Pathway As 
Drug Target in Human Cancer', Journal of Clinical Oncology, 28(6), pp. 1075-1083. 
Crafter, C., Vincent, J.P., Tang, E., Dudley, P., James, N.H., Klinowska, T. and Davies, 
B.R. (2015) 'Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, 
with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour 
efficacy in HER2-amplified breast cancer models', Int J Oncol, 47(2), pp. 446-54. 
Crawford, E.D., Stone, N.N., Yu, E.Y., Koo, P.J., Freedland, S.J., Slovin, S.F., 
Gomella, L.G., Berger, E.R., Keane, T.E., Sieber, P., Shore, N.D. and Petrylak, D.P. 
(2014) 'Challenges and recommendations for early identification of metastatic disease in 
prostate cancer', Urology, 83(3), pp. 664-9. 
CRUKD/12/007. Available at: http://www.cancerresearchuk.org/science/research/who-
and-what-we-fund/browse-by-location/leicester/university-of-leicester/grants/anne-
thomas-14112-crukd-12-007-debioc-a-phase-i. 
CRUKD/12/015. Available at: http://www.cancerresearchuk.org/about-cancer/find-a-
clinical-trial/a-trial-of-azd8931-with-chemotherapy-for-bowel-cancer-panther. 
Bibliography 
184 
Culig, Z., Hobisch, A., Cronauer, M.V., Radmayr, C., Trapman, J., Hittmair, A., 
Bartsch, G. and Klocker, H. (1994) 'Androgen receptor activation in prostatic tumor cell 
lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth 
factor', Cancer Res, 54(20), pp. 5474-8. 
Cunha, G.R., Fujii, H., Neubauer, B.L., Shannon, J.M., Sawyer, L. and Reese, B.A. 
(1983) 'Epithelial-mesenchymal interactions in prostatic development. I. morphological 
observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the 
adult rodent urinary bladder', J Cell Biol, 96(6), pp. 1662-70. 
Cutress, M.L., Whitaker, H.C., Mills, I.G., Stewart, M. and Neal, D.E. (2008) 'Structural 
basis for the nuclear import of the human androgen receptor', J Cell Sci, 121(Pt 7), pp. 
957-68. 
da Silva, H.B., Amaral, E.P., Nolasco, E.L., de Victo, N.C., Atique, R., Jank, C.C., 
Anschau, V., Zerbini, L.F. and Correa, R.G. (2013) 'Dissecting Major Signaling 
Pathways throughout the Development of Prostate Cancer', Prostate Cancer, 2013, p. 
920612. 
Dankort, D.L., Wang, Z., Blackmore, V., Moran, M.F. and Muller, W.J. (1997) 'Distinct 
tyrosine autophosphorylation sites negatively and positively modulate neu-mediated 
transformation', Molecular and Cellular Biology, 17(9), pp. 5410-25. 
de Bono, J.S., Bellmunt, J., Attard, G., Droz, J.P., Miller, K., Flechon, A., Sternberg, C., 
Parker, C., Zugmaier, G., Hersberger-Gimenez, V., Cockey, L., Mason, M. and 
Graham, J. (2007) 'Open-label phase II study evaluating the efficacy and safety of two 
doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory 
prostate cancer', J Clin Oncol, 25(3), pp. 257-62. 
de Bono, J.S., Logothetis, C.J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K.N., 
Jones, R.J., Goodman, O.B., Jr., Saad, F., Staffurth, J.N., Mainwaring, P., Harland, S., 
Flaig, T.W., Hutson, T.E., Cheng, T., Patterson, H., Hainsworth, J.D., Ryan, C.J., 
Sternberg, C.N., Ellard, S.L., Flechon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, 
A., Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C.M. and Scher, H.I. (2011) 
'Abiraterone and increased survival in metastatic prostate cancer', N Engl J Med, 
364(21), pp. 1995-2005. 
Dey, N., Williams, C., Leyland-Jones, B. and De, P. (2015) 'A critical role for HER3 in 
HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK', 
American Journal of Translational Research, 7(4), pp. 733-750. 
Dhillon, A.S., Hagan, S., Rath, O. and Kolch, W. (2007) 'MAP kinase signalling 
pathways in cancer', Oncogene, 26(22), pp. 3279-90. 
Dhupkar, P., Dowling, M., Cengel, K. and Chen, B. (2010) 'Effects of anti-EGFR 
antibody cetuximab on androgen-independent prostate cancer cells', Anticancer Res, 
30(6), pp. 1905-10. 
Di Lorenzo, G., Bianco, R., Tortora, G. and Ciardiello, F. (2003) 'Involvement of 
growth factor receptors of the epidermal growth factor receptor family in prostate 
cancer development and progression to androgen independence', Clinical Prostate 
Cancer, 2(1), pp. 50-57. 
Bibliography 
185 
Dittmann, K., Mayer, C., Rodemann, H.P. and Huber, S.M. (2013) 'EGFR cooperates 
with glucose transporter SGLT1 to enable chromatin remodeling in response to ionizing 
radiation', Radiother Oncol, 107(2), pp. 247-51. 
Djerf Severinsson, E.A., Trinks, C., Green, H., Abdiu, A., Hallbeck, A.L., Stal, O. and 
Walz, T.M. (2011) 'The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes 
apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo', 
Biochem Biophys Res Commun, 414(3), pp. 563-8. 
Domingo-Domenech, J., Fernandez, P.L., Filella, X., Martinez-Fernandez, A., Molina, 
R., Fernandez, E., Alcaraz, A., Codony, J., Gascon, P. and Mellado, B. (2008) 'Serum 
HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA 
response in hormone-independent prostate cancer patients treated with docetaxel', Ann 
Oncol, 19(2), pp. 269-75. 
Doolan, G.W., Benke, G., Giles, G.G., Severi, G. and Kauppinen, T. (2014) 'A case 
control study investigating the effects of levels of physical activity at work as a risk 
factor for prostate cancer', Environ Health, 13, p. 64. 
Downward, J. and Weigelt, B. (2012) 'Genomic determinants of PI3K pathway inhibitor 
response in cancer', Frontiers in Oncology, 2. 
Duskova, K. and Vesely, S. (2015) 'Prostate Specific Antigen. Current clinical 
application and future prospects', Biomedical papers, 159(1), pp. 018-026. 
Edlind, M.P. and Hsieh, A.C. (2014) 'PI3K-AKT-mTOR signaling in prostate cancer 
progression and androgen deprivation therapy resistance', Asian Journal of Andrology, 
16(3), pp. 378-386. 
Edwards, J., Mukherjee, R., Munro, A.F., Wells, A.C., Almushatat, A. and Bartlett, 
J.M.S. (2004) 'HER2 and COX2 expression in human prostate cancer', European 
Journal of Cancer, 40(1), pp. 50-55. 
Edwards, J., Traynor, P., Munro, A.F., Pirret, C.F., Dunne, B. and Bartlett, J.M. (2006) 
'The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer', Clin 
Cancer Res, 12(1), pp. 123-30. 
Egeblad, M. and Werb, Z. (2002) 'New functions for the matrix metalloproteinases in 
cancer progression', Nat Rev Cancer, 2(3), pp. 161-74. 
Elenius, K., Corfas, G., Paul, S., Choi, C.J., Rio, C., Plowman, G.D. and Klagsbrun, M. 
(1997) 'A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific 
tissue distribution and differential processing in response to phorbol ester', J Biol Chem, 
272(42), pp. 26761-8. 
Engelman, J.A., Luo, J. and Cantley, L.C. (2006) 'The evolution of phosphatidylinositol 
3-kinases as regulators of growth and metabolism', Nat Rev Genet, 7(8), pp. 606-19. 
Enting, D. and Spicer, J. (2012) 'EGFR inhibition and more: a new generation growing 
up', Journal of Thoracic Disease, 4(6), pp. 553-555. 
Epstein, J.I. (2011) 'Update on the Gleason grading system', Ann Pathol, 31(5 Suppl), 
pp. S20-6. 
Bibliography 
186 
Esfahani, M., Ataei, N. and Panjehpour, M. (2015) 'Biomarkers for evaluation of 
prostate cancer prognosis', Asian Pac J Cancer Prev, 16(7), pp. 2601-11. 
Fang, W.B., Jokar, I., Zou, A., Lambert, D., Dendukuri, P. and Cheng, N. (2012) 
'CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer 
cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-
dependent mechanisms', J Biol Chem, 287(43), pp. 36593-608. 
Feldman, B.J. and Feldman, D. (2001) 'The development of androgen-independent 
prostate cancer', Nat Rev Cancer, 1(1), pp. 34-45. 
Feng, S., Shao, L., Yu, W., Gavine, P. and Ittmann, M. (2012) 'Targeting fibroblast 
growth factor receptor signaling inhibits prostate cancer progression', Clin Cancer Res, 
18(14), pp. 3880-8. 
Ferraldeschi, R., Welti, J., Luo, J., Attard, G. and de Bono, J.S. (2015) 'Targeting the 
androgen receptor pathway in castration-resistant prostate cancer: progresses and 
prospects', Oncogene, 34(14), pp. 1745-1757. 
Fizazi, K., Scher, H.I., Molina, A., Logothetis, C.J., Chi, K.N., Jones, R.J., Staffurth, 
J.N., North, S., Vogelzang, N.J., Saad, F., Mainwaring, P., Harland, S., Goodman, O.B., 
Jr., Sternberg, C.N., Li, J.H., Kheoh, T., Haqq, C.M. and de Bono, J.S. (2012) 
'Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final 
overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-
controlled phase 3 study', Lancet Oncol, 13(10), pp. 983-92. 
Freedland, S.J., Isaacs, W.B., Platz, E.A., Terris, M.K., Aronson, W.J., Amling, C.L., 
Presti, J.C. and Kane, C.J. (2005) 'Prostate Size and Risk of High-Grade, Advanced 
Prostate Cancer and Biochemical Progression After Radical Prostatectomy: A Search 
Database Study', Journal of Clinical Oncology, 23(30), pp. 7546-7554. 
Gann, P.H. (2002) 'Risk Factors for Prostate Cancer', Reviews in Urology, 4(Suppl 5), 
pp. S3-S10. 
Gaughan, L., Stockley, J., Wang, N., McCracken, S.R.C., Treumann, A., Armstrong, K., 
Shaheen, F., Watt, K., McEwan, I.J., Wang, C., Pestell, R.G. and Robson, C.N. (2011) 
'Regulation of the androgen receptor by SET9-mediated methylation', Nucleic Acids 
Research, 39(4), pp. 1266-1279. 
Ghosh, R., Narasanna, A., Wang, S.E., Liu, S., Chakrabarty, A., Balko, J.M., Gonzalez-
Angulo, A.M., Mills, G.B., Penuel, E., Winslow, J., Sperinde, J., Dua, R., Pidaparthi, S., 
Mukherjee, A., Leitzel, K., Kostler, W.J., Lipton, A., Bates, M. and Arteaga, C.L. 
(2011) 'Trastuzumab has preferential activity against breast cancers driven by HER2 
homodimers', Cancer Res, 71(5), pp. 1871-82. 
Gleason, D.F. (1966) 'Classification of prostatic carcinomas', Cancer Chemother Rep, 
50(3), pp. 125-8. 
Gleason, D.F. and Mellinger, G.T. (1974) 'Prediction of prognosis for prostatic 
adenocarcinoma by combined histological grading and clinical staging', J Urol, 111(1), 
pp. 58-64. 
Bibliography 
187 
Goc, A., Al-Husein, B., Kochuparambil, S.T., Liu, J., Heston, W.W. and Somanath, 
P.R. (2011) 'PI3 kinase integrates Akt and MAP kinase signaling pathways in the 
regulation of prostate cancer', Int J Oncol, 38(1), pp. 267-77. 
Goldenberg, M.M. (1999) 'Trastuzumab, a recombinant DNA-derived humanized 
monoclonal antibody, a novel agent for the treatment of metastatic breast cancer', 
Clinical Therapeutics, 21(2), pp. 309-318. 
Goyal, J. and Antonarakis, E.S. (2013) 'Clinical Evaluation of Abiraterone in the 
Treatment of Metastatic Prostate Cancer', Clin Med Insights Urol, 2013(7), pp. 1-14. 
Grasso, A.W., Wen, D., Miller, C.M., Rhim, J.S., Pretlow, T.G. and Kung, H.J. (1997) 
'ErbB kinases and NDF signaling in human prostate cancer cells', Oncogene, 15(22), pp. 
2705-16. 
Graus-Porta, D., Beerli, R.R., Daly, J.M. and Hynes, N.E. (1997) 'ErbB-2, the preferred 
heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling', 
EMBO J, 16(7), pp. 1647-55. 
Gravis, G., Bladou, F., Salem, N., Goncalves, A., Esterni, B., Walz, J., Bagattini, S., 
Marcy, M., Brunelle, S. and Viens, P. (2008) 'Results from a monocentric phase II trial 
of erlotinib in patients with metastatic prostate cancer', Ann Oncol, 19(9), pp. 1624-8. 
Groblewska, M., Siewko, M., Mroczko, B. and Szmitkowski, M. (2012) 'The role of 
matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of 
esophageal cancer', Folia Histochem Cytobiol, 50(1), pp. 12-9. 
Gschwind, A., Fischer, O.M. and Ullrich, A. (2004) 'The discovery of receptor tyrosine 
kinases: targets for cancer therapy', Nat Rev Cancer, 4(5), pp. 361-370. 
Guerin, O., Formento, P., Lo Nigro, C., Hofman, P., Fischel, J.L., Etienne-Grimaldi, 
M.C., Merlano, M., Ferrero, J.M. and Milano, G. (2008) 'Supra-additive antitumor 
effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new 
therapeutic perspective in hormone refractory prostate cancer', J Cancer Res Clin 
Oncol, 134(1), pp. 51-7. 
Guertin, D.A., Stevens, D.M., Saitoh, M., Kinkel, S., Crosby, K., Sheen, J.H., 
Mullholland, D.J., Magnuson, M.A., Wu, H. and Sabatini, D.M. (2009) 'mTOR 
complex 2 is required for the development of prostate cancer induced by Pten loss in 
mice', Cancer Cell, 15(2), pp. 148-59. 
Gum, R., Lengyel, E., Juarez, J., Chen, J.H., Sato, H., Seiki, M. and Boyd, D. (1996) 
'Stimulation of 92-kDa Gelatinase B Promoter Activity by ras Is Mitogen-activated 
Protein Kinase Kinase 1-independent and Requires Multiple Transcription Factor 
Binding Sites Including Closely Spaced PEA3/ets and AP-1 Sequences', Journal of 
Biological Chemistry, 271(18), pp. 10672-10680. 
Gutierrez, C. and Schiff, R. (2011) 'HER2: Biology, detection, and clinical 
implications', Archives of Pathology and Laboratory Medicine, 135(1), pp. 55-62. 
Han, G., Buchanan, G., Ittmann, M., Harris, J.M., Yu, X., DeMayo, F.J., Tilley, W. and 
Greenberg, N.M. (2005) 'Mutation of the androgen receptor causes oncogenic 
transformation of the prostate', Proceedings of the National Academy of Sciences of the 
United States of America, 102(4), pp. 1151-1156. 
Bibliography 
188 
Han, W. and Lo, H.W. (2012) 'Landscape of EGFR signaling network in human 
cancers: biology and therapeutic response in relation to receptor subcellular locations', 
Cancer Letters, 318(2), pp. 124-34. 
Hanahan, D. and Weinberg, R.A. (2011) 'Hallmarks of cancer: The next generation', 
Cell, 144(5), pp. 646-674. 
Harris, W.P., Mostaghel, E.A., Nelson, P.S. and Montgomery, B. (2009) 'Androgen 
deprivation therapy: progress in understanding mechanisms of resistance and optimizing 
androgen depletion', Nat Clin Pract Urol, 6(2), pp. 76-85. 
He, B., Kemppainen, J.A. and Wilson, E.M. (2000) 'FXXLF and WXXLF sequences 
mediate the NH2-terminal interaction with the ligand binding domain of the androgen 
receptor', J Biol Chem, 275(30), pp. 22986-94. 
Hedvig Hricak, P.S. (2009) Prostate Cancer. First Edition edn. Cambridge University 
Press. 
Heidenreich, A., Scholz, H.J., Rogenhofer, S., Arsov, C., Retz, M., Muller, S.C., Albers, 
P., Gschwend, J., Wirth, M., Steiner, U., Miller, K., Heinrich, E., Trojan, L., Volkmer, 
B., Honecker, F., Bokemeyer, C., Keck, B., Otremba, B., Ecstein-Fraisse, E. and Pfister, 
D. (2013) 'Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer 
progressing after docetaxel: results from the German compassionate-use programme', 
Eur Urol, 63(6), pp. 977-82. 
Heinlein, C.A. and Chang, C. (2002) 'Androgen receptor (AR) coregulators: an 
overview', Endocr Rev, 23(2), pp. 175-200. 
Hickinson, D.M., Klinowska, T., Speake, G., Vincent, J., Trigwell, C., Anderton, J., 
Beck, S., Marshall, G., Davenport, S., Callis, R., Mills, E., Grosios, K., Smith, P., 
Barlaam, B., Wilkinson, R.W. and Ogilvie, D. (2010) 'AZD8931, an equipotent, 
reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), 
and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer', Clin 
Cancer Res, 16(4), pp. 1159-69. 
Horoszewicz, J.S., Leong, S.S. and Kawinski, E. (1983) 'LNCaP model of human 
prostatic carcinoma', Cancer Research, 43(4), pp. 1809-1818. 
Hsieh, A.C. and Moasser, M.M. (2007) 'Targeting HER proteins in cancer therapy and 
the role of the non-target HER3', British Journal of Cancer, 97(4), pp. 453-457. 
Hsu, F.N., Yang, M.S., Lin, E., Tseng, C.F. and Lin, H. (2011) 'The significance of 
Her2 on androgen receptor protein stability in the transition of androgen requirement in 
prostate cancer cells', American Journal of Physiology - Endocrinology and 
Metabolism, 300(5), pp. E902-E908. 
Hu, R., Dunn, T.A., Wei, S., Isharwal, S., Veltri, R.W., Humphreys, E., Han, M., Partin, 
A.W., Vessella, R.L., Isaacs, W.B., Bova, G.S. and Luo, J. (2009) 'Ligand-independent 
androgen receptor variants derived from splicing of cryptic exons signify hormone-
refractory prostate cancer', Cancer Res, 69(1), pp. 16-22. 
Bibliography 
189 
Hu, R., Lu, C., Mostaghel, E.A., Yegnasubramanian, S., Gurel, M., Tannahill, C., 
Edwards, J., Isaacs, W.B., Nelson, P.S., Bluemn, E., Plymate, S.R. and Luo, J. (2012) 
'Distinct transcriptional programs mediated by the ligand-dependent full-length 
androgen receptor and its splice variants in castration-resistant prostate cancer', Cancer 
Res, 72(14), pp. 3457-62. 
Huang, Z., Brdlik, C., Jin, P. and Shepard, H.M. (2009) 'A pan-HER approach for 
cancer therapy: background, current status and future development', Expert Opin Biol 
Ther, 9(1), pp. 97-110. 
Huggins, C. and Hodges, C.V. (1941) 'Studies on Prostatic Cancer. I. The Effect of 
Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic 
Carcinoma of the Prostate', Cancer Research, 1(4), pp. 293-297. 
Humphrey, P.A. (2004) 'Gleason grading and prognostic factors in carcinoma of the 
prostate', Mod Pathol, 17(3), pp. 292-306. 
Hung, L.Y., Tseng, J.T., Lee, Y.C., Xia, W., Wang, Y.N., Wu, M.L., Chuang, Y.H., 
Lai, C.H. and Chang, W.C. (2008) 'Nuclear epidermal growth factor receptor (EGFR) 
interacts with signal transducer and activator of transcription 5 (STAT5) in activating 
Aurora-A gene expression', Nucleic Acids Res, 36(13), pp. 4337-51. 
Hung, S.H., Shen, K.H., Wu, C.H., Liu, C.L. and Shih, Y.W. (2009) 'Alpha-mangostin 
suppresses PC-3 human prostate carcinoma cell metastasis by inhibiting matrix 
metalloproteinase-2/9 and urokinase-plasminogen expression through the JNK signaling 
pathway', J Agric Food Chem, 57(4), pp. 1291-8. 
Hynes, N.E. and Lane, H.A. (2005) 'ERBB receptors and cancer: the complexity of 
targeted inhibitors', Nat Rev Cancer, 5(5), pp. 341-354. 
Hynes, N.E. and MacDonald, G. (2009) 'ErbB receptors and signaling pathways in 
cancer', Current Opinion in Cell Biology, 21(2), pp. 177-184. 
Invitrogen. Available at: 
https://www.thermofisher.com/order/catalog/product/V49610?ICID=search-product. 
Jaiswal, Bijay S., Kljavin, Noelyn M., Stawiski, Eric W., Chan, E., Parikh, C., Durinck, 
S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, Kyle A., Janakiraman, V., Scholz, R.-
P., Bowman, Krista K., Lorenzo, M., Li, H., Wu, J., Yuan, W., Peters, Brock A., Kan, 
Z., Stinson, J., Mak, M., Modrusan, Z., Eigenbrot, C., Firestein, R., Stern, Howard M., 
Rajalingam, K., Schaefer, G., Merchant, Mark A., Sliwkowski, Mark X., de Sauvage, 
Frederic J. and Seshagiri, S. (2013) 'Oncogenic ERBB3 Mutations in Human Cancers', 
Cancer Cell, 23(5), pp. 603-617. 
Jathal, M.K., Chen, L., Mudryj, M. and Ghosh, P.M. (2011) 'Targeting ErbB3: The new 
RTK(id) on the prostate cancer block', Immunology, Endocrine and Metabolic Agents in 
Medicinal Chemistry, 11(2), pp. 131-149. 
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011) 'Global 
cancer statistics', CA Cancer Journal for Clinicians, 61(2), pp. 69-90. 
Jennifer, D. and Iain, J.M. (2005) 'Mutation of Histidine 874 in the Androgen Receptor 
Ligand-Binding Domain Leads to Promiscuous Ligand Activation and Altered p160 
Coactivator Interactions', Molecular Endocrinology, 19(12), pp. 2943-2954. 
Bibliography 
190 
Jenster, G., van der Korput, H.A., van Vroonhoven, C., van der Kwast, T.H., Trapman, 
J. and Brinkmann, A.O. (1991) 'Domains of the human androgen receptor involved in 
steroid binding, transcriptional activation, and subcellular localization', Mol Endocrinol, 
5(10), pp. 1396-404. 
Jiang, N., Saba, N.F. and Chen, Z.G. (2012) 'Advances in Targeting HER3 as an 
Anticancer Therapy', Chemother Res Pract, 2012, p. 817304. 
Jin, J.K., Dayyani, F. and Gallick, G.E. (2011) 'Steps in prostate cancer progression that 
lead to bone metastasis', Int J Cancer, 128(11), pp. 2545-61. 
Joseph, J.D., Lu, N., Qian, J., Sensintaffar, J., Shao, G., Brigham, D., Moon, M., 
Maneval, E.C., Chen, I., Darimont, B. and Hager, J.H. (2013) 'A clinically relevant 
androgen receptor mutation confers resistance to second-generation antiandrogens 
enzalutamide and ARN-509', Cancer Discov, 3(9), pp. 1020-9. 
Junttila, M.R., Li, S.P. and Westermarck, J. (2008) 'Phosphatase-mediated crosstalk 
between MAPK signaling pathways in the regulation of cell survival', Faseb j, 22(4), 
pp. 954-65. 
Kahn, B., Collazo, J. and Kyprianou, N. (2014) 'Androgen receptor as a driver of 
therapeutic resistance in advanced prostate cancer', Int J Biol Sci, 10(6), pp. 588-95. 
Kaighn, M.E., Shankar Narayan, K. and Ohnuki, Y. (1979) 'Establishment and 
characterization of a human prostatic carcinoma cell line (PC-3)', Investigative Urology, 
17(1), pp. 16-23. 
Kashihara, M., Azuma, K., Kawahara, A., Basaki, Y., Hattori, S., Yanagawa, T., 
Terazaki, Y., Takamori, S., Shirouzu, K., Aizawa, H., Nakano, K., Kage, M., Kuwano, 
M. and Ono, M. (2009) 'Nuclear Y-box binding protein-1, a predictive marker of 
prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small 
cell lung cancer', J Thorac Oncol, 4(9), pp. 1066-74. 
Kato, H., Sekine, Y., Furuya, Y., Miyazawa, Y., Koike, H. and Suzuki, K. (2015) 
'Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the 
downregulation of insulin-like growth factor 1 receptor', Biochem Biophys Res 
Commun, 461(1), pp. 115-21. 
Keller, E.T., Fu, Z., Yeung, K. and Brennan, M. (2004) 'Raf kinase inhibitor protein: a 
prostate cancer metastasis suppressor gene', Cancer Letters, 207(2), pp. 131-137. 
Kelly, W.K., Halabi, S., Carducci, M., George, D., Mahoney, J.F., Stadler, W.M., 
Morris, M., Kantoff, P., Monk, J.P., Kaplan, E., Vogelzang, N.J. and Small, E.J. (2012) 
'Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and 
prednisone with or without bevacizumab in men with metastatic castration-resistant 
prostate cancer: CALGB 90401', J Clin Oncol, 30(13), pp. 1534-40. 
Kirby, M., Hirst, C. and Crawford, E.D. (2011) 'Characterising the castration-resistant 
prostate cancer population: a systematic review', Int J Clin Pract, 65(11), pp. 1180-92. 
Kolonel, L.N. (2001) 'Fat, meat, and prostate cancer', Epidemiol Rev, 23(1), pp. 72-81. 
Koul, H.K., Pal, M. and Koul, S. (2013) 'Role of p38 MAP Kinase Signal Transduction 
in Solid Tumors', Genes & Cancer, 4(9-10), pp. 342-359. 
Bibliography 
191 
Koumakpayi, I.H., Diallo, J.-S., Le Page, C., Lessard, L., Gleave, M., Bégin, L.R., Mes-
Masson, A.-M. and Saad, F. (2006) 'Expression and Nuclear Localization of ErbB3 in 
Prostate Cancer', Clinical Cancer Research, 12(9), pp. 2730-2737. 
Koutras, A.K., Fountzilas, G., Kalogeras, K.T., Starakis, I., Iconomou, G. and 
Kalofonos, H.P. (2010) 'The upgraded role of HER3 and HER4 receptors in breast 
cancer', Critical Reviews in Oncology/Hematology, 74(2), pp. 73-78. 
Kraus, M.H., Issing, W., Miki, T., Popescu, N.C. and Aaronson, S.A. (1989) 'Isolation 
and characterization of ERBB3, a third member of the ERBB/epidermal growth factor 
receptor family: evidence for overexpression in a subset of human mammary tumors', 
Proceedings of the National Academy of Sciences, 86(23), pp. 9193-9197. 
Kuriyama, M., Wang, M.C., Papsidero, L.D., Killian, C.S., Shimano, T., Valenzuela, L., 
Nishiura, T., Murphy, G.P. and Chu, T.M. (1980) 'Quantitation of prostate-specific 
antigen in serum by a sensitive enzyme immunoassay', Cancer Res, 40(12), pp. 4658-
62. 
Lallous, N., Dalal, K., Cherkasov, A. and Rennie, P.S. (2013) 'Targeting alternative 
sites on the androgen receptor to treat castration-resistant prostate cancer', Int J Mol Sci, 
14(6), pp. 12496-519. 
Lamb, A.D. and Neal, D.E. (2013) 'Role of the androgen receptor in prostate cancer', 
Trends in Urology & Men's Health, 4(3), pp. 26-30. 
Lara, P.N., Jr., Chee, K.G., Longmate, J., Ruel, C., Meyers, F.J., Gray, C.R., Edwards, 
R.G., Gumerlock, P.H., Twardowski, P., Doroshow, J.H. and Gandara, D.R. (2004) 
'Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results 
from the California Cancer Consortium Screening and Phase II Trial', Cancer, 100(10), 
pp. 2125-31. 
Lee, C., Kozlowski, J.M. and Grayhack, J.T. (1997) 'Intrinsic and extrinsic factors 
controlling benign prostatic growth', Prostate, 31(2), pp. 131-8. 
Lee, D.K. and Chang, C. (2003) 'Endocrine mechanisms of disease: Expression and 
degradation of androgen receptor: mechanism and clinical implication', J Clin 
Endocrinol Metab, 88(9), pp. 4043-54. 
Lemmon, M.A., Schlessinger, J. and Ferguson, K.M. (2014) 'The EGFR family: not so 
prototypical receptor tyrosine kinases', Cold Spring Harb Perspect Biol, 6(4), p. 
a020768. 
Li, Y., Chan, S.C., Brand, L.J., Hwang, T.H., Silverstein, K.A. and Dehm, S.M. (2013) 
'Androgen receptor splice variants mediate enzalutamide resistance in castration-
resistant prostate cancer cell lines', Cancer Res, 73(2), pp. 483-9. 
Liao, G., Chen, L.Y., Zhang, A., Godavarthy, A., Xia, F., Ghosh, J.C., Li, H. and Chen, 
J.D. (2003) 'Regulation of androgen receptor activity by the nuclear receptor 
corepressor SMRT', J Biol Chem, 278(7), pp. 5052-61. 
Lilja, H., Oldbring, J., Rannevik, G. and Laurell, C.B. (1987) 'Seminal vesicle-secreted 
proteins and their reactions during gelation and liquefaction of human semen', Journal 
of Clinical Investigation, 80(2), pp. 281-285. 
Bibliography 
192 
Lin, D.L., Whitney, M.C., Yao, Z. and Keller, E.T. (2001) 'Interleukin-6 induces 
androgen responsiveness in prostate cancer cells through up-regulation of androgen 
receptor expression', Clin Cancer Res, 7(6), pp. 1773-81. 
Lin, P.C., Chiu, Y.L., Banerjee, S., Park, K., Mosquera, J.M., Giannopoulou, E., Alves, 
P., Tewari, A.K., Gerstein, M.B., Beltran, H., Melnick, A.M., Elemento, O., 
Demichelis, F. and Rubin, M.A. (2013) 'Epigenetic repression of miR-31 disrupts 
androgen receptor homeostasis and contributes to prostate cancer progression', Cancer 
Res, 73(3), pp. 1232-44. 
Lin, Y. and Wang, F. (2010) 'FGF signalling in prostate development, tissue 
homoeostasis and tumorigenesis', Biosci Rep, 30(5), pp. 285-91. 
Liu, A.Y., True, L.D., LaTray, L., Nelson, P.S., Ellis, W.J., Vessella, R.L., Lange, P.H., 
Hood, L. and van den Engh, G. (1997) 'Cell-cell interaction in prostate gene regulation 
and cytodifferentiation', Proc Natl Acad Sci U S A, 94(20), pp. 10705-10. 
Liu, L.L., Xie, N., Sun, S., Plymate, S., Mostaghel, E. and Dong, X. (2014) 
'Mechanisms of the androgen receptor splicing in prostate cancer cells', Oncogene, 
33(24), pp. 3140-50. 
Liu, Y., Karaca, M., Zhang, Z., Gioeli, D., Earp, H.S. and Whang, Y.E. (2010) 
'Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 
and Src kinases', Oncogene, 29(22), pp. 3208-3216. 
Lo, H.-W., Ali-Seyed, M., Wu, Y., Bartholomeusz, G., Hsu, S.-C. and Hung, M.-C. 
(2006) 'Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin 
β1 and CRM1', Journal of Cellular Biochemistry, 98(6), pp. 1570-1583. 
Locke, J.A., Guns, E.S., Lubik, A.A., Adomat, H.H., Hendy, S.C., Wood, C.A., 
Ettinger, S.L., Gleave, M.E. and Nelson, C.C. (2008) 'Androgen levels increase by 
intratumoral de novo steroidogenesis during progression of castration-resistant prostate 
cancer', Cancer Res, 68(15), pp. 6407-15. 
Lonergan, P.E. and Tindall, D.J. (2011) 'Androgen receptor signaling in prostate cancer 
development and progression', J Carcinog, 10, p. 20. 
Longva, K.E., Blystad, F.D., Stang, E., Larsen, A.M., Johannessen, L.E. and Madshus, 
I.H. (2002) 'Ubiquitination and proteasomal activity is required for transport of the EGF 
receptor to inner membranes of multivesicular bodies', The Journal of Cell Biology, 
156(5), pp. 843-854. 
Lorenzo, P.I. and Saatcioglu, F. (2008) 'Inhibition of apoptosis in prostate cancer cells 
by androgens is mediated through downregulation of c-Jun N-terminal kinase 
activation', Neoplasia, 10(5), pp. 418-28. 
Lynch, H.T. and Lynch, J.F. (1996) 'The Lynch Syndrome: Melding Natural History 
and Molecular Genetics to Genetic Counseling and Cancer Control', Cancer Control, 
3(1), pp. 13-19. 
Madu, C.O. and Lu, Y. (2010) 'Novel diagnostic biomarkers for prostate cancer', J 
Cancer, 1, pp. 150-77. 
Bibliography 
193 
Majumder, P.K., Yeh, J.J., George, D.J., Febbo, P.G., Kum, J., Xue, Q., Bikoff, R., Ma, 
H., Kantoff, P.W., Golub, T.R., Loda, M. and Sellers, W.R. (2003) 'Prostate 
intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT 
model', Proc Natl Acad Sci U S A, 100(13), pp. 7841-6. 
Manning, B.D. and Cantley, L.C. (2007) 'AKT/PKB signaling: navigating downstream', 
Cell, 129(7), pp. 1261-74. 
Martinelli, E., De Palma, R., Orditura, M., De Vita, F. and Ciardiello, F. (2009) 'Anti-
epidermal growth factor receptor monoclonal antibodies in cancer therapy', Clinical and 
Experimental Immunology, 158(1), pp. 1-9. 
Masiello, D., Cheng, S., Bubley, G.J., Lu, M.L. and Balk, S.P. (2002) 'Bicalutamide 
Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally 
Inactive Receptor', Journal of Biological Chemistry, 277(29), pp. 26321-26326. 
McCracken, S.R., Ramsay, A., Heer, R., Mathers, M.E., Jenkins, B.L., Edwards, J., 
Robson, C.N., Marquez, R., Cohen, P. and Leung, H.Y. (2008) 'Aberrant expression of 
extracellular signal-regulated kinase 5 in human prostate cancer', Oncogene, 27(21), pp. 
2978-88. 
McCubrey, J.A., Lahair, M.M. and Franklin, R.A. (2006) 'Reactive oxygen species-
induced activation of the MAP kinase signaling pathways', Antioxid Redox Signal, 8(9-
10), pp. 1775-89. 
McMenamin, M.E., Soung, P., Perera, S., Kaplan, I., Loda, M. and Sellers, W.R. (1999) 
'Loss of PTEN Expression in Paraffin-embedded Primary Prostate Cancer Correlates 
with High Gleason Score and Advanced Stage', Cancer Research, 59(17), pp. 4291-
4296. 
McNeal, J.E. and Bostwick, D.G. (1986) 'Intraductal dysplasia: a premalignant lesion of 
the prostate', Hum Pathol, 17(1), pp. 64-71. 
Mellinghoff, I.K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J. and Sawyers, C.L. 
(2004) 'HER2/neu kinase-dependent modulation of androgen receptor function through 
effects on DNA binding and stability', Cancer Cell, 6(5), pp. 517-527. 
Memarzadeh, S., Xin, L., Mulholland, D.J., Mansukhani, A., Wu, H., Teitell, M.A. and 
Witte, O.N. (2007) 'Enhanced paracrine FGF10 expression promotes formation of 
multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor', 
Cancer Cell, 12(6), pp. 572-85. 
Miyamoto, H., Messing, E.M. and Chang, C. (2004) 'Androgen deprivation therapy for 
prostate cancer: current status and future prospects', Prostate, 61(4), pp. 332-53. 
Miyoshi, Y., Uemura, H., Fujinami, K., Mikata, K., Harada, M., Kitamura, H., Koizumi, 
Y. and Kubota, Y. (2000) 'Fluorescence in situ hybridization evaluation of c-myc and 
androgen receptor gene amplification and chromosomal anomalies in prostate cancer in 
Japanese patients', Prostate, 43(3), pp. 225-32. 
Bibliography 
194 
Molife, L.R., Omlin, A., Jones, R.J., Karavasilis, V., Bloomfield, D., Lumsden, G., 
Fong, P.C., Olmos, D., O'Sullivan, J.M., Pedley, I., Hickish, T., Jenkins, P., Thompson, 
E., Oommen, N., Wheatley, D., Heath, C., Temple, G., Pelling, K. and de Bono, J.S. 
(2014) 'Randomized Phase II trial of nintedanib, afatinib and sequential combination in 
castration-resistant prostate cancer', Future Oncol, 10(2), pp. 219-31. 
Montironi, R., Mazzucchelli, R., Lopez-Beltran, A., Scarpelli, M. and Cheng, L. (2011) 
'Prostatic intraepithelial neoplasia: its morphological and molecular diagnosis and 
clinical significance', BJU Int, 108(9), pp. 1394-401. 
Morris, M.J., Reuter, V.E., Kelly, W.K., Slovin, S.F., Kenneson, K., Verbel, D., Osman, 
I. and Scher, H.I. (2002) 'HER-2 profiling and targeting in prostate carcinoma', Cancer, 
94(4), pp. 980-6. 
Mostaghel, E.A., Marck, B.T., Plymate, S.R., Vessella, R.L., Balk, S., Matsumoto, 
A.M., Nelson, P.S. and Montgomery, R.B. (2011) 'Resistance to CYP17A1 inhibition 
with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and 
androgen receptor splice variants', Clin Cancer Res, 17(18), pp. 5913-25. 
Mu, Z., Klinowska, T., Dong, X., Foster, E., Womack, C., Fernandez, S.V. and 
Cristofanilli, M. (2014) 'AZD8931, an equipotent, reversible inhibitor of signaling by 
epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in 
HER2 non-amplified inflammatory breast cancer models', J Exp Clin Cancer Res, 33, p. 
47. 
Mulholland, D.J., Tran, L.M., Li, Y., Cai, H., Morim, A., Wang, S., Plaisier, S., 
Garraway, I.P., Huang, J., Graeber, T.G. and Wu, H. (2011) 'Cell autonomous role of 
PTEN in regulating castration-resistant prostate cancer growth', Cancer Cell, 19(6), pp. 
792-804. 
Myers, R.B., Srivastava, S., Oelschlager, D.K. and Grizzle, W.E. (1994) 'Expression of 
p160erbB-3 and p185erbB-2 in Prostatic Intraepithelial Neoplasia and Prostatic 
Adenocarcinoma', Journal of the National Cancer Institute, 86(15), pp. 1140-1145. 
Nakabayashi, M., Werner, L., Courtney, K.D., Buckle, G., Oh, W.K., Bubley, G.J., 
Hayes, J.H., Weckstein, D., Elfiky, A., Sims, D.M., Kantoff, P.W. and Taplin, M.E. 
(2012) 'Phase II trial of RAD001 and bicalutamide for castration-resistant prostate 
cancer', BJU Int, 110(11), pp. 1729-35. 
Nardella, C., Carracedo, A., Alimonti, A., Hobbs, R.M., Clohessy, J.G., Chen, Z., Egia, 
A., Fornari, A., Fiorentino, M., Loda, M., Kozma, S.C., Thomas, G., Cordon-Cardo, C. 
and Pandolfi, P.P. (2009) 'Differential requirement of mTOR in postmitotic tissues and 
tumorigenesis', Sci Signal, 2(55), p. ra2. 
Nazareth, L.V. and Weigel, N.L. (1996) 'Activation of the Human Androgen Receptor 
through a Protein Kinase A Signaling Pathway', Journal of Biological Chemistry, 
271(33), pp. 19900-19907. 
Nguyen, D.P., Li, J. and Tewari, A.K. (2014) 'Inflammation and prostate cancer: the 
role of interleukin 6 (IL-6)', BJU International, 113(6), pp. 986-992. 
Bibliography 
195 
Ni, M., Chen, Y., Lim, E., Wimberly, H., Bailey, S.T., Imai, Y., Rimm, D.L., Liu, X.S. 
and Brown, M. (2011) 'Targeting Androgen Receptor in Estrogen Receptor-Negative 
Breast Cancer', Cancer cell, 20(1), pp. 119-131. 
Nickerson, T., Chang, F., Lorimer, D., Smeekens, S.P., Sawyers, C.L. and Pollak, M. 
(2001) 'In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen 
independence is associated with increased expression of insulin-like growth factor I 
(IGF-I) and IGF-I receptor (IGF-IR)', Cancer Res, 61(16), pp. 6276-80. 
Nogueira, L., Corradi, R. and Eastham, J.A. (2010) 'Other biomarkers for detecting 
prostate cancer', BJU Int, 105(2), pp. 166-9. 
Nowsheen, S. and Yang, E.S. (2012) 'The Intersection Between DNA Damage 
Response And Cell Death Pathways', Experimental oncology, 34(3), pp. 243-254. 
Oesterling, J.E. (1991) 'Prostate specific antigen: a critical assessment of the most useful 
tumor marker for adenocarcinoma of the prostate', J Urol, 145(5), pp. 907-23. 
Olayioye, M.A., Neve, R.M., Lane, H.A. and Hynes, N.E. (2000) The ErbB signaling 
network: receptor heterodimerization in development and cancer. 
Ooi, A., Suzuki, S., Nakazawa, K., Itakura, J., Imoto, I., Nakamura, H. and Dobashi, Y. 
(2009) 'Gene amplification of Myc and its coamplification with ERBB2 and EGFR in 
gallbladder adenocarcinoma', Anticancer Research, 29(1), pp. 19-26. 
Overall, C.M. and Lopez-Otin, C. (2002) 'Strategies for MMP inhibition in cancer: 
innovations for the post-trial era', Nat Rev Cancer, 2(9), pp. 657-72. 
Park, H., Kim, Y., Sul, J.W., Jeong, I.G., Yi, H.J., Ahn, J.B., Kang, J.S., Yun, J., 
Hwang, J.J. and Kim, C.S. (2015) 'Synergistic anticancer efficacy of MEK inhibition 
and dual PI3K/mTOR inhibition in castration-resistant prostate cancer', Prostate. 
Pei, J., Lou, Y., Zhong, R. and Han, B. (2014) 'MMP9 activation triggered by epidermal 
growth factor induced FoxO1 nuclear exclusion in non-small cell lung cancer', Tumour 
Biol, 35(7), pp. 6673-8. 
Perlmutter, M.A. and Lepor, H. (2007) 'Androgen Deprivation Therapy in the 
Treatment of Advanced Prostate Cancer', Reviews in Urology, 9(Suppl 1), pp. S3-S8. 
Petrylak, D.P. (2014) 'Practical guide to the use of chemotherapy in castration resistant 
prostate cancer', Can J Urol, 21(2 Supp 1), pp. 77-83. 
Platz, E.A., Smit, E., Curhan, G.C., Nyberg, L.M. and Giovannucci, E. (2002) 
'Prevalence of and racial/ethnic variation in lower urinary tract symptoms and 
noncancer prostate surgery in U.S. men', Urology, 59(6), pp. 877-83. 
Priest, R., Garzotto, M. and Kaufman, J. (2012) 'Benign prostatic hyperplasia: a brief 
overview of pathogenesis, diagnosis, and therapy', Tech Vasc Interv Radiol, 15(4), pp. 
261-4. 
Puri, N. and Salgia, R. (2008) 'Synergism of EGFR and c-Met pathways, cross-talk and 
inhibition, in non-small cell lung cancer', J Carcinog, 7, p. 9. 
Bibliography 
196 
Purvis, J., Ilango, V. and Radhakrishnan, R. (2008) 'Role of network branching in 
eliciting differential short-term signaling responses in the hypersensitive epidermal 
growth factor receptor mutants implicated in lung cancer', Biotechnol Prog, 24(3), pp. 
540-53. 
Radmayr, C., Lunacek, A., Schwentner, C., Oswald, J., Klocker, H. and Bartsch, G. 
(2008) '5-alpha-reductase and the development of the human prostate', Indian Journal of 
Urology : IJU : Journal of the Urological Society of India, 24(3), pp. 309-312. 
Ramsay, A.K., McCracken, S.R., Soofi, M., Fleming, J., Yu, A.X., Ahmad, I., Morland, 
R., Machesky, L., Nixon, C., Edwards, D.R., Nuttall, R.K., Seywright, M., Marquez, R., 
Keller, E. and Leung, H.Y. (2011) 'ERK5 signalling in prostate cancer promotes an 
invasive phenotype', Br J Cancer, 104(4), pp. 664-72. 
Rathkoph, D. (2015) Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant 
Prostate Cancer (CRPC) Patients. 
Reese, J.H., McNeal, J.E., Redwine, E.A., Stamey, T.A. and Freiha, F.S. (1988) 'Tissue 
type plasminogen activator as a marker for functional zones, within the human prostate 
gland', Prostate, 12(1), pp. 47-53. 
Reif, R., Adawy, A., Vartak, N., Schroder, J., Gunther, G., Ghallab, A., Schmidt, M., 
Schormann, W. and Hengstler, J.G. (2015) 'Activated ErbB3 translocates to the nucleus 
via clathrin-independent endocytosis which is associated with proliferating cells', J Biol 
Chem. 
Rocks, N., Paulissen, G., El Hour, M., Quesada, F., Crahay, C., Gueders, M., Foidart, 
J.M., Noel, A. and Cataldo, D. (2008) 'Emerging roles of ADAM and ADAMTS 
metalloproteinases in cancer', Biochimie, 90(2), pp. 369-379. 
Rodriguez-Berriguete, G., Fraile, B., Martinez-Onsurbe, P., Olmedilla, G., Paniagua, R. 
and Royuela, M. (2012) 'MAP Kinases and Prostate Cancer', J Signal Transduct, 2012, 
p. 169170. 
Roskoski, R., Jr. (2014) 'The ErbB/HER family of protein-tyrosine kinases and cancer', 
Pharmacol Res, 79, pp. 34-74. 
Sakr, W.A., Grignon, D.J., Crissman, J.D., Heilbrun, L.K., Cassin, B.J., Pontes, J.J. and 
Haas, G.P. (1994) 'High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic 
adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases', In Vivo, 
8(3), pp. 439-43. 
Sarbassov, D.D., Guertin, D.A., Ali, S.M. and Sabatini, D.M. (2005) 'Phosphorylation 
and regulation of Akt/PKB by the rictor-mTOR complex', Science, 307(5712), pp. 
1098-101. 
Sato, Y., Yashiro, M. and Takakura, N. (2013) 'Heregulin induces resistance to 
lapatinib-mediated growth inhibition of HER2-amplified cancer cells', Cancer Science, 
104(12), pp. 1618-1625. 
Bibliography 
197 
Scaltriti, M., Rojo, F., Ocaña, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., 
Matias-Guiu, X., Ramon y Cajal, S., Arribas, J. and Baselga, J. (2007) 'Expression of 
p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 
Therapies in Breast Cancer', Journal of the National Cancer Institute, 99(8), pp. 628-
638. 
Schechter, A.L., Stern, D.F., Vaidyanathan, L., Decker, S.J., Drebin, J.A., Greene, M.I. 
and Weinberg, R.A. (1984) 'The neu oncogene: an erb-B-related gene encoding a 
185,000-Mr tumour antigen', Nature, 312(5994), pp. 513-6. 
Scheller, J., Chalaris, A., Garbers, C. and Rose-John, S. (2011) 'ADAM17: a molecular 
switch to control inflammation and tissue regeneration', Trends in Immunology, 32(8), 
pp. 380-387. 
Scher, H.I., Beer, T.M., Higano, C.S., Anand, A., Taplin, M.E., Efstathiou, E., 
Rathkopf, D., Shelkey, J., Yu, E.Y., Alumkal, J., Hung, D., Hirmand, M., Seely, L., 
Morris, M.J., Danila, D.C., Humm, J., Larson, S., Fleisher, M. and Sawyers, C.L. 
(2010) 'Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 
1-2 study', Lancet, 375(9724), pp. 1437-46. 
Schulz, W.A., Burchardt, M. and Cronauer, M.V. (2003) 'Molecular biology of prostate 
cancer', Molecular Human Reproduction, 9(8), pp. 437-448. 
Sciarra, A., Panebianco, V., Cattarino, S., Busetto, G., De Berardinis, E., Ciccariello, 
M., Gentile, V. and Salciccia, S. (2012) 'Multiparametric magnetic resonance imaging 
of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 
test in patients with elevated prostate-specific antigen levels and a previous negative 
biopsy', BJU International, pp. 1-5. 
Sergina, N.V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K.M. and Moasser, 
M.M. (2007) 'Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-
inactive HER3', Nature, 445(7126), pp. 437-441. 
Seshacharyulu, P., Ponnusamy, M.P., Haridas, D., Jain, M., Ganti, A.K. and Batra, S.K. 
(2012) 'Targeting the EGFR signaling pathway in cancer therapy', Expert Opin Ther 
Targets, 16(1), pp. 15-31. 
Setlur, S.R. and Rubin, M.A. (2005) 'Current thoughts on the role of the androgen 
receptor and prostate cancer progression', Adv Anat Pathol, 12(5), pp. 265-70. 
Shen, H.C., Buchanan, G., Butler, L.M., Prescott, J., Henderson, M., Tilley, W.D. and 
Coetzee, G.A. (2005) 'GRIP1 mediates the interaction between the amino- and 
carboxyl-termini of the androgen receptor', Biol Chem, 386(1), pp. 69-74. 
Shen, K.H., Hung, S.H., Yin, L.T., Huang, C.S., Chao, C.H., Liu, C.L. and Shih, Y.W. 
(2010) 'Acacetin, a flavonoid, inhibits the invasion and migration of human prostate 
cancer DU145 cells via inactivation of the p38 MAPK signaling pathway', Mol Cell 
Biochem, 333(1-2), pp. 279-91. 
Shi, F., Telesco, S.E., Liu, Y., Radhakrishnan, R. and Lemmona, M.A. (2010) 
'ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze 
autophosphorylation', Proceedings of the National Academy of Sciences of the United 
States of America, 107(17), pp. 7692-7697. 
Bibliography 
198 
Shiota, M., Bishop, J.L., Takeuchi, A., Nip, K.M., Cordonnier, T., Beraldi, E., Kuruma, 
H., Gleave, M.E. and Zoubeidi, A. (2015) 'Inhibition of the HER2-YB1-AR axis with 
Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration 
resistant prostate cancer', Oncotarget, 6(11), pp. 9086-9098. 
Shiota, M., Takeuchi, A., Song, Y., Yokomizo, A., Kashiwagi, E., Uchiumi, T., 
Kuroiwa, K., Tatsugami, K., Fujimoto, N., Oda, Y. and Naito, S. (2011) 'Y-box binding 
protein-1 promotes castration-resistant prostate cancer growth via androgen receptor 
expression', Endocr Relat Cancer, 18(4), pp. 505-17. 
Shu, S.K., Liu, Q., Coppola, D. and Cheng, J.Q. (2010) 'Phosphorylation and activation 
of androgen receptor by Aurora-A', J Biol Chem, 285(43), pp. 33045-53. 
Siddiqui, E., Mumtaz, F.H. and Gelister, J. (2004) 'Understanding prostate cancer', J R 
Soc Promot Health, 124(5), pp. 219-21. 
Signoretti, S., Montironi, R., Manola, J., Altimari, A., Tam, C., Bubley, G., Balk, S., 
Thomas, G., Kaplan, I., Hlatky, L., Hahnfeldt, P., Kantoff, P. and Loda, M. (2000) 'Her-
2-neu expression and progression toward androgen independence in human prostate 
cancer', Journal of the National Cancer Institute, 92(23), pp. 1918-1925. 
Sithanandam, G. and Anderson, L.M. (2008) 'The ERBB3 receptor in cancer and cancer 
gene therapy', Cancer Gene Therapy, 15(7), pp. 413-448. 
Skolnik, E.Y., Margolis, B., Mohammadi, M., Lowenstein, E., Fischer, R., Drepps, A., 
Ullrich, A. and Schlessinger, J. (1991) 'Cloning of PI3 kinase-associated p85 utilizing a 
novel method for expression/cloning of target proteins for receptor tyrosine kinases', 
Cell, 65(1), pp. 83-90. 
Smith, M.R., Antonarakis, E.S., Ryan, C.J., Berry, W., Shore, N.D., Liu, G., Alumkal, 
J., Higano, C., Chow-Maneval, E. and Rathkopf, D. (2012) 'ARN-509 In Men With 
High Risk Non-Metastatic Castration-Resistant Prostate Cancer', Annals of Oncology, 
23, pp. 303-303. 
Sonn, G.A., Aronson, W. and Litwin, M.S. (2005) 'Impact of diet on prostate cancer: a 
review', Prostate Cancer Prostatic Dis, 8(4), pp. 304-10. 
Squire, J.A. (2009) 'TMPRSS2-ERG and PTEN loss in prostate cancer', Nat Genet, 
41(5), pp. 509-510. 
Sridhar, S.S., Hotte, S.J., Chin, J.L., Hudes, G.R., Gregg, R., Trachtenberg, J., Wang, 
L., Tran-Thanh, D., Pham, N.A., Tsao, M.S., Hedley, D., Dancey, J.E. and Moore, M.J. 
(2010) 'A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally 
untreated advanced prostate cancer', Am J Clin Oncol, 33(6), pp. 609-13. 
Stamey, T.A., Yang, N., Hay, A.R., McNeal, J.E., Freiha, F.S. and Redwine, E. (1987) 
'Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate', N Engl 
J Med, 317(15), pp. 909-16. 
Stephens, L., Smrcka, A., Cooke, F.T., Jackson, T.R., Sternweis, P.C. and Hawkins, 
P.T. (1994) 'A novel phosphoinositide 3 kinase activity in myeloid-derived cells is 
activated by G protein beta gamma subunits', Cell, 77(1), pp. 83-93. 
Bibliography 
199 
Tai, W., Mahato, R. and Cheng, K. (2010) 'The role of HER2 in cancer therapy and 
targeted drug delivery', Journal of Controlled Release, 146(3), pp. 264-275. 
Templeton, A.J., Dutoit, V., Cathomas, R., Rothermundt, C., Bartschi, D., Droge, C., 
Gautschi, O., Borner, M., Fechter, E., Stenner, F., Winterhalder, R., Muller, B., Schiess, 
R., Wild, P.J., Ruschoff, J.H., Thalmann, G., Dietrich, P.Y., Aebersold, R., Klingbiel, 
D. and Gillessen, S. (2013) 'Phase 2 trial of single-agent everolimus in chemotherapy-
naive patients with castration-resistant prostate cancer (SAKK 08/08)', Eur Urol, 64(1), 
pp. 150-8. 
Thomas, C., Lamoureux, F., Crafter, C., Davies, B.R., Beraldi, E., Fazli, L., Kim, S., 
Thaper, D., Gleave, M.E. and Zoubeidi, A. (2013) 'Synergistic targeting of PI3K/AKT 
pathway and androgen receptor axis significantly delays castration-resistant prostate 
cancer progression in vivo', Mol Cancer Ther, 12(11), pp. 2342-55. 
Tilki, D. and Evans, C.P. (2014) 'The changing landscape of advanced and castration 
resistant prostate cancer: latest science and revised definitions', Can J Urol, 21(2 Supp 
1), pp. 7-13. 
Titus, M.A., Li, Y., Kozyreva, O.G., Maher, V., Godoy, A., Smith, G.J. and Mohler, 
J.L. (2014) '5α-reductase type 3 enzyme in benign and malignant prostate', The 
Prostate, 74(3), pp. 235-249. 
Tjulandin, S., Moiseyenko, V., Semiglazov, V., Manikhas, G., Learoyd, M., Saunders, 
A., Stuart, M. and Keilholz, U. (2014) 'Phase I, dose-finding study of AZD8931, an 
inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients 
with advanced solid tumors', Investigational New Drugs, 32(1), pp. 145-153. 
Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J. and Jemal, A. (2015) 
'Global cancer statistics, 2012', CA Cancer J Clin, 65(2), pp. 87-108. 
Traish, A.M. and Morgentaler, A. (2009) 'Epidermal growth factor receptor expression 
escapes androgen regulation in prostate cancer: a potential molecular switch for tumour 
growth', Br J Cancer, 101(12), pp. 1949-56. 
Tran, C., Ouk, S., Clegg, N.J., Chen, Y., Watson, P.A., Arora, V., Wongvipat, J., Smith-
Jones, P.M., Yoo, D., Kwon, A., Wasielewska, T., Welsbie, D., Chen, C.D., Higano, 
C.S., Beer, T.M., Hung, D.T., Scher, H.I., Jung, M.E. and Sawyers, C.L. (2009) 
'Development of a second-generation antiandrogen for treatment of advanced prostate 
cancer', Science, 324(5928), pp. 787-90. 
Trocme, E., Mougiakakos, D., Johansson, C.C., All-Eriksson, C., Economou, M.A., 
Larsson, O., Seregard, S., Kiessling, R. and Lin, Y. (2012) 'Nuclear HER3 is associated 
with favorable overall survival in uveal melanoma', Int J Cancer, 130(5), pp. 1120-7. 
Trojan, L., Kiknavelidze, K., Knoll, T., Alken, P. and Michel, M.S. (2005) 'Prostate 
cancer therapy: standard management, new options and experimental approaches', 
Anticancer Res, 25(1b), pp. 551-61. 
Bibliography 
200 
Tsilidis, K.K., Allen, N.E., Appleby, P.N., Rohrmann, S., Nothlings, U., Arriola, L., 
Gunter, M.J., Chajes, V., Rinaldi, S., Romieu, I., Murphy, N., Riboli, E., Tzoulaki, I., 
Kaaks, R., Lukanova, A., Boeing, H., Pischon, T., Dahm, C.C., Overvad, K., Quiros, 
J.R., Fonseca-Nunes, A., Molina-Montes, E., Gavrila Chervase, D., Ardanaz, E., Khaw, 
K.T., Wareham, N.J., Roswall, N., Tjonneland, A., Lagiou, P., Trichopoulos, D., 
Trichopoulou, A., Palli, D., Pala, V., Tumino, R., Vineis, P., Bueno-de-Mesquita, H.B., 
Malm, J., Orho-Melander, M., Johansson, M., Stattin, P., Travis, R.C. and Key, T.J. 
(2015) 'Diabetes mellitus and risk of prostate cancer in the European Prospective 
Investigation into Cancer and Nutrition', Int J Cancer, 136(2), pp. 372-81. 
van de Wijngaart, D.J., Dubbink, H.J., van Royen, M.E., Trapman, J. and Jenster, G. 
(2012) 'Androgen receptor coregulators: recruitment via the coactivator binding groove', 
Mol Cell Endocrinol, 352(1-2), pp. 57-69. 
Venderbos, L.D. and Roobol, M.J. (2011) 'PSA-based prostate cancer screening: the 
role of active surveillance and informed and shared decision making', Asian J Androl, 
13(2), pp. 219-24. 
Vieira, A.V., Lamaze, C. and Schmid, S.L. (1996) 'Control of EGF receptor signaling 
by clathrin-mediated endocytosis', Science, 274(5295), pp. 2086-9. 
Villers, A.A., McNeal, J.E., Freiha, F.S. and Stamey, T.A. (1991) 'Development of 
prostatic carcinoma. Morphometric and pathologic features of early stages', Acta Oncol, 
30(2), pp. 145-51. 
Vincent T. DeVita Jr., T.S.L., Steven A. Rosenberg. (2008) 'Cancer : principles & 
practice of oncology '. 
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg, C., 
Palotie, A., Tammela, T., Isola, J. and Kallioniemi, O.P. (1995) 'In vivo amplification of 
the androgen receptor gene and progression of human prostate cancer', Nat Genet, 9(4), 
pp. 401-6. 
Waltering, K.K., Helenius, M.A., Sahu, B., Manni, V., Linja, M.J., Janne, O.A. and 
Visakorpi, T. (2009) 'Increased expression of androgen receptor sensitizes prostate 
cancer cells to low levels of androgens', Cancer Res, 69(20), pp. 8141-9. 
Wan, X., Corn, P.G., Yang, J., Palanisamy, N., Starbuck, M.W., Efstathiou, E., Li Ning 
Tapia, E.M., Zurita, A.J., Aparicio, A., Ravoori, M.K., Vazquez, E.S., Robinson, D.R., 
Wu, Y.-M., Cao, X., Iyer, M.K., McKeehan, W., Kundra, V., Wang, F., Troncoso, P., 
Chinnaiyan, A.M., Logothetis, C.J. and Navone, N.M. (2014) 'Prostate cancer cell–
stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone 
metastases', Science Translational Medicine, 6(252), pp. 252ra122-252ra122. 
Wang, S.C., Lien, H.C., Xia, W., Chen, I.F., Lo, H.W., Wang, Z., Ali-Seyed, M., Lee, 
D.F., Bartholomeusz, G., Ou-Yang, F., Giri, D.K. and Hung, M.C. (2004) 'Binding at 
and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2', 
Cancer Cell, 6(3), pp. 251-61. 
Weihua, Z., Tsan, R., Huang, W.-C., Wu, Q., Chiu, C.-H., Fidler, I.J. and Hung, M.-C. 
(2008) 'Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase 
Activity', Cancer Cell, 13(5), pp. 385-393. 
Bibliography 
201 
Wen, Y., Hu, M.C.T., Makino, K., Spohn, B., Bartholomeusz, G., Yan, D.H. and Hung, 
M.C. (2000) 'HER-2/neu promotes androgen-independent survival and growth of 
prostate cancer cells through the Akt pathway', Cancer Research, 60(24), pp. 6841-
6845. 
Whang, Y.E., Armstrong, A.J., Rathmell, W.K., Godley, P.A., Kim, W.Y., Pruthi, R.S., 
Wallen, E.M., Crane, J.M., Moore, D.T., Grigson, G., Morris, K., Watkins, C.P. and 
George, D.J. (2013) 'A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine 
kinase inhibitor, in patients with castration-resistant prostate cancer', Urol Oncol, 31(1), 
pp. 82-6. 
Whitworth, H., Bhadel, S., Ivey, M., Conaway, M., Spencer, A., Hernan, R., Holemon, 
H. and Gioeli, D. (2012) 'Identification of Kinases Regulating Prostate Cancer Cell 
Growth Using an RNAi Phenotypic Screen', PLoS ONE, 7(6), p. e38950. 
Whyte, J., Bergin, O., Bianchi, A., McNally, S. and Martin, F. (2009) 'Key signalling 
nodes in mammary gland development and cancer. Mitogen-activated protein kinase 
signalling in experimental models of breast cancer progression and in mammary gland 
development', Breast Cancer Res, 11(5), p. 209. 
Wolf, I.M., Heitzer, M.D., Grubisha, M. and DeFranco, D.B. (2008) 'Coactivators and 
nuclear receptor transactivation', J Cell Biochem, 104(5), pp. 1580-6. 
Xie, Y. and Hung, M.C. (1994) 'Nuclear localization of p185neu tyrosine kinase and its 
association with transcriptional transactivation', Biochem Biophys Res Commun, 203(3), 
pp. 1589-98. 
Xu, D., Zhan, Y., Qi, Y., Cao, B., Bai, S., Xu, W., Gambhir, S.S., Lee, P., Sartor, O., 
Flemington, E.K., Zhang, H., Hu, C.D. and Dong, Y. (2015) 'Androgen Receptor Splice 
Variants Dimerize to Transactivate Target Genes', Cancer Res, 75(17), pp. 3663-71. 
Xu, J., Neale, A.V., Dailey, R.K., Eggly, S. and Schwartz, K.L. (2012) 'Patient 
Perspective on Watchful Waiting/Active Surveillance for Localized Prostate Cancer', 
Journal of the American Board of Family Medicine : JABFM, 25(6), pp. 763-770. 
Yarden, Y. (2001) 'The EGFR family and its ligands in human cancer. signalling 
mechanisms and therapeutic opportunities', Eur J Cancer, 37 Suppl 4, pp. S3-8. 
Yewale, C., Baradia, D., Vhora, I., Patil, S. and Misra, A. (2013) 'Epidermal growth 
factor receptor targeting in cancer: A review of trends and strategies', Biomaterials, 
34(34), pp. 8690-8707. 
Yin, L. and Hu, Q. (2014) 'CYP17 inhibitors[mdash]abiraterone, C17,20-lyase 
inhibitors and multi-targeting agents', Nat Rev Urol, 11(1), pp. 32-42. 
Yu, Y., Anderson, L.L., Li, Z., Mellenberg, D.E., Nath, R., Schell, M.C., Waterman, 
F.M., Wu, A. and Blasko, J.C. (1999) 'Permanent prostate seed implant brachytherapy: 
report of the American Association of Physicists in Medicine Task Group No. 64', Med 
Phys, 26(10), pp. 2054-76. 
Yuan, X. and Balk, S.P. (2009) 'Mechanisms mediating androgen receptor reactivation 
after castration', Urol Oncol, 27(1), pp. 36-41. 
Bibliography 
202 
Zaczek, A., Brandt, B. and Bielawski, K.P. (2005) 'The diverse signaling network of 
EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for 
therapeutic approaches', Histol Histopathol, 20(3), pp. 1005-15. 
Zhang, L., Altuwaijri, S., Deng, F., Chen, L., Lal, P., Bhanot, U.K., Korets, R., Wenske, 
S., Lilja, H.G., Chang, C., Scher, H.I. and Gerald, W.L. (2009) 'NF-kappaB regulates 
androgen receptor expression and prostate cancer growth', Am J Pathol, 175(2), pp. 
489-99. 
Zhang, Y., Linn, D., Liu, Z., Melamed, J., Tavora, F., Young, C.Y., Burger, A.M. and 
Hamburger, A.W. (2008) 'EBP1, an ErbB3-binding protein, is decreased in prostate 
cancer and implicated in hormone resistance', Molecular Cancer Therapeutics, 7(10), 
pp. 3176-3186. 
Ziada, A., Barqawi, A., Glode, L.M., Varella-Garcia, M., Crighton, F., Majeski, S., 
Rosenblum, M., Kane, M., Chen, L. and Crawford, E.D. (2004) 'The use of trastuzumab 
in the treatment of hormone refractory prostate cancer; phase II trial', Prostate, 60(4), 
pp. 332-7. 
Zimonjic, D.B., Alimandi, M., Miki, T., Popescu, N.C. and Kraus, M.H. (1995a) 
'Localization of the human HER4/erbB-4 gene to chromosome 2', Oncogene, 10(6), pp. 
1235-7. 
Zimonjic, D.B., Rezanka, L., DiPaolo, J.A. and Popescu, N.C. (1995b) 'Refined 
localization of the erbB-3 proto-oncogene by direct visualization of FISH signals on 
LUT-inverted and contrast-enhanced digital images of DAPI-banded chromosomes', 
Cancer Genetics and Cytogenetics, 80(2), pp. 100-102. 
Zoubeidi, A., Zardan, A., Beraldi, E., Fazli, L., Sowery, R., Rennie, P., Nelson, C. and 
Gleave, M. (2007) 'Cooperative interactions between androgen receptor (AR) and heat-
shock protein 27 facilitate AR transcriptional activity', Cancer Res, 67(21), pp. 10455-
65. 
 
 
